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Abstract 
The commercialisation of Biotechnology is the process of taking innovations to market 
through different pathways. There is strong involvement by business networks that play 
a key role during the process of biotechnology innovation and commercialisation. 
Theoretical developments in the network-based commercialisation management literature 
have challenged our understandings of the effects of network interactions during the 
process of technology commercialisation. This study focuses on exploring the effects of 
networks on the process of commercialisation in the biotechnology industry. The 
biotechnology industry itself has a specific position in the industrial markets because of 
its capability of successfully employing network knowledge to innovate products and 
services. However, the industry struggles to implement the resource networks to take 
innovations to market. 
Despite a significant body of available research regarding the role of networks in 
innovation and commercialisation processes, there is still a need to understand more about 
how networks influence the biotechnology commercialisation process. It is shown 
through the literature and through industry publications that managers still lack important 
empirical insights regarding network-based interactions that would assist them in 
designing strategies and roadmaps for the commercial success of biotechnology 
innovations. Thus, the overarching questions guiding this research are: 
1. How do networks influence the commercialisation of new biotechnologies? 
2. How does network configuration inhibit or promote the biotechnology 
commercialisation process? 
3. How do the networks dynamic interactions affect the process of biotechnology 
commercialisation? 
The thesis adopts a qualitative approach and a three-paper structure to help answer the 
questions. The structure of this thesis has been adapted to fulfill RMIT University’s thesis 
publication criterion that allows a thesis to be written in a three-paper format. RMIT states 
that the eligibility for submission does not demand the three papers to be submitted or 
published.  An ethics approval was received by RMIT University before this study was 
persued. 
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In the first paper, the network-based commercialisation process is conceptualised as the 
process of taking innovation through to different commercial outcomes under the 
influence of the different types of network effects. A content analysis approach has been 
adopted for this study. This provides theoretical clarity on the units of analysis regarding 
the network actors, resources, activities, types of network influences and outcomes, and 
links with the stages of the commercialisation process. 
In the second paper, the aim is to understand the dual nature of networks and how it affects 
the stages of the biotechnology commercialisation process. Eight types of network-based 
barriers and eight types of network-based promoters have been identified that affect the 
different stages of the commercialisation process. A qualitative approach was adopted for 
this study, with 30 semi-structured in-depth interviews with experts in the field of 
biotechnology. The findings will help managers and researchers in developing strict 
selection criteria for taking network-based decisions and assist in designing strategies to 
overcome barriers that inhibit the progression of the process. 
In the third paper, the aim is to identify the mechanics of interactions within a network 
ecosystem that generate the dynamics around the process of biotechnology 
commercialisation. Thirty network-based interactions were identified, which were further 
grouped under four key network-based influences (network movements, structure, 
relationships and acuity). A qualitative approach with 30 semi-structured interviews with 
biotechnology experts was adopted for this study. The 30 semi-structured interviews were 
the same as study 2 however; the interviews were re-analysed with a different perspective 
to understand the underlying dynamic network interactions. The findings suggest that 
these influences generate dynamics around the biotechnology commercialisation process 
that may affect the process positively or negatively at different stages. This will assist the 
managers mapping resource development pathways and relationship development 
techniques. 
The findings from this research, undertaken in the context of the Australian biotechnology 
industry, provide empirical evidence for how different network components within a 
commercialisation ecosystem influence the stages of the commercialisation process. 
Overall, the findings show how biotechnology innovation organisations can implement 
network knowledge to improve the process for successful commercialisation of 
innovations.  
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Chapter 1: Introduction to Research 
1.1 Context and Questions 
1.1.1 Biotechnology industry overview and challenges 
The Australian Trade Commission Report (2014) indicates that Australia is considered a 
powerhouse of biotechnology, possessing state-of-the-art research facilities and skilled 
and experienced scientists for developing commercially viable innovations and a speedy 
legal approval regime. The Australian biotechnology sector has grown at an average of 
3.1% per year for the last ten years. The annual growth rate for the industry is 4.4% per 
year, forecast to reach $8.67 billion in revenue by 2021 (Bio-Savvy, 2016; Grant 
Thornton, 2017). In 2016–2017, almost AUD 1.3 billion in capital investments was raised 
across the sector. The research conducted through this investment generated promising 
innovations in the fields of food and agriculture, pharmaceuticals, and medical and health 
technology (AusBiotech Snapshot, 2017). 
As defined by Pisano (1990) “Biotechnology is a body of knowledge and techniques for 
using live organisms in a particular productive process”.  It has developed from being just 
a multi-technology field (Powell 1998) to a well-established industry that has contributed 
by providing knowledge (Fontes 2005; Ausretsch & Stephan 2002), initiating the 
acquisition of capabilities (Deeds et al. 2000) and tools (Chrispeels 2000) that bolster and 
initiate innovation in various industrial sectors (Europe Innova 2011). In its current phase, 
biotechnology is considered as an essential sector with useful prospects for economic 
welfare (Caswell et al. 2003), employment (Arundell 2002, Feldman 1983), healthcare 
(Arora 2005; Visalakshi & Mohan 2002) and sustainability (Verstraete 2002; Aguilar et 
al. 2008). The different biotechnological products and processes can be combined with 
the products and services of other industries and together they can form effective, 
innovative and useful technological products that can be applied across various sectors of 
the market.  
The biotechnology industry network has been the most robust support for the success of 
the biotechnology sector in the last two decades (AusBiotech Snapshot, 2017). The 
biotechnology industry operates within a strong ecosystem comprised of webs of 
networks consisting of different types of entities, both individual and organisational, 
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including funding bodies, government and regulatory bodies, research institutes (private 
and public), patent support, IP consulting firms, incubating organisations, accelerating 
organisations, suppliers and manufacturers, accounting and legal services, distributors 
and contract research organisations. The industry network provides enormous support to 
the biotechnology organisations for innovating potential products. For example, several 
biotechnology-based associations offer innovation funds and technology translation funds 
to the innovating organisations (AusBiotech, 2017; BioMelbourne Network, 2017; 
MTPConnect, 2017). The Australian biotechnology sector includes a range of intellectual 
property protection programs that have been organised by government bodies and private 
associations; these provide a diverse, transparent and effective regulatory system 
(AusBiotech, 2017; Butterworth, 2014) that attracts investors and funding bodies from 
across the globe. The innovation policies give the Australian biotechnology sector a 
competitive advantage over its international competitors (AusBiotech, 2016; Parliament 
of Australia, 2014; Vitale, 2004). 
However, one of the prominent challenges faced by this sector continues to be the 
development and commercialisation of Biotechnology innovations (AusBiotech 
Snapshot, 2017; Australian Biotechnology Report, 2001; Bio-Savvy, 2016; Vitale, 2004; 
Williamsons, 2014). It has been reported that the Australian biotechnology sector has a 
good record in research, but the risks and uncertainties associated with government 
approvals for the development and adoption of new innovative products have been a 
challenge (Parliament of Australia, 2014). Multinational companies supporting the 
biotechnology research institutes and small to medium firms in their research and 
development are keen to see a return on their investments (Butler, 2014). 
The Australian Government has also stressed a range of emerging issues that may affect 
successful commercialisation of biotechnology products in Australia. The issues include 
inefficient regulatory, ethical and legal frameworks; several production and 
manufacturing challenges; limitations in forming start-ups or spin-offs; access to funds 
for marketing activities; development and licencing capability for accessing proof-of-
concept; limited multidisciplinary infrastructure and researchers; and lack of proactive 
commercialisation approaches and skills for technology transfer (Australian Institute for 
Commercialisation, 2013; Biotechnology Australian, 2000; Hill, 2016). Research 
institutes and universities that are key players in the biotechnology network have limited 
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commercialisation capabilities, which further affect the collaborations these bodies have 
within the industry. Such deficiencies in skill sets affect the overall rate of 
commercialisation success within the biotechnology industry. 
Innovation networks are specifically defined as organizational relationships between 
different actors in the external environment and the internal organizational hierarchy, 
which provide information and all the complementary assets, which help to develop 
innovations by conjoint learning between different actors of the network (Koschatzky et 
al. 2001). Often firms collaborate or form alliances with other competent firms to innovate 
efficiently and commercialize viable products and services (Doloreux, 2004; 
Vanhaverbeke & Cloodt 2005). Several interconnected networks form network webs 
within a specific network boundary to form a network ecosystem (Corallo, Passiante, & 
Prencipe 2007).  Network ecosystems play a crucial role in biotechnology innovation and 
commercialisation processes (Qi Dong, McCarthy, & Schoenmakers, 2017; Jiang, Xia, 
Cannella, & Xiao, 2018). The biotechnology industry has recognised the need for 
networks as an essential requirement for delivering successful innovation outcomes 
(AusBiotech Snapshot, 2017; BioMelbourne Network, 2017). Industry reports 
(AusBiotech Snapshot, 2017; Bio-Savvy, 2016) indicate that both public and private 
innovating organisations have become aware of the effects of network clusters and 
collaborations and have been able to identify areas where network involvement can 
improve the development of potential and viable biotechnology innovations. Conversely, 
the industry has also recognised that despite the increasing innovation growth rate, the 
industry is struggling to take innovations to market (AusBiotech Snapshot, 2017; Bio-
Savvy, 2016; Vitale, 2004). Networks are extensively used in the form of mergers and 
alliances for developing biotechnology products (Bauer, Hansen, & Hellsmark, 2018; Qi 
Dong et al., 2017); however, rarely does a biotechnology firm commercialise a product 
using those collaborations (AusBiotech Snapshot, 2017; Bio-Savvy, 2016). 
Although industry practitioners are aware of the advantages of operating within a network 
ecosystem during the biotechnology commercialisation process (BCP), the effect of the 
network on the process is not well understood by managers in the biotechnology industry. 
Network support that is available to the industry cannot be utilised to its full capacity 
unless managers understand how to implement the interactions that occur within a 
network to favour the commercialisation process. Managers lack empirical knowledge of 
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critical factors that contribute to promoting or inhibiting the progression of the 
commercialisation process, such as actors, resources and the nature of activities and 
interactions (Bauer, Hansen & Hellsmark, 2018; Clarysse, Wright, Bruneel, & Mahajan, 
2014; Guan, Zhang, & Yan, 2015). Hence the need for an in-depth research study on the 
effects of business networks on the BCP. It is expected that the critical insights of this 
study will help in making strategic choices that counter the challenges of 
commercialisation in the Australian biotechnology industry. 
1.1.2 Theoretical positioning 
Innovation is defined as a new method of doing things, which in the business context, 
involves generating new technologies, technological processes, new products and 
associated services (Graff et al 2010). Innovations (products/services) are developed 
through a series of stages and gates during the course of the innovation process, also 
sometimes referred to as the new product development process (Cooper 1991) depending 
on the type of innovation. These stages involve different activities that may overlap time 
to time due to the non-linear nature of this process (Stenroos & Sandberg 2012; Hags & 
Hollingsworth, 2013). Commercialization is the concluding step of the innovation 
process, but it does not involve combining different resources to innovate rather it 
involves combining resources to help prevent market resistance (Woodside & Biemans 
2005). Commercialization is defined as a process that turns innovation concepts and ideas 
into marketable products to obtain commercial value (Pellikka & Lauronen 2007).  The 
commercialization step in itself is a complex process (Roosenberg 1994). It starts when 
the potential innovations are compatible with a lucrative market (Jolly 1997; Pellikka & 
Lauronen 2007).  Commercialization is an essential part of an organization’s business 
plans as specific resources are used to commercialize products for gaining competitive 
advantage (Kasch & Dowling 2008). An innovation process occurs within cooperative 
ventures, partnerships and networks (Story et al 2011).  
More firms prefer innovating within networks because these associations provide intricate 
R&D advantages, shorter product life cycles, and international endorsement (Rampersad 
et al. 2010). It also reduces competition for specific and scarce scientific resources 
(Tushman 2004). Business networks are important sources of new technologies, markets, 
resources, knowledge and complementary skills that are external to the focal firm 
(Rampersad et al 2010; Moorman 1995, Powell 1987).  It also helps in reducing risks and 
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uncertainties (Powell 1987; Jhonston et al. 1999). Many companies are unable to afford 
the required complementary assets to commercialize independently therefore they join 
other organization that assist them in commercializing the product (Aldrich 1999, Ernst 
& Young 2000). It is also known that the absence of network and it components would 
have a huge impact on the commercialization process of an innovation, especially if it is 
a part for a business strategy (Stenroos & Sandberg 2012). It has been established that 
networks play an important role in the innovation and commercialization process [For 
Example see: Gans & Stern (2003); Ernst & Young (2000); Kasch & Dowling (2008); 
Strenitzke (2010); Walsh (2012)]. 
There is an increasing interest for understanding the relationships between innovation 
processes, commercialisation and interorganisational network management for emerging 
industries such as Biotechnology (Gilsing & Nooteboom 2006; Aarikka-Stenroos and 
Sandberg 2014; Leppaho et al 2017). Biotechnology industry is a chosen setting for this 
research as it represents different industries that emphasise on network collaborations and 
have extensive involvement of external and internal networks for innovation management 
(Kim & Lui 2015).  Several practitioners and managers are increasingly soliciting 
strategies to develop and seize value from different network collaborations within the 
Biotechnology industry, as it is economically beneficial. In addition to that, prior research 
(Powell et al 1996; Yoon, Lee, Song 2015; Aarikka-Stenroos & Sandberg 2014) in the 
network management literature has focused on examining alliance activities in small-
medium organisations (SME’s) in the Biotechnology industry as the industry has a strong 
requirement for alliance formation due to the complex nature of the innovation processes. 
The complexity of the process further demands the development of inter-organisational 
relationships as it is difficult for one organisation to manage it alone. Amongst the several 
high-tech industries available for network-based analysis, Biotechnology industry is most 
dynamic in terms of alliance formation and relationship development (Sytch & Bubenzer 
2008; Yoon et al 2015). The Biotechnology sector represents a technology defined sector, 
has a geographical scope nationally and internationally and it involves multiple individual 
and organisational actors with overlapping roles across several innovation and 
commercialisation processes.     
The biotechnology innovation and commercialisation process is viewed as a transitional 
outcome of interactions between different individuals or organisations within an 
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ecosystem (Baraldi & Stormsten, 2009; Chen & Lin, 2017; Hagedoorn, Lokshin, & Malo, 
2018; Leppaaho, Chetty, & Dimitratos, 2017; lbert & Muller, 2015; Roesler & Broekel, 
2017). In this research, interactions within a network are defined as resource exchanges, 
linkages, ties, communications and different network activities. From the network-based 
perspective, innovation processes are theorised as open systems that operate within a 
collaborative environment (Aoboen, Dubois & Lind, 2013; Auerswald & Dani, 2017; 
Graff, Zilberman & Bennett 2010) and commercialisation is an extension as well as an 
outcome of the interactions that occur during the innovation process (Aarikka-Stenroos 
& Sandberg, 2014; Clayton, Feldman, & Lowe, 2018; Miller, McAdam, & McAdam, 
2018). The network ecosystems that surround these processes are a combination of a 
range of actors, resources and activities (Hakansson & Johanson, 1992).  
Earlier research has identified the role of different network actors, resources and activities 
during the biotechnology innovation process ( Di Benedetto, DeSarbo & Song 2008, 
Graff et al., 2010; Foxon, Gross, Chase, Howes, Arnall & Anderson 2005; Gay & 
Dousset, 2005). While researchers’ understanding of the network phenomena around the 
Biotechnology innovation process has been remarkably increasing, the understanding of 
a variety of mechanisms (that lead to the development of different network 
configurations, heterogeneous network combinations, structures, relationships, 
perceptions and network positions ) and level at which they exist within a network 
ecosystem (individual, organisational and inter-organisational level) present us with a 
need to examine the mechanisms and their impact during the process Biotechnology 
commercialisation. This presents significant challenges for industry practitioners in 
understanding how to strategically make network-based decisions that would facilitate 
favourable commercial outcomes. However, despite increasing attention from academics 
(Beer & Jain, 2018; Dutta & Hora, 2017; Najafi-Tavani; Najafi-Tavani, Naude, Oghazi, 
& Zeynaloo, 2018), there is limited research into how these networks influence the BCP.  
While it has generally been acknowledged that the commercialisation process is network 
supported (Stenroos & Sandberg, 2012), the nature of interactions within the network 
ecosystem and how they influence the process of commercialisation has been overlooked. 
This means that practitioners in both research and industry settings have limited insights 
into the complicated process by which networks affect the BCP. Managers lack strategic 
knowledge as to how should they guide the BCP or how to facilitate the identification of 
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network-based opportunities for gaining a successful commercialisation outcome 
(Eveleens, Rijnsoever, & Niesten, 2017; Mattila, 2017; Nabulsi, 2017; Nassiri-Koopaei 
et al., 2014). Recent research in the field of network and commercialisation management 
has discussed the role of specific components of networks in the technology 
commercialisation process (Chen & Lin, 2017). For example, Mattila (2017) has 
identified the configuration of network actors and their changing position in the network 
during the technology commercialisation process. However, a holistic approach to 
investigate the network’s effect on the BCP has not been commonly used. 
Although there is an extensive body of literature investigating different types of network 
effects on the commercialisation process (Aarikka-Stenroos & Sandberg, 2014; Clauss & 
Kesting, 2017; Heirati & O’Cass 2016), there are important limitations to the findings. 
For example, some researchers have highlighted the positive contributions of network 
components to the commercialisation process (Aarikka-Stenroos & Sandberg, 2014; 
Breznitz, Clayton, Defazio, & Islett, 2018; Laage-Hellman, Landqvist, & Lind, 2017), 
while others have highlighted the limiting or even negative influences of networks on 
commercialisation (Ranganathan & Rosenkopf, 2014; Tinoco & Ambrose, 2017). 
From an empirical perspective, such inconsistencies may relate to different types of 
network phenomena that have been examined in different research settings. For example, 
Aarikka-Stenroos and Sandberg (2014) studied network-based technology 
commercialisation by examining the role of network actors and their contributions by 
using examples from different network approaches. In contrast, Capaldo, Fontes and 
Cannavacciuolo (2015) focused on the resource gathering behaviour of networks by 
examining biotechnology innovation start-ups in specific European locations. They found 
that biotechnology firms located at disadvantageous locations used networks to alleviate 
issues related to relationship building and resource gathering. A recent study by Clayton, 
Feldman and Lowe (2018) explores the role of specific intermediaries that provide 
services to facilitate scientific commercialisation through entrepreneurship. 
From a theoretical perspective, the limitations may be related to the lack of attention being 
paid to network effects that are specific to the commercialisation process (Aarikka-
Stenroos & Sandberg, 2014; Capaldo et al., 2015; Clayton et al. 2018). Findings that are 
not specific to the BCP and the mechanisms related to how network effects are generated 
or how they influence the BCP are not likely to be accurate. It is crucial to investigate the 
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fundamental units of analysis of network components (such as the actors, resources and 
their activities), the interactions that transpire between these components and how these 
interactions generate network effects that may or may not be beneficial for the BCP. 
Understanding these interactions will help identify how and under what network 
influence the BCP operates. Further, research should investigate whether networks help 
to enhance and accelerate the BCP or, conversely, hamper the BCP. Such knowledge 
would allow managers to identify the critical network effects, interactions and their 
effects on the stages of the commercialisation process. Hence, there is a need for empirical 
research that adopts the network-based lens to understand the BCPs that lead to successful 
commercial outcomes. 
1.2 Research Problem 
Despite the strategic attempts made by the Australian biotechnology industry to 
understand the implications of network ecosystems to facilitate the commercialisation 
process, knowledge that would assist the industry in designing better commercialisation 
strategies regarding key aspects of networks and their effects on the stages of the BCP is 
lacking (AusBiotech Snapshot, 2017; Bio-Savvy, 2016; Grant Thornton, 2017; Vitale, 
2004). The introduction of biotechnology innovations into the market and their 
acceptance is becoming an essential issue for biotechnology companies (Kamurivo, 
Baden-Fuller, & Zhang, 2017; Rothaermel & Deeds, 2004;). The main argument in this 
study is that while expanding on understandings of the network ecosystem and innovation 
processes is necessary, it is not a sufficient condition for enhancing an organisation’s 
commercialisation capabilities and success. This research theorises the need to 
understand different network effects that evolve around the BCP; that is, network 
influences improve an organisation’s innovation capabilities, but the success of an 
innovation is dependent on the useful implementation of those network influence for 
taking the innovations through to a successful commercialisation outcome. 
Previous studies have suggested that networks are an essential antecedent for innovation 
(Baraldi & Stormsten, 2009; Bramwell, Hepburn, Wolfe, 2012; Cooke, 2002; Dogson 
Mathews, Kastelle & Hu, 2008; Gertler & Levitte, 2005). Recent studies have highlighted 
the role of networks during commercialisation (Chen & Lin, 2017; Clayton et al., 2018; 
Dutta & Hora, 2017; Hagedoorn, Lokshin, Malo, 2018; Lehtimaki, 2017). Much 
emphasis has been placed on the importance of the effects of the network on the 
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innovation process. However, the existing literature has not paid sufficient attention to 
understanding the effects of network-based interactions on different stages of the BCP. 
The current literature has not considered a holistic approach to investigate the importance 
or significance of network-based BCPs.  Prior studies have advanced the understanding 
about contributions of the large, diverse networks within Biotechnology and during the 
innovation process, there exists a need for more empirical findings to further investigate 
how those contributions affect commercialisation of those innovative outcomes. The 
value of this research lies in the fact that it provides deeper understanding on network 
mechanisms and highlights the properties of the network interaction that lead to 
development of the underlying network mechanisms which evolve around the 
Biotechnology commercialisation process.   
The primary objective of this study is to examine the role of collaborative network 
ecosystems during the BCP. The study aims to answer the following research questions: 
• How do networks influence the commercialisation of new biotechnologies? 
• How does network configuration inhibit or promote the BCP? 
• How do network dynamics interactions affect the BCP? 
1.3 Thesis Three-Paper Format 
The overarching research questions will be addressed in three related studies that respond 
to calls for such research (Aarikka-Stenroos & Sandberg, 2014; Baraldi & Stromsten, 
2009; Clayton et al., 2018; Dutta & Hora, 2017; Terziovski & Morgan, 2006; Thompson 
& Hermann, & Hekkert ,2018; Vitale, 2004). That is, this thesis has been divided into 
three sequential investigations to address each question in detail and to study the effects 
of business networks on the process of commercialisation from every dimension. This 
structure fulfils RMIT University’s thesis publication criteria that allow a thesis to be 
written in a three-paper format. RMIT states that the eligibility for submission does not 
demand the three papers to be submitted or published in a journal. An ethics approval was 
received by RMIT University before this study was pursued. 
The topic was complex, as the initial step required the development of a model to 
understand the links between networks and commercialisation. This involved 
understanding the different components of the network and various network interactions 
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that generated dynamics around the process. While the three studies share some overlap 
in its literature, each is the basis for a future potential journal publication. Each study 
consists covers theoretical positioning, methodology, findings, contributions and 
limitations. The thesis predominantly uses the realist lens the use of literature from 
multiple ontologies is appropriate in analyzing and understanding background theoretical 
knowledge. This approach has been used by several well-respected researchers (e.g. 
Prenkert 2017; Aarikka-Stenroos and Sandberg 2014; Moller & Rajala 2007) as an 
effective method of understanding specialized concepts, and, more importantly 
understanding the links between different concepts to gain insights into a multifaceted 
phenomenon. This approach allows for the investigation of the research problem from 
different perspectives, provides access to unique concepts, and examines the interaction 
of concepts that are linked but have only previously been examined in isolation within a 
confined ontological perspective.  
Business networks are a result of complex interactions between network entities and the 
environment around them (Håkansson and Ford, 2002; Prenkert 2017; Wilkinson and 
Young, 2013). In this research the environment around the network is the process of 
Biotechnology commercialization. Therefore, it becomes important to understand 
network ontology that involves understanding the network and its different dimensions 
and how interaction takes place between these dimensions, through specific network 
elements (actors, resources and actors). On the other hand, it is also important to 
understand the process ontology, in which networks are not fixed in one space and time 
but are an outcome continuous interaction between involved entities, resources and 
activities (Tsoukas & Chia 2002; Bizzi & Langley 2012).  
A combination of the network and process ontology aided in understanding the different 
types of factors in a specific context that will influence the network interactions. It is 
important to understand the relationship between the two ontologies to identify the impact 
of networks on the environment and vice versa. There are some consequences of using a 
multiple ontology approach, one of the key consequences of using a multiple ontological 
approach for network-based studies is related to defining the network boundaries. 
However, despite the fact that network boundaries are necessary they are random and are 
continuously changing (Gadde 2014; Prenkert 2017) which makes it a complex system to 
examine if multiple perspectives are not applied. Also, the decision around the length and 
breadth of a network boundary also depends on different viewpoints of the involved 
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network actors which also require specific conceptualizations of those perspectives. 
Therefore, to examine network-based interaction mechanisms around a process, which 
involves multiple actors and multiple stages at a given point in the process, increases the 
complexity of the investigation; this requires a combination of different ontologies to 
simplify the process of understanding a set of interactions within a complex system. 
A qualitative method is most suitable for this study. The first study is conceptual, whereas 
a qualitative approach was applied to Study 2 and Study 3, with semi-structured in-depth 
interviews. The qualitative approach aligns with the value of a critical relativist approach 
that focuses on diverse explanatory systems. There are two key reasons for selecting a 
qualitative approach; first the qualitative method is useful for unfolding a complex 
phenomenon as it allows the researcher to get a magnified view of the unit of. analysis 
(Johnson and Onwuegbuzie 2004).  
Prior network research has preferred the use of qualitative approach to examine networks 
within a context as it allows understanding issues of network complexity, 
interdependence, contextuality and time, purposely if it is related to a specific process 
rather than individual units of analysis (Burca & McLoughlin 1996), which for this 
research is quite relevant as it intends to examine the impact of different network 
mechanisms on the process of Biotechnology commercialization. Second, the adoption of 
qualitative methods allows the researcher to study dynamics of specific innovation 
processes in rich detail. In this study this approach allowed the researcher to study the 
impact of networks (phenomena) on BCP (context). The use of this method allowed the 
researcher to understand and develop a narrative of actor’s experiences related to the 
phenomena. This research has used a qualitative approach with semi-structured 
interviews to collect data from a diverse range of Biotechnology experts who provided a 
pragmatic view of the ongoing mechanisms during BCP. By understanding the 
background ontologies related to specific interactions of the mechanisms, it was effective 
in identifying the contributions of each network dimension individually as well as 
cumulatively. It also assisted in identifying the impact of such network dimensions on the 
BCP in a similar manner. It was also easy to identify the patterns of interactions that were 
common across BCP. Since each ontology directly represents a network dimension within 
the BCP network, using multiple ontologies implied that, the different network 
perspectives related to each of the ontologies can be applied during data 
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A triangulation approach was used for validation of the appropriate theories and emerging 
themes during the investigation (Huberman & Miles, 1994; Raftery, McGeorge, & 
Walters, 1997; Yin, 1994). Study 2 focuses on understanding the network-based barriers 
and promoters that affect the BCP. Study 3 focuses on understanding the network-based 
interaction dynamics related to network movements, structures, relationships and acuities 
that influence the stages of the BCP. The participants for Studies 2 and 3 were 
biotechnology experts from industry, academic, government and research organisations. 
The following sections summarise each paper. 
1.3.1 Study 1: A conceptual model of the required network effects for the 
commercialisation of new biotechnology innovations 
The first study integrates the industrial (B2B) marketing and innovation management 
literature by advancing the knowledge regarding the BCP as a process progressing under 
the influence of network-based influences and outcomes. It is argued that the BCP 
operates within an ecosystem of interactions between different individuals/organisations, 
the resources they provide or acquire and the activities that are involved in conducting 
the resource exchange (Chen & Lin, 2017; Clayton et al., 2018; Dutta & Hora, 2017; 
Hagedoorn, Lokshin, Malo, 2018; Lehtimaki, 2017). These interactions are classified as 
network influences and network outcomes. Therefore, the different stages of the BCP are 
affected by the different network influences and outcomes. 
Study 1 is a content analysis (Aarikka-Stenroos & Sandberg, 2014) of the existing 
literature to develop a framework that would assist in linking the key theories and 
concepts in this research (Krippendorff, 2004). The network management, new product 
development and commercialisation management literature is quite extensive and broad; 
a content analysis approach assists in reducing the volume of texts and collected data and 
allows the grouping of the literature into meaningful categories for the development of 
the conceptual framework (Bengtsson, 2016). Based on the content analysis, a set of 
research questions about the effects of networks on the BCP was formulated. A 
conceptual model was outlined that highlights the key units of analysis, including network 
actors, resources, activities, influences and outcomes, and that demonstrates their 
interrelationship with the stages of the BCP. 
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This study provides a theoretical understanding of the progression of the potential 
products from one stage of commercialisation to another and how the different network 
outcomes affect the process. It contributes to theory in the field of technology transfer 
regarding the social aspects of commercialisation in a specialised, technology-based 
industry. Further, an agenda for future research is presented based on the concepts that 
provide theoretical foundations for future research and that highlight the theoretical and 
managerial contributions of the study. 
1.3.2 Study 2: Network-Based Barriers and Promoters from biotechnology Labs to 
Australian Markets 
Building on Study 1, Study 2 focuses on understanding the effects of business networks 
on the BCP by identifying the network-based barriers and promoters that influence the 
different stages. The commercialisation process is network bound (Aarikka-Stenroos & 
Sandberg, 2012; Siegel, Waldman, Atwater, & Link, 2004) and the networks are capable 
of barring or promoting the commercialisation of the innovation in the market (Bandarian, 
2007). Network barriers can be defined as the outcomes of interactions between different 
network components (network actors, resources and activities) that delay, decelerate or 
barricade any network bound processes. On the other hand, network promoters are 
defined as outcomes of interactions that accelerate, enable or facilitate any network bound 
process. Thus, it was essential to identify the network barriers in order to prevent failure 
and, conversely, to identify the promoters in order to facilitate the BCP. 
Study 2 is based on a qualitative approach and involves semi-structured in-depth 
interviews with 30 experts from the field of biotechnology innovation and 
commercialisation. Participants in Study 2 were asked to share their knowledge of, level 
of involvement with, experience of and contribution to the commercialisation process. 
They were also asked to share their attitude towards and recommendations for 
improvements to the BCP. Therefore, the application of qualitative research methods was 
appropriate for gaining detailed verbal descriptions of the participants’ experiences to 
understand this social phenomenon. This approach allowed flexibility as it is an iterative 
process that allowed modification of the selected data collection instruments (please refer 
to Appendix 1) simultaneously with the continuing analysis (Yin, 2009). This was 
important as participants who were members of biotechnology commercialisation 
networks had different profiles; else using the same interview instrument to gather data 
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from them would have restricted the gathering of in-depth and specific information. Semi-
structured interviews combined with a snowball sampling approach allowed the 
researcher to understand complex network links and relationships that further contributed 
to understanding the involvement of networks during the BCP. Considering the broad 
context of the study, the range of participants and their profiles, this approach was 
advantageous as it further simplified the gathering of new information that led to new 
findings. 
The resulting data were subjected to two rounds of coding and analysis. The key themes 
have been organised based on the thematic coding of the collected data. Thematic coding 
led to the identification of several aggregates of information, which were then combined 
into themes based on commonalities. The first round of coding identified the network-
related interactions, which were further classified as barriers and promoters that influence 
the process. The second round of coding ordered themes to categorise interactions into 
different types of barriers and promoters. The data analysis process cycled between data 
and literature to develop a detailed understanding of the emerging themes (Gioia, Corley, 
& Hamilton, 2013; Tierney, 2016). From this analysis, an empirically evident framework 
was developed. The framework shows the stages of BCP and the eight network-based 
barriers and eight promoters that affect those stages during different phases of the BCP. 
The framework demonstrates the key issues during the BCP and identifies the network 
actors’ roles and relationships, the outcomes of their interactions during the process and 
their perspectives on different network components acting as barriers or promoters. 
Study 2 contributes to industrial marketing and commercialisation management theory by 
identifying and explaining the eight network-based barriers and eight promoters that 
affect the stages of BCP. In doing so, the study provides an insight into how selection 
criteria for taking network-based decisions can be developed and can assist in the design 
of strategies to overcome the barriers that inhibit the process. This study also contributes 
to establishing guidelines that would influence the process of decision-making regarding 
investments, partnering and resourcing during the BCP. This will provide researchers and 
managers with information on the type of network-based interactions that should be 
avoided and the kind of network-based interactions that can be employed to develop 
commercialisation strategies. 
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1.3.3 Study 3: Ecosystem Mechanics and its Effect on the Process of biotechnology 
Commercialisation 
Building upon Study 2, Study 3 identifies the different types of network influences that 
generate dynamics around the BCP. It does so by identifying the different kinds of 
network interactions and whether the effects of such interactions on the stages of the BCP 
are negative or positive. Studies on business ecosystems have focused on understanding 
the evolution of different network interactions that emerge as a result of the interplay 
among the key dimensions of a business ecosystem (Adner 2006; Peltoniemi & Vuori, 
2004). The heterogeneous nature of the networks influences exploration and exploitation 
of scientific knowledge and technologies (Iansisti & Levien, 2004). Given that the 
dynamic nature of network ecosystems affects the technology commercialisation process, 
it made sense to study the effect of the changing network dynamics. 
A qualitative approach was employed. Semi-structured in-depth interviews were 
conducted with 30 biotechnology innovation and commercialisation experts. The data 
collection approach was the same as for Study 2; the participant profiles were also the 
same. 
The collected data were subjected to three rounds of coding and analysis. The first round 
of coding identified 30 network-related interactions. The second round of coding grouped 
them into 12 themes based on the types of interactions. The third round further arranged 
them into four key categories, classified as network movement, structure, relationship and 
acuity. The data analysis process cycled between the data and literature to develop a 
detailed understanding of the emerging themes (Gioia, et al., 2013; and Tierney, 2016). 
This research advances the network ecosystem and industrial marketing literature by 
investigating the BCP from an ecosystems perspective. This study contributes to 
expanding the knowledge and understanding of the motives and manifestations of the 
network exchanges and their role in generating network dynamics during the BCP. It also 
contributes to understanding the network behaviour by identifying whether the 
interactions have a positive or negative influence on the process. This will allow managers 
and researchers to understand how individual interactions can alter the course of the BCP. 
By studying the interactions, managers can identify the cause of conflicts during the 
process and design strategies to eliminate them by applying a proactive approach. The 
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identification of these interactions would assist in mapping resource development 
pathways and relationship development techniques. 
Overall, the findings from Studies 1, 2 and 3 will provide multiple actor-perspectives on 
how BCP progresses within an ecosystem and how firms can control and manage the 
effects of network involvement to favour the commercialisation of biotechnology 
innovations. 
The studies are written in journal format mainly a QI-level journal with a high impact 
factor (e.g., the R & D Management journal). Other journals with similar rankings in the 
fields of management, innovation and industrial marketing are assumed to be suitable 
publication platforms to publish the information on this topic. The focus of the selected 
journals will align with this research as the journals expand knowledge in the areas of 
innovation management, social innovation processes, and technology transfer and 
commercialisation activities. 
1.4 Thesis Structure 
This thesis has been organised into five main chapters. Chapter 1 describes the context of 
research, conveys the research questions, sets out the thesis aims and objectives, and 
provides a synopsis of the methodology employed for the research. Chapter 1 also 
identifies the overall scope of this research and describes some limitations to the research. 
Chapters 2, 3 and 4 (Study 1, 2 and 3 respectively) address the research problem through 
different types of network analysis: network effects and their impact, its impact effects 
on the BCP. Each chapter is structured with sections for literature review, methodology, 
findings and contribution. Each paper presents theoretical and managerial contributions. 
Chapter 5 provides an overall discussion of the findings and the causal links between the 
different research problems. It provides a combined view on how networks influence the 
BCP and an overall conclusion regarding this research. It also discusses future research 
possibilities regarding biotechnology commercialisation networks. A series of appendices 
will display supporting evidence associated with the research. 
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1.5 Summary 
This chapter has introduced the background to the research that identifies an argument 
for poor commercialisation of the biotechnology industry and lack of understanding about 
the effects of networks on the BCP. The research aims were stated and a series of 
questions have been proposed to focus on this research activity. The research problem, 
research questions and a justification of the problem to signify the importance of this 
research were outlined. 
A methodological approach was described, which included conducting a literature 
review, developing an initial conceptual framework using the method of content analysis, 
collecting data using semi-structured interviews and then using coding, thematic analysis 
and triangulation techniques for analysis. An outline for each chapter of the thesis was 
provided and the scope and limitations of this research were outlined. Given the 
framework of this research, the next chapter covers Study 1. It develops a framework for 
understanding the research problem.  
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Chapter 2: A Conceptual Model of the Required Network 
Effects for Commercialisation of new Biotechnology 
Innovations (Paper 1) 
 
Abstract: To innovate successful, new, technologically advanced and commercially 
viable products, firms undergo a series of steps that gradually leads to 
commercialisation, often with support from network partners. Previous research 
explores the contribution of network members and their activities to the initial stages 
of the innovation process. However, there is limited information about the influence 
of these surrounding business networks on the commercialisation stage. This paper 
reviews the current knowledge on the influence of business networks on the 
commercialisation of highly innovative new technologies and suggests the focus for 
future research. This study contributes to both organisational innovation management 
and academic network theory through a model that is expected to guide future 
commercialisation activities. 
Keywords: innovation; commercialisation; networks; biotechnology innovation 
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2.1 Introduction 
Biotechnology innovations are developed through a new product development process 
under the influence of interdependent business networks within a network ecosystem 
(Baraldi & Stormsten, 2009; Chen & Lin, 2017; Qi Dong, McCarthy, & 
Schoenmakers 2017; Jiang, Xia, Cannella, & Xiao, 2018; Olbert & Muller, 2015). The 
Biotechnology product development process is complex in nature due to the 
integration of living organisms in technology-based production processes. Hence 
there is a strong need for inter and intra organisational collaboration and alliance 
formation to access resources which the innovating firms cannot manage individually 
(Sytch & Bubenzer 2008; Yoon et al 2015). The network ecosystem consists of actors, 
resources and activities (Ford et al. 2008; Hakansson & Johanson, 1992; Hakansson 
& Senhota, 1995) that provide access to complementary resources that are required 
for the management of the innovation and commercialisation process (Aarikka-
Stenroos & Sandberg, 2014; Kirchberger & Pohl, 2016; Miles, Miles, & Snow, 2005; 
Romero, 2018; Tinoco & Ambrose, 2017). Commercialisation is the last stage of the 
new product development process, which involves taking new products and services 
to market (Aarikka-Stenroos & Sandberg, 2014; Clayton, Feldman, & Lowe, 2018; 
Miller, McAdam, & McAdam, 2018). The network components that support the 
product innovation process also extend their support to the commercialisation process 
(Aarikka-Stenroos & Sandberg, 2014; Clayton, Feldman, & Lowe, 2018).  
There are increasing number of publications that have attempted to examine the role 
of business networks and its components during the Biotechnology innovation 
process, it identifies the influence of biotechnology networks during all stages of the 
new biotechnology product development process (Auserwald & Dani, 2017; Brunetta, 
Boccardelli, & Lipparini, 2018; Gay & Dousset, 2005; Gilsing & Nooteboom, 2006; 
Hu & McNamara, 2017; Rampersad, Quester, & Troshani, 2010). However, the 
commercialisation of Biotechnology products which is a challenging task for the 
innovating organisations specifically in Australia, due to the decreasing rate of 
commercialisation within the Australian biotechnology industry (AusBiotech, 2016; 
AusBiotech Snapshot, 2017; Parliament of Australia, 2014; Vitale, 2004), has limited 
explanation in the broad network innovation literature.  
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The Biotechnology commercialisation process (BCP) has assumed considerable 
importance in the past decade (Baraldi & Stormsten, 2009; Chen & Lin, 2017; 
Hagedoorn, Lokshin, & Malo 2018; Leppaaho, Chetty, & Dimitratos, 2017; lbert & 
Muller, 2015; Roesler & Broekel, 2017) as some of the key Biotechnology network 
stakeholders have raised concerns regarding the poor commercialisation rate in 
Australia . For the Australian government it is important to find a solution to take 
potential innovations to market through successful commercialisation pathways 
(AusBiotech Snapshot, 2017; Bio-Savvy, 2016; Parliament of Australia Website, 
2014; Vitale, 2004) for development of innovations for public welfare. For 
Biotechnology companies, the innovation and commercialisation processes are the 
key drivers for the success and are an important tool for the organisation to sustain 
them in the market (Kunz & Lloyd, 2017; Prajogo, 2016; Velu, 2016). Innovation and 
commercialisation activities provide a competitive advantage to an organisation and 
surrounding networks add value to these processes (Aarikka-Stenroos & Sandberg, 
2014; Prajogo, 2016; Tinoco & Ambrose, 2017; Velu, 2016). The economically-
beneficial biotechnology industry, like other tech-based industries largely depends on 
business networks (Kim & Lui 2015; Yoon, Lee, Song 2015); hence, partnerships, 
ventures, collaborations and alliances are of critical importance, as mentioned by 
industry managers in industry reports (AusBio Feature, 2016; AusBiotech Snapshot, 
2017; Auserwald & Dani, 2017; Vitale, 2004). The literature also highlights the 
importance of and evidence for network involvement during the BCP (Aarikka-
Stenroos & Sandberg, 2014; Clayton et al. 2018; Miller et al., 2018) and it reveals a 
growing body of knowledge regarding the significance of a networked BCP. However, 
few studies shed light on the underlying network mechanisms that affect the BCP.  
Despite the existing research, the Biotechnology network landscape still needs to be 
better understood. Specifically, the commercialisation end of the Biotechnology 
innovation process. Hence, it becomes imperative to understand the effects of business 
networks during the different stages of the BCP. Given the significant need to improve 
the understanding of the impact of Biotechnology networks with a focus on the 
commercialization of the Biotechnology innovations (Chen & Lin, 2017; Hagedoorn, 
et al.  2018). The interest of this study lies in the identifying the types of network 
effects anf how they impact the stages of a BCP.  
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A systematic literature review has been a dominant approach to identify the 
conceptual links between different network components and technology innovation 
management processes in the industrial marketing and innovation management 
domain (Saebi & Foss, 2015; Takey & Carvalho, 2016). Several studies have 
employed a content analysis approach to examine the links between specific network 
components and the technology commercialisation process, such as Aarikka-Stenroos 
and Sandberg (2012) and Aarikka-Stenroos and Sandberg (2014). Aarikka-Stenroos 
& Sandberg (2014), published a content literature analysis broadly understanding the 
role of divergent network actors on the process of technology commercialization. This 
study adopts a similar content analysis approach to develop a network-integrated 
biotechnology commercialisation framework by reviewing the innovation, 
commercialisation and network management literature. This study examines the 
characteristic of commercialization networks interactions and then suggests a pathway 
through which the underlying mechanisms that lead to development of network 
interactions influencing the BCP can be identified and examined.  
Recent research has focused on understanding the effects of networks on 
biotechnology innovation processes by examining the role of network relationships 
(Moller & Halinen, 2017; lbert & Muller, 2015; Partanene, Chetty, & Rajala, 2014;), 
network actors (Broekel, Fornahl, & Morrison, 2015; Cohen & Munshi, 2017; lbert & 
Muller, 2015; Roesler & Broekel, 2017), network resources (Laurell, Achtenhagen, & 
Andersson, 2017; Salman & Saives, 2005; Zheng, Liu, & George, 2010) and network 
activities (Aarikka-Stenroos, & Ritala, 2017; Gertler & Levitte, 2005; Roesler & 
Broekel, 2017), with some of them, using an integrated model approach. The 
aforementioned literature also indicates the need for more network-based perspectives 
of the commercialisation process (Aarikka-Stenroos & Sandberg, 2014). To assist in 
examining the impact of different network effects on BCP this study proposes an 
integrated conceptual model of a networked commercialization process. In doing so, 
Further, the development of a conceptual framework will facilitate the identification 
of areas where there is limited information regarding the influence of network 
interactions on the BCP.  
This research aims to contribute to the commercialisation management and industrial 
marketing literature by advancing the knowledge of network-based interactions 
around the process of BCP by overviewing a large numbers of ex-ante network 
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interactions which then becomes a point for future research. By synthesizing the 
existing results this study can advance the network management literature by mapping 
of these network-based interactions around the BCP can channel future studies 
focussing on the network-based technology process-mapping. This study also 
provides a conceptual framework that affords an improved understanding of 
commercialisation outcomes (Florida & Kenney, 1988; Kortum & Lerner, 2000) that 
are a result of network-based interactions; this framework will assist researchers and 
industry professionals seeking to understand the networked BCP. Lastly, by 
identifying the network interactions and their effects, it is expected that this study will 
also facilitate managers in selecting collaborations and relationships that are 
advantageous in terms of achieving successful commercialisation outcomes. 
The following section discusses the theoretical focus and key concepts, the section 
after that discusses the methodology by discussing the details of the process of content 
analysis. The next section discusses the theoretical analysis and the conceptual 
framework. The final section discusses the conclusion, implications and future 
research. 
2.2 Theoretical Focus and Key Concepts 
The definition of innovation and innovation process in the scientific literature varies 
greatly from one domain to another, therefore a clarification is needed in this study to 
suggest the meaning of innovation for this study. In this study, Innovation refers to 
the development of unique and productive solutions that contribute to resolving 
particular problems by generating new products, services, protocols and systems 
(Dosi, 1982; McDermott & O’Connor, 2002). Here the innovation process only 
includes the ideation and development of new products and services. The established 
literature on innovation management has included exploitation of newly developed 
products and services, a process known as commercialisation, as a part of the 
innovation process (Auserwald & Dani, 2017; Brunetta, Boccardelli, & Lipparini, 
2018; Gay & Dousset, 2005) however in some studies commercialisation is 
considered a complex process that runs parallel to the innovation process (Aarikka-
Stenroos & Sandberg 2014), specifically in the recent innovation management 
literature that focuses on understanding agile and lean innovation models (Cooper 
2017; Kumar, Luthra, Govindan & Kumar 2016; McAdam, Miller & McAdam 2018). 
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For simplicity this study defines commercialisation as a process of introducing 
potential and viable products and services (innovations) into their respective markets. 
It is the final and most crucial phase of the innovation process (Luoma, Paasi, & 
Nordlund, 2008) 
As this study aims to examine the diverse literature, the term ‘commercialisation’ has 
been employed in a broad sense, encompassing concepts of diffusion, adoption and 
launch based on diverse perspectives. A commercialisation process facilitates the 
innovating organisation to generate profits by taking new products to market through 
strategic planning, marketing activities and organisational networking (Aarikka-
Stenroos & Sandberg, 2014). To take an innovation to market, it is important to 
introduce the product to market, which is done through the launch process (Cooper, 
2017; Di Bendetto, 1999). The term ‘adoption’ refers to the acceptance or rejection of 
a technological innovation by an actor in the commercialisation network (Straub, 
2009) and ‘diffusion’ is the process through which the innovation is dispersed in the 
market and within the network (Bianchi, Benedetto, & Franzo, & Frattini, 2017; 
Millers, 2018; Rogers, 1976). Launch, adoption and diffusion activities may overlap 
and interact during the initial stage of the innovation and commercialisation process. 
The process of technology adoption, diffusion and launch involves activities being 
network dependent are constructive concepts to understand the influence of networks 
during the commercialisation process.  
The innovation and commercialisation processes have been described in the literature 
as systems whereby diverse resources (Hsieh Yeh, & Chen, 2010; Ivens, Pardo, Salle, 
& Cova, 2009) with different configurations (Lenney & Easton, 2009) are combined 
together and transformed into useful innovations. Both innovation and 
commercialisation processes are network bound (Aaboen, Dubois, & Lind, 2013; 
Vowles, Thirkell, & Sinha, 2011). In this study ‘networks’ are defined as entities that 
provide complementary assets to innovating and commercialising organisations that 
are requires for exploring and exploiting new ideas, products and services (Ballantyne 
& Williams, 2008; Kim & Rhee, 2017; Mouzas & Ford, 2009). Innovating 
organisations have to develop new resources, knowledge and competencies to 
successfully commercialise a viable innovation (Lehtimaki, 2017; McDermott & 
O’Connor, 2002). Firms often collaborate or ally with other competent firms to 
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innovate efficiently and commercialise innovations (Aarikka-Stenroos & Sandberg, 
2012; Doloreux, 2004; Kim & Rhee, 2017; Vanhaverbeke & Cloodt, 2005). The 
established literature on technology commercialisation highlights the importance of 
network involvement during the technology commercialisation process to access the 
resources required for commercialisation (Aarikka-Stenroos & Sandberg, 2012; 
Brugmann & Prahlad, 2007; Kim & Rhee, 2017; Siegel et al., 2004; Woodside & 
Biemans, 2005).  
The emerging body of literature suggests that an interaction-based network approach 
is important for understanding the dimensions, characteristics, attributes and effects 
of networks on a process. In this study, interactions within a network are defined as 
resource exchanges, linkages, ties, communications and different network activities. 
Previous studies have examined the effect of networks using the individual network-
based interaction perspective (Coviello, 2006; Johnston, Peters, & Gassenheimer 
2006; La Rocca, Hoholm, & Mørk 2017; Moller, 1995; Woo & Ennew, 2004). For 
example, Moller (1995) emphasised understanding the development and evolution of 
business relationships from an interaction perspective. Woo and Ennew (2004) used 
the interaction-based view of business relationships to understand the dimensions of 
business relationships that affect the quality of the relationship between actors. 
Johnston et al. (2006) also attempted to study network dynamics using the interaction-
based view and recommends the use of the interaction-based perspective as a tool for 
examining network structure and characteristics for different industries. Research 
conducted by Halinen, Medlin, & Törnroos, (2012) and Medlin & Saren (2012) used 
the interaction approach to explain the role of human time in process-based networks, 
which aligns well with the interaction-based network approach the present study 
applies to understand the BCP. A recent study conducted by La Rocca, Hoholm, & 
Mørk (2017) highlighted the importance of an interaction-based approach to 
investigate multiple cross-sections of a business process in order to understand the 
underlying interdependencies and multiple fluid roles of network actors during a 
process.  
This study uses the actor-resource-activity (ARA) framework (Hakansson & 
Johanson, 1992) to study the interactions that transpire between the ARA components 
and lead to commercialisation. It also uses the ARA framework as an analytical tool 
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to understand the effect of the interactions on the Biotechnology commercialisation 
process. Based on the ARA framework (Hakansson & Johanson, 1992), the network 
influences the internal and external processes through three network-based 
components in an integrated manner (Ford, Gadde, Håkansson, Snehota, & 
Waluszewski 2008; Håkansson & Snehota, 1995). The first component is actor bonds 
(Ford & Mouzas, 2008; Masuda, Liu, Reddy, & Frank 2018; Vargo, Wieland, & 
Akaka, 2015), where members of the network interact individually to their mutual 
benefit. The second component is activity links (Biemans, 2018; Pelikka & Lauronen, 
2007) that has integrated activities and coordination. The third component is resource 
ties (Ivens et al., 2009; Aarikka-Stenroos & Sandberg, 2014), where a combination 
and exchange of tangible and intangible products and services materialise, with each 
involved actor adapting to the needs of the other actor (De Silva, Howells, & Meyer, 
2018; Hakansson & Senhota, 1995). 
As noted in the literature of commercialisation networks a number of literature 
reviews, and content analysis present role of different network actors, relationships, 
resources and activities. Nonetheless, the published analysis is insufficient to 
understand the characteristics of network effects that influence the different stages of 
the BCP. Thus far, an integrated networked commercialisation process has not been 
investigated, in adequate detail (Aaboen, Laage-Hellman, Lind, Öberg, & Shih, 2016; 
Miller, McAdam, Moffett, Alexander, & Puthusserry, 2016). In particular a holistic 
approach to understand the impact of different network-based interaction perspectives 
on commercialisation is not well grounded (Aarikka-Stenroos & Sandberg, 2014; 
Aaboen, La Rocca, Lind, Perna, & Shih, 2017). Instead, researchers have focussed on 
understanding the role of different network effects on the during the innovation 
process which leads to a partial understanding of network effects and their 
involvement in taking new Biotechnology products to market (Chen & Lin, 2017; 
Hagedoorn et al., 2018; Rojas, Solis, & Zhu, 2018; Roseler & Broekel, 2017). Table 
1 illustrates several examples of the links between the different network actors, 
resources and activities and their effects on the biotechnology innovation process. 
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Table 1: Effect of ARA Network Components on the Innovation Process 
Actors Innovation Resources Effect on Innovation 
Stakeholder Market knowledge 
(Clauss & Ketsing, 
2017), competitive 
advantage (Najafi-
Tavani, Najafi-
Tavani, , Naudé, 
Oghazi, & Zeynaloo 
2013), product 
performance and 
enhanced absorption 
capability (Dodgson, 
2018). 
Financial 
resources 
Purchasing capability, 
human resources, 
sustainable 
competitive advantage, 
crowd funding 
reputation (Lee et al. 
2001; Bertoni & 
Tykvova, 2015; 
Mollick & Robb, 
2016) 
Suppliers Strategy 
development, new 
idea development, co-
designing (Baldwin & 
Hanel, 2003; Dutta & 
Hora, 2017), patent 
development 
knowledge (Alleto, 
Bruccoleri, & 
Mazzola, 2017) 
Informational 
resources 
Product development 
(Raesfeld, 2012), 
increase customer 
needs integration 
(Tsai, 2009) 
Buyer Information and 
market knowledge 
(Lundkevst & 
Yakhlef, 2004; 
Tinoco & Ambrose, 
2017), risk mitigation 
and increase 
compatibility (Gales 
& Mansour-Cole, 
1995), provides 
regular feedback 
(Laage-Hellman, 
Landqvist, & Lind, 
2017 
Technological 
resources 
Competitive 
advantage (Miller, 
2004), knowledge, 
enhanced innovation 
performance (Ahuja & 
Katila, 2001, Dodgson, 
2018) 
Government Interaction 
opportunities, 
learning (Cohen & 
Human 
resources 
Skills, knowledge 
(Marvel & Lumpkin, 
2007), experience, 
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Munshi, 2017), new 
ideas (Baum, 
Calabrese,  & 
Silverman, 2000), 
patenting, licensing 
and low rate of 
revenue growth 
(Baum et al., 2000; 
Grabowski, DiMasi, 
& Long, 2015; 
Bertoni, Colombo & 
Quas, 2017) 
expertise, innovative 
climate (Kehoe & 
Tzabbar, 2015) 
Competitors Establish benchmarks 
(Nieto & Santamaria, 
2007; Tether, 2002), 
collaborative 
extensions (Martin-de 
Castro, 2015), 
motivation (Ritter, 
Wilkinson, & 
Johnston, 2004), risks 
of information 
leakage, time surplus 
and conflicts 
Legal 
resources 
Market penetration 
(Graff et al., 2010), 
protection (Allen, 
2003; Niosi & 
McKelvey, 2018), 
ownership (Hall, 
1992), prevents 
imitation (Amara, 
Landry, & Traore, 
2008) 
The literature in Table 1 indicates that biotechnology networks influence the 
biotechnology innovation process through the contributions of multiple actors, such 
as involved stakeholders, suppliers, buyers, government bodies and competitors. The 
actors contribute in the form of knowledge sharing, enhancing absorptive capacity, 
providing interaction opportunities, understanding of regulatory frameworks, 
innovation protection, learning, process development and improvement. The literature 
also shows that the actors contribute different types of complementary resources in 
the form of finance, information, technology and human and legal resources that lead 
to the development of viable biotechnology innovations. The literature also identifies 
the different types of activities as shown in table 1, within a network that are important 
for the innovation process. For example, the formation and maintenance of 
relationships among actors (Laurell, Achtenhagen, & Andersson, 2017; 
Mazzola, Perrone, & Kamuriwo 2015), acquisition of resources (Cheng & Yang, 
2017; Gadde, Huemer, & Håkansson, 2003; Sears & Hoetker, 2014; Shepherd, 2017), 
reconfiguration of relationships and resources to maintain compatibility with new 
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processes and shared organisational learning (Havila et al., 1999; Love, Roper, & 
Vahter, 2014; Powell et al., 1996). The ability of a firm to learn and utilise that 
information to increase opportunities depends upon the ability of the firm to 
participate in such activities (Powell et al. 1996). 
The biotechnology innovation networks extend to the stages of the BCP owing to the 
flexible nature of networks, which allows the network relationships to extend and 
maximise the innovation potential (Laursen & Salter, 2006). Different network 
activities, actors and resources can serve different roles at different moments during 
the process (Ford, Verreynne, & Steen, 2017). Biotechnology innovation networks 
assist in the shaping and development of biotechnology products and also build a 
pathway for taking biotechnology products to market. 
In addition to that, in published network literature, researchers have focused on 
network perspectives around commercialisation such as role network actors during 
the commercialisation process, the types of collaborations during the process, the role 
of networks for resource mobility and the effects of social media networks on 
commercialisation as shown in table 2 (Aarikka-Stenroos & Sandberg, 2014; Capaldo, 
Fontes, Cannavacciuolo, Rippa, & Sousa 2015; Delerue & Cronje, 2015; Moller & 
Rajala, 2007). As can be observed in Table 2, wide-ranging research has been 
conducted on the roles of specific actors during the commercialisation. For example, 
Jolly (1997) identified the stages of commercialisation and key actors involved in the 
process. Siegel, et al. (2004) and Clayton et al. (2018) studied the role of technology 
transfer offices (TTOs) as organisational actors that facilitate knowledge transfer from 
universities and research organisations. Clayton et al. (2018) emphasised the need to 
gain an improved understanding of the role of TTOs in the commercialisation of 
science-based innovations. The need of network-based resources for managing the 
BCP has been highlighted in many studies. For instance, Bourelos et al. (2012) and 
Farid et al. (2017) underlined the importance of network collaborations for knowledge 
sharing and intellectual capital. Other researchers, such as Harryson (2008) and 
Ninawe and Indulkar (2017), have studied the need for legal resources to assist the 
exploitation of biotechnology innovations and to increase the value of the innovations 
within the global biotechnology ecosystem. 
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The published literature (Baglieri et al., 2015; Kesting et al., 2014; Siegel et al., 2004) 
also shows the role of different network activities, such as coordination, marketing 
evaluation/analysis and reputation building, in developing market opportunities and 
generating new marketing ideas and relationships for commercialising biotechnology  
Table 2: Effect of ARA Network Components on the Commercialisation Process 
Network Components Effect on Commercialisation 
Network Actors 
Government R & D support, early-
stage venture capitalists (Bridge, 2017; 
Jolly, 1997; Philip & Winickoff, 2017) 
Technology transfer office (Clayton et 
al., 2018; Siegel et al., 2004) 
Universities (Chen & Lin, 2017) 
Customers, suppliers and competitors 
(Alletto et al. 2017; Cooper & 
Klienschmidth, 1986; Harrington & 
Srai, 2017; Moktar & Velu, 2018) 
Network champions (Woodside & 
Biemans, 2005) 
Multinational corporations (Agmon & 
Von Glinow, 1991) 
Stimulating entrepreneurship, new schemes for 
funding and building infrastructure and policy 
designs (Bridge 2017, Philip & Winickoff 2017) 
Lack of actor commitment modulates value of 
the patent (Siegel et al., 2004) 
TTO & Multi-national companies facilitate 
global technology and knowledge transfer 
(Clayton et al. 2018; Siegel et al., 2004) 
Generation and adoption of new technologies 
(Chen & Lin, 2017) 
Access to R & D and smooth flow of knowledge 
(Alletto et al., 2017; Moktar & Velu, 2018) 
Market credibility and reliable data from 
customer involvement (Harriangton & Srai, 
2017) 
Quick market take-offs for new innovations 
(Woodside & Biemans, 2005) 
Weak network links hinder rapid 
commercialisation (Harryson, 2008) 
Network Resources 
Information, intellectual capital; 
knowledge (Amponsah & Adams, 
2017; Bourelos, Magnusson, & 
McKelvey 2012; Farid, Hakimian, 
Ismail, & Nair, 2017) 
Funding, capital and investments 
(Yoon, Rosales, & Talluri, 2017) 
Grants (Datta Avimanyu, Mukherjee, 
Debmalya, Jessup, & Len., 2014) 
Negotiation power and social networks 
(Brugmann & Prahlad, 2007) 
Social capital (Ortiz & Donate, 2018; 
See, 2003). 
Licensing, patents, Intellectual 
Property Rights ( Harryson, 2008; 
Ninawe & Indulkar, 2017)  
Collaboration is a constructive process for 
commercialisation and expedites the process of 
taking innovation to market (Amponsah & 
Adams, 2017; Bourelos et al., 2012; Farid et al., 
2017) 
Strategic partnerships provide different types of 
financial incentives (Yoon et al., 2017) 
Enhances access to extended markets and new 
opportunities (Brugmann & Prahlad, 2007) 
Multi-firm network generates social capital that 
allows shared integration (Ortiz & Donate 2018; 
See, 2003) 
Networking promotes global exploitation and 
increases innovation standards (Harryson, 2008; 
Ninawe & Indulkar, 2017) 
Network Activities 
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Coordination among internal network 
members (Baglieri, Belussi, & Orsi, 
2015; Kesting, Kliewe, & Baaken 
2014; Siegel et al., 2004) 
Marketing activities (Kim, 2018; 
Vowels et al., 2011) 
Reputation building (Fuertes-Callen & 
Cuellar-Fernandez, 2014; Varey 2008) 
Network activities such as market analysis and 
market search activities help in analysing market 
opportunities (Baglieri et al., 2015; Kesting et 
al., 2014; Siegel et al., 2004) 
Networks help in developing new ideas for 
marketing strategies and help in reputation 
building (Kim, 2018; Varey, 2008) 
Network suppliers enhance product adoption 
(Vowels et al., 2011) 
innovations. While the results of such studies add to the understanding of the 
underlying network-based interactions (the result of the aftermath between the ARA 
network components), there is limited information on how these network-based 
effects holistically influence the BCP at different stages. Academic research does not 
indicate a common overall networked commercialization framework. Moreover, 
whether the understanding of network impact from academic findings are applicable 
to all technology-based commercialization processes remains unclear. 
The innovation process is viewed as a complex system of interactions that links the 
network structure of an organisation with its knowledge development and sharing 
capabilities (Bernstein & Singh, 2006). The role of network structures and network 
centrality that affect the process of new product development in the biopharmaceutical 
industry, has been studied by mapping different network linkages and their 
configurations (Mazzola et al., 2015). The role of business incubators in enabling 
biotechnology organisations to acquire technical assistance and business capabilities 
to facilitate the process of innovation has been studied using network interactions as 
a tool of analysis (Scillitoe & Chakrabarti, 2010). The actor-based network interaction 
has been studied to explore the contributions of different network actors during the 
commercialisation process (Aarikka-Stenroos et al., 2014). Much of the research 
evolved as a result of limitations of the established literature in terms of providing an 
integrated interaction-based view of the behaviours of networks and the network 
environments in which innovations are developed and organised for adoption and 
diffusion in the market. Biotechnology innovations are developed within a mesh of 
network-based interactions. As a result, we need to identify and understand network-
based interactions and their influence on the BCP. 
Research studies in the networked biotechnology innovation and commercialisation 
process have come a long way since the early work of Shan, Walker & Kogut (1994) 
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examining the effect of inter-firm cooperation on the process of biotechnology 
innovation. Since then, many scholars have attempted to study the role of networks in 
the biotechnology innovation process (Chen & Lin, 2017; Chiesa & Toletti, 2004; Gay 
& Dousset, 2005; Hagedoorn et al., 2018; Mohannak, 2007; Murray, 2002; Rojas et 
al., 2018; Roseler & Broekel, 2017). Conversely, some scholars have focused on 
understanding the role of networks in the BCP (Aarikka-Stenroos & Sandberg, 2014; 
Chen & Lin, 2017; Fiedler & Welpe, 2011; Weisenfeld, Reeves, & Hunck-
Meiswinkel, 2001). Though the diverse body of research in this area has provided a 
decent understanding of the roles that networks play during the BCP, these studies are 
nonetheless intrinsically limited because they took a broad network-based view and 
did not consider the holistic impact of the underlying network-based mechanism that 
directly and indirectly affects the BCP at multiple stages. In addition, the 
biotechnology innovation studies that considered an interaction-based approach 
focused on the front end of the innovation process and did not separately study the 
commercialisation stage. 
In sum, despite network interactions and some effects have been analysed in academic 
literature, additional understanding of network interactions and effects is needed to 
evaluate the impact of such impacts on the stages of the commercialisation process. 
Specifically, network effects that can improve the commercialisation rate of 
Biotechnology innovation are required. To summarise, managers and emphasise the 
importance for understanding the network effects in research and practise with a need 
for a better understanding of the Biotechnology commercialisation process.  
This study has an explorative nature, with an objective to increase the understanding 
of network impact on the process of Biotechnology commercialisation by developing 
an integrated conceptual model. A model that would help in understanding the links 
between the stages of the BCP and different network interactions. It intends to do so 
by applying the knowledge from the previous literature and study the effect of 
network-based interactions on the BCP. It is expected to shed light on the level of 
involvement and impact of the network interactions and extend the knowledge of the 
individual network interactions together in a functional process of taking valuable 
innovations to market. 
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2.3 Methodology 
The research problem was addressed by conducting a content analysis of the academic 
articles, that theoretically discussed innovation networks, commercialisation networks 
and the biotechnology innovation and commercialisation processes. The content 
analysis also included the discussion from industry reports and business articles that 
discuss the current innovation and commercialisation scenario within the 
Biotechnology industry. 
2.3.1 Inductive content analysis 
An inductive content analysis method was selected to analyse and review the literature 
from the articles (Elo & Kyngas, 2007), as shown in Figure 1. Several researchers, 
such as Cavangh (1997), Elo and Kyngas (2007) and Ledermann (1991), have 
suggested the use of content analysis to study processes, while a few researchers, such 
as Aarikka-Stenroos and Sandberg (2014), Oliver and Ebers (1998) and Reingen and 
Kernan (1986), have applied this method to conduct studies related to network 
referrals, network clusters and network mapping to understand the role of networks in 
different contexts. This method of analysis provided the flexibility to identify the 
multidisciplinary nature of the phenomenon, as there existed diversity in disciplines 
within which business networks related to technology commercialisation were 
discussed (Aarikka-Stenroos & Sandberg, 2014). This diversity in disciplines is based 
on the application of biotechnology to several industries, such as bioprocessing, 
pharmaceuticals, policy development and marketing (Arora, 2005; Arundel, 2003; 
Visalakshi & Mohan, 2002; Walsh, 2012). Content analysis is a relevant method for 
this study as it eliminates researcher interference during the study of the phenomena 
and allows for easy handling of large amounts of data (Krippendroff, 2004). 
Studies suggest that the use of content analysis leads to the development of a 
conceptual framework (Campbell, Pound, Pope, Britten, Pill, Morgan, & Donovan 
2003; Huberman, & Miles 1994; Levering, 2002). Based on the research by Huberman 
and Miles (1994), developing a conceptual framework would help in identifying the 
key network components and the different relationships between those components 
and the stages of the BCP. 
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The content analysis method involves several stages specifically designed to achieve 
a logical and categorical method for reviewing the relevant literature with the aim of 
developing a strong conceptual understanding. The stepwise approach was based on 
the usual content analysis methodology and parts of it were adapted to suit the research 
process studying the specific network phenomena (Jack, 2005). The methodology was 
divided into three key stages, as shown in Figure 1: (i) identification of relevant 
journal articles, (ii) analysis of the content to generate conceptual categories and (iii) 
the formation of the conceptual model based on the key findings from the analysis. 
Based on the analysis, the findings were discussed. 
2.3.1.1 Identification of relevant articles 
The objective of the research was to develop an integrated conceptual model of a 
networked Biotechnology commercialisation process based on the analysis of the 
exiting literature, which would assist in linking the areas of network influence with 
the stages of the commercialisation process. This builds a channel for identifying the 
areas of limited information. Despite the significant number of studies conducted on 
innovation, networks and commercialisation, little effort has been made to interpret 
these findings analytically to form a comprehensive review of current knowledge and 
further link this knowledge to identify network effects on the BCP. The complexity of 
this issue, which relates to the lack of commercialisation and the limited knowledge 
of network effects on the process, requires a content analysis of all the different 
aspects of the existing literature and the empirical studies. The identification of articles 
for analysis involved multiple stages, designed to provide an organised and overt 
method for reviewing the content (Pittaway, Robertson, Munir, Denyer, & Neely 
2004). 
As suggested by Aarikka-Stenroos and Sandberg (2014), the selection of academic 
databases for this research was based on the level of flexibility they would provide 
because of the multidisciplinary nature of the phenomenon. For this research, Emerald 
and Science Direct were selected, as they cover a wide range of high-quality journals 
in the fields of science and technology, product and technology management. Another 
source was Australian Biotechnology industry-based business reports which were 
searched using specific keywords on a search engine as there are no specific databases 
for Australia specific Biotechnology industry reports. The sources used were annual 
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reports from the largest Australian Biotechnology network organisation AusBiotech, 
Australian government websites and some company generated industry reports. The 
business reports and journals were selected on the basis of the year of publication, 
specifically from 1995–2017, the period of 22 years was selected as it allows the 
analysis of a wide-range of articles which assist in understanding the evolution of the 
technology innovation and commercialisation processes. It also allows to understand 
the involvement of networks and their contributions to the innovation and 
commercialisation processes. Only the business articles that discussed the innovation 
process, commercialisation process, commercialisation management and 
biotechnology commercialisation management with reference to network 
involvement and different network studies were selected. 
An initial search of the databases was started by searching the first basic keyword 
string: innovation and networks (Pittaway et al., 2004). The results were analysed and 
then further keywords associated with innovation and networks, such as new product 
development, clusters, organisational networks, linkages and webs, alliances and 
collaborations were also taken into consideration. Then the next keyword string—
network and commercialisation—was searched for, and related words such as 
technology transfer, translation of technology, licensing, patenting and spin-offs were 
analysed. The third string of keywords was network and technology. The third string 
showed results from different technology-based industries; considering the wide 
application of biotechnology in various other fields, terms such as biofuel, 
nanotechnology, stem-cell technology and several others were used. The fourth 
keyword string was for biotechnology and commercialisation and biotechnology and 
networks. All the words related to the main category of terms were considered 
important and analysed. 
All the main strings were searched in both databases. Based on the initial search, 
Science Direct showed 128,911 articles and Emerald showed 37,013 relevant articles. 
These numbers include results based on the main strings and the strings of relatively 
similar terms in all categories. As shown in Figure 1, the number of articles from all 
databases was reduced to a relevant number based on the filters applied to the results. 
These filters included the title of journals, whether they were peer-reviewed and 
whether they constituted original research. This assisted in maintaining the reliability 
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of the results. This was subjected to another round of evaluation and elimination based 
on the number of articles that were repeating in each string. 
The extracts selected for analysis were assessed based on the inclusion and exclusion 
criteria. This was done in two stages. Based on the exclusion criteria, the first stage 
was to identify the relevant articles based on title and the abstract. The title and 
abstract were read, and the reference list of articles was referred to for the selection of 
the most suitable articles. The articles were then classified into three levels of priority, 
where 1 represents the most important and 3 represents the least important. At this 
stage using the inclusion criteria, the level of importance was established. It was based 
on the title including at least two key terms (e.g., networks and innovation or 
collaborations and commercialisation) and the abstract discussing the specific details 
of network characteristics and behaviours concerning technology innovation and 
transfer processes. The priority 1 category included articles that discussed networks, 
commercialisation and biotechnology in detail, the priority 2 category included 
articles that discussed either of the key terms with reference to other technology-
related network behaviours, and the priority 3 category included articles that discussed 
key terms relevant to networks and commercialisation but not specific to technology-
based industry. 
The articles in categories 1 and 2 were compiled and read with two other researchers 
to ensure the validity of the content and subject it to triangulation. After review and 
discussion, 115 articles were selected from academic journals and 7 business reports 
and articles were selected for content analysis (See Appendix A in this study). The 
business articles were selected on a similar basis—if they showed evidence or 
examples of network involvement during the process of innovation and 
commercialisation within the industry. The selected articles were subjected to 
thematic analysis and open manual coding. The articles were reviewed in detail for 
analysis. 
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Figure 1: Figure of Inductive Content Analysis 
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2.3.1.2 Analysis of the content to generate conceptual categories 
The analysis started with a first round of reading to establish a broad perspective of 
the focal research. Based on the content of the article, the papers from categories 1 
and 2 were further classified into three subcategories: (1) networks, (2) innovation and 
(3) commercialisation. Note that some papers that discussed two categories were 
considered in both categories. For example, if any paper included networked 
innovation as a key theme it was included in both categories. The classification 
percentages are shown in Appendix B of this study. From the shortlisted articles 
72.13% were related to the category of networks, 33.60% were related to innovation 
and 31.14% were related to commercialisation literature.  
The papers were then analysed using the open coding method (Elo & Kyngas, 2007), 
whereby relevant information was marked under headings and notes were made on 
article margins. Specific information was collected under emerging codes (Burnard, 
1991; Elo & Kyngas, 2007). The coding was developed and collated using an excel 
spread sheet. The researchers discussed the relevant categories, and this facilitated in 
sorting similar types of codes into relevant categories. The process of coding the 
content was compiled, evaluated and discussed with other researchers to increase 
reliability (Aarikka-Stenroos et al., 2014). For example, a sample of 30 articles was 
initially coded and then checked by each researcher; the initial coding showed an 87% 
agreement, which improved to 94% as the conceptual model was developed. The 122 
articles were aggregated under the following category headings: 
• Networks 
• Network influences 
• Network outcomes. 
The knowledge of the network related themes was important throughout the analysis 
to configure the links between them (Aarikka-Stenroos et al., 2014). The categories 
networks, network influences and network outcomes were “initial priori” categories. 
Further, based on the researcher’s interpretation, the data from the selected articles 
was classified (see Table 3) into 17 different codes that emerged from the analysis. 
The 17 codes were classified into three different categories: networks (1st), network 
influences (2nd) and network outcomes (3rd). 
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Table 3: Network Effects and its Components 
Categories Networks Network Influences Network Outcomes 
Components/
Codes 
Actors 
Resources 
Activities 
Configurations 
Relationships 
Position 
Complexity 
Control 
Interdependence 
Limitations 
Technology transfer 
strategy 
Capital 
Ownership 
Market intelligence 
Regulations 
Patents 
Licensing 
Number of 
References 
122 24 46 
The analysis of the articles related to biotechnology, innovation and 
commercialisation also resulted in codes and categories that assisted in establishing 
an adapted outline of the BCP. The data were coded and categorised as three phases 
of the commercialisation process: pre-commercialisation, commercialisation and 
post-commercialisation process. The analysis also facilitated the identification of 12 
stages of the BCP: imagining, incubating, demonstration, innovation disclosure, 
market assessment, innovation protection, prospecting, resourcing, licensing, 
adoption, diffusion and sustaining. The stages and phases were categorised based on 
the types of network activities, actors and resources that contributed to the process. 
The details of the BCP and the network contributions during the process are discussed 
later (in the analysis and results section). 
2.3.1.3 The formation of the conceptual model 
The result of this process was a matrix showing links between networks components 
(actors, activities and resources), network influences (configuration, relationships, 
position, complexity, control, interdependencies and limitations), network outcomes 
(technology transfer strategies, capital, ownership, market intelligence, regulations, 
patents, licensing and policy changes) and the BCP. From this information, a model 
showing the points of network influence on the stages of the BCP was developed. All 
the categories and codes were discussed with other researchers; therefore, 
triangulation of data increased the reliability of the findings. The findings were aligned 
with the established literature to check for consistency and validity of the data. 
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2.4 Analysis and Results 
2.4.1 The emergence of networked biotechnology commercialisation process 
A high number of articles showed that research in the areas of a networked BCP is 
growing rapidly as organisations are keen to find solutions to take biotechnology 
innovations to market (AusBiotech Snapshot, 2017; Biosavvy, 2016; Vitale, 2004). 
The established literature has emphasised the need for understanding the BCP from a 
network perspective, as it is known to affect the success and competence of the 
innovating organisations (Aarikka-Stenroos, Sandberg & Lehtimaki 2014; Auserwald 
& Dani, 2017; Clarysee, Wright, Bruneel, & Mahajan, 2014; Gilding, 2008; Owen-
Smith & Powell, 2004). In addition, the literature indicated that a holistic 
understanding involving the examination of the BCP from the perspective of different 
network-based interactions is often missing, so it is important to investigate the effects 
of different network interactions to understand the reasons behind poor 
commercialisation of biotechnology innovations (Sandberg & Aarikka-Stenroos, 
2014; Cross, 2017). 
Early research examined the roles of networks during the BCP by seeking to 
understand the effects of different characteristics and attributes of networks, such as 
inter-firm R & D partnering, collaborations, alliances, inter-firm cooperation 
relationships and clustering (Gilding, 2008; Roijakkers & Hagedoorn, 2006; Stuart, 
Ozdemir, & Ding, 2007; Tinoco & Ambrose, 2017). Most of the research conducted 
in this discipline is more recent, mainly from the period 2004–2018 (Bourelos, 
Magnusson, & McKelvey 2012; Chiesa & Toletti, 2004; Cooke, 2004; De Coster & 
McEwen, 2018; Delerue & Cronje, 2015; Gilding, 2008; Harrington & Srai, 2017; 
Kollmer & Dowling, 2004; Lee et al., 2010; Rampersad Quester, & Troshani 2010; 
Roijakkers & Hagedoorn, 2006; Salman & Saives, 2005; Todtling & Trippl, 2007). 
This indicates that, although industry and academia are paying attention to the role of 
networks during the BCP, the research in this area is still developing. 
This analysis also led to the finding that the effects of networks on the BCP comprise 
a multidisciplinary phenomenon. There is a significant variety of disciplines that have 
discussed the role of different types of network characteristics during the BCP, such 
as strategic management, industrial marketing, information and technology, and 
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entrepreneurship. Several journals within different disciplines have published articles 
and papers investigating the role of individual network components during the BCP. 
2.4.1.1 Networked biotechnology commercialisation process 
Analysis of the research articles revealed how different network-based activities, 
actors and activities contribute to taking new biotechnology innovations to market 
through the process of commercialisation. The BCP as explained in the literature is a 
combination of activities divided into phases: pre-commercialisation, 
commercialisation and post-commercialisation. Each phase has different stages based 
on the types of activities that occur during that phase (see Figure 2). 
 
Figure 3: Biotechnology Commercialisation Process. 
The BCP consists of a total of 12 overlapping stages: imagining, incubating, 
demonstration, innovation disclosure, market assessment, innovation protection, 
prospecting, resourcing, licensing, adoption, diffusion and sustaining. The stages 
differ not only based on activities but also based on different knowledge and resource 
needs and the contributions of different network actors. The brief description of 
activities conducted at each stage of the BCP is highlighted in Table 4. The stages of 
the pre-commercialisation phase that include imagining, incubating, and 
demonstration and innovation disclosure are the planning stages of the BCP (Jolly, 
1997; Khilji Mroczkowski, & Bernstein., 2006; Price, Huston, & Meyers 2008; 
Kutvonen, Torkkeli & Lin, 2010; Zucker & Darby 2001). Several network activities 
at this stage are related to market assessment, preliminary market planning and 
strategizing, and product testing. Diverse network relationships can enhance idea 
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generation and knowledge creation capability during the initial stages of technology 
transfer (McAdam, Miller, McAdam, & Teague 2012; Miller, McAdam, Moffett, & 
Brennan, 2011). The analysis of the articles showed that the activities during the pre-
commercialisation stages share commonalities with the intermediate stages of a new 
product development process. 
Table 4: The Phases and Stages of Biotechnology Commercialisation Process 
Phase 1: 
Pre-Commercialisation 
Phase 2: 
Commercialisation 
Phase 3: 
Post-
Commercialisation 
Stage 1: Imagining Stage 5: Market 
Assessment 
Stage 9: Licensing 
Strong competition of 
ideas 
Identification of the 
market requirement and 
consumer insights 
Identify the areas of focus 
Market assessment to 
design entry strategy 
and technology 
exploration strategy 
Development of a 
preliminary 
commercialisation 
strategy 
Negotiation between 
selected participating 
network actors 
Preparation of legal 
agreements and 
defining negotiations 
and business terms 
Decisions regarding 
launch, spin-off or 
market introduction 
Stage 2: Incubating Stage 6: Innovation 
Protection 
Stage 10: Adoption 
Selection of appropriate 
technologies for 
application that would add 
value to the final outcome 
Identification of the 
potential of the new 
technology 
Designs to achieve grants 
and funds, and to attract 
investors 
Exposes the innovation to 
business opportunities 
Innovation is assessed 
for patenting and 
obtaining IPRs, 
trademarks or 
copyrights 
Filing of patent 
applications and 
regulatory approvals 
Tracking competitor 
activities for 
identifying the time to 
enter the market 
Identification of 
market response to 
new technology 
Preparing for a 
market launch 
Marketing analysis 
for projecting sales 
and costs, distribution 
strategies 
Promotion strategy 
design, including 
different 
communication 
channels 
Stage 3: Demonstration Stage 7: Prospecting Stage 11: Diffusion 
Checking product market 
compatibility 
Market testing and 
preliminary consumer 
feedback 
Product pitching to 
other network actors 
Seeking investors, 
partners and funding 
Implementation of 
promotional strategies 
Communicating with 
diffusion channels for 
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Testing strategy 
improvements 
bodies for taking 
technology to market 
Identifying commercial 
outcome expectations 
depending on types of 
collaboration 
diffusing the product 
to market 
Collecting consumer 
responses for growth 
and performance 
measurement 
Stage 4: Innovation 
Disclosure 
Stage 8: Resourcing Stage 12: Sustaining 
Disclosing the product 
prototype to the network 
and stakeholders and 
establish criteria for 
market assessment 
Check if market standards 
and potential viability 
have been achieved 
Selection of 
commercial pathways 
varies depending on the 
type innovation and the 
motivations of the 
participating actors 
The collection of 
resources for 
commercialisation 
Strategy designing for 
market growth and 
product management 
in the established 
market 
This marks the 
growth stage of the 
product lifecycle and 
establishes the value 
of the technology 
after launch 
 
The commercialisation phase consists of the stages of market assessment, innovation 
protection, prospecting and resourcing/commercial pathways (Edwards, 2007; Glick, 
2008; Jolly, 1997; Markmen, Siegel, & Wright 2008). These stages involve key 
activities, such as identifying the market segments for launch, testing products through 
final clinical trial testing, investigating the applicability of the prototypes, searching 
for collaborative opportunities for investments and further building industry 
relationships. The last phase of the BCP is post-commercialisation, consisting of the 
last four stages of licensing, adoption, diffusion and sustaining. The activities during 
this phase are mainly related to launching the product in the market, generating 
commercial outcomes, diffusing the technology, planning for the growth of market 
share and increasing sales outputs. Most activities during this phase are related to 
generating successful commercial outcomes after the product has been introduced into 
the biotechnology network and the market.  
The data also revealed that the BCP is surrounded by integrated network structures 
and each stage has a surrounding network structure with its own actors, activities and 
shared resources, which is a result of numerous network interactions. In this research, 
the interactions were labelled network effects and were classified as network 
influences and network outcomes. The analysis of the articles also showed that each 
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network effect has a different role during the BCP; however, there was a strong 
interdependency between the network-based influences and network-based outcomes, 
which also affects the BCP at various stages. 
2.4.1.2 Identified network effects: network influences and outcomes 
The processes occurring in a business network are the consequences of the multi-
layered tangential interactions (including the unconscious and imperceptible) among 
the individually important actors (Ford & Mouzas, 2008; Hakkanson & Ford, 2002). 
Network effects can be defined as a consequence of single or multiple interactions 
between the actors (at the individual or organisational level), the resource 
requirements and the activities that are conducted to manage and acquire the actors 
and the resources during a process. Analysis of the articles showed that there were 
clearly identifiable network-based interactions or network effects that can be 
classified as network outcomes and influences. The effects were classified into 
influences and outcomes based on the characteristic of the network interactions and 
the resulting effects of the interactions. A detailed description of different types of 
network influences and outcomes is shown in Table 5 and 6, respectively. 
The analysis applied the ARA theory as an analytical tool to understand the different 
types of network-based interactions. The literature provides examples where the 
different permutations and combinations of the interactions among the ARA 
components of the network have influenced functions of the BCP, as highlighted in 
Table 2 of the study. Therefore, to understand the network effects during the BCP, it 
is important to understand the effects of each network influence and outcome in detail 
and then consolidate the findings using an integrated approach. 
2.4.1.3 Network influences and outcomes 
It is evident from the established literature that relationships, interdependencies, 
network configurations, network complexities, network control, network alignment 
and network position are the key influences that result from the heterogeneous 
collaborations and interactions among different actors, their resources and the 
activities that they conduct within the network (Aaboen, La Rocca, Lind, Perna, & 
Shih 2017; Ballantyne & Williams, 2008; Hakansson & Ford, 2002; Montaguti, 
Kuester, & Robertson, 2002). 
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It is interesting to note that different researchers, such as Ballantyne and Williams 
(2009), Ford and Mouzas (2008) and Baraldi & Stromsten (2009, have identified these 
network influences as factors that affect the innovation process. For example, different 
network configurations generate a source of valuable information to stimulate the 
process of biotechnology innovation (Salman & Saives, 2005). Network position also 
influences resource gathering, such that a central position in the network allows the 
accumulation of more knowledge compared with firms external to the network (Ford 
& Mouzas, 2008). It was also noticed that network interdependencies induce 
coordinating behaviour among network members (Montaguti et al., 2002). 
Table 5: Types of Network Influences  
Network Influence Description 
Network relationships Long-lasting, productive exchange activities 
between two or more organisations involved in a 
value-creating business network (Aaboen et al., 
2017; Hakansson & Ford, 2002; Varey, 2008) 
Network 
interdependencies 
Actors in a network depend directly or indirectly on 
other actors or organisations to have specific inter-
firm exchange relations (Ballentyne & Williams, 
2008; Harrington & Srai, 2017; Huang Jong, 2014; 
Montaguti et al., 2002) 
Network configuration Interwoven patterns of relationships and resources 
in a network arranged to be compatible with the 
requirements of the innovation process of an 
organisation (Azzone & Pozza, 2003; Fontes et al., 
2009; Harrington, Phillips, & Srai, 2017) 
Network position The specific place of a firm within a mesh of 
different network relationships (Ford & Mouzas, 
2008; Kong, Wan, , Hu, Su, & Hu, 2017) 
Network control Control is viewed as the influence of actor 
behaviours on each other (Baraldi & Stromsten, 
2008) 
Network limitation Network interactions and exchanges among actors 
that hinder the process of innovation (Goldenberg, 
Han, Lehmann, & Hong, 2009; Harrison & 
Waluszewski, 2008; Harryson, 2008) 
Network complexity Result of cross-functional interactions and 
generates a requirement to induce transparency in 
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the network (Chiesa & Toletti, 2004; Ford & 
Mouzas, 2009) 
 
Network outcomes are the result of the interactions between different network 
influences with the different functions of a process. Based on the analysis of the 
literature, the different types of network outcomes are identified as technology transfer 
strategy, quick market entry, ownership of the innovation, financial resources, 
forecasted market situations, reputation building and social capital (see Table 6). The 
literature discusses evidence of different network outcomes and their effects on the 
innovation process (Althouse et al., 2017; Bertoni, Colombo, & Quas, 2017; Chen, 
Dowling, & Helm, 2011; Chen, Hsu, & Chang, 2014; Ernst, 2003; Evens & Kaitin, 
2014; Festel, 2015; Haywards, Caldwell, Steen, Gow, & Liesch, 2017; 
Kalaitzandonakes, Alston, & Bradford, 2007; Markman, Phan, & Balkin, 2005; Nicol 
et al., 2014; Peres, Muller, & Mahajan, 2010; Saban & Lanasa, Lackman, & Peace 
2000; Seldon, 2011; Walsh, 2012). 
Table 6: Types of Network Outcomes 
Network Outcome Description 
Technology 
transfer strategy 
Transfer of applicable and potential technology between a 
technology-innovating organisation and technology-
applying organisation (Festel, 2015; Markman et al., 2005; 
Perez & Sanchez, 2003; Walker & Ellis, 2000) 
Capital Capital is the financial, natural, physical, social and human 
capability required for conducting different types of 
activities (Benhabib & Spiegel, 2005; Bertoni et al., 2017;  
Galor & Moav, 2004; Goodwin, 2003; Haywards et al., 
2017; Marvel & Lumpkin, 2007; Perez, 2003) 
Ownership The exclusive rights provided to an organisation to own, 
use, sell, transfer, licence, control, further develop and 
exploit new or existing innovations, inventions and ideas 
(Chen et al., 2014; Song et al., 2015) 
Market 
intelligence 
The information obtained through formal and informal 
sources within a network to facilitate the process of 
forecasting and projecting market trends and orientation 
(Evens & Kaitin, 2014; Saban, et al. 2000; Song & 
Thieme, 2009) 
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Network Outcome Description 
Technology 
regulations 
A set of directives and guidelines specified by 
government/bureaucratic authorities using instruments 
such as taxes, technology requirements, trade allowances 
and information disclosures (Althouse et al., 2017; 
Kalaitzandonakes, Alston, & Bradford, 2007; Wiener, 
2004) 
Patents An authorised government license that gives the innovator 
of an idea, concept, product or process exclusive 
ownership and the rights to develop, produce or sell the 
invention within a stated and specific period (Ernst, 2003; 
Nicol et al., 2014; Walsh, 2012) 
Licensing A method of technology commercialisation that involves 
an agreement to transfer the rights of intellectual property 
from one entity (individual and organisation) to another 
that allows controlling, using and selling of the intellectual 
property (Chen, Dowling & Helm 2011; Fosfuri, 2006; 
Powers & McDougall, 2005; Seldon, 2011) 
Market take-off 
strategies 
Strategies designed and focused on increasing sales of 
industrial product innovations after the initial 
commercialisation period (Agarwal & Bayus, 2002; Peres 
et al., 2010) 
 
For example, network outcomes related to technology transfer strategy, capital, and 
market intelligence and ownership affect the ideation to product development stage of 
the biotechnology innovation process (e.g., see Chen et al., 2013; Edwards, 2007; 
Festel, 2015; Graff, Cullen, & Bradford, Zilberman, & Bennett, 2003; Mireles, 2004). 
Supplier networks and early adopters of technological innovation assist in the 
dissemination of technological knowledge and the gaining of market intelligence 
during the innovation process (Evens & Kaitin, 2014; van der Bij, Song, & 
Weggeman, 2003). 
In technology-intensive industries, strategic alliance formation helps to spread the 
costs and risks of innovation (Graff et al., 2010) and in exploiting the capabilities of 
the collaborating organisations (Mowery, Oxley, & Silverman 1996). This further 
helps in designing strategies for rapid penetration in the market and increasing market 
power (Bertoni et al., 2017; Hagedoom, 1993; Mowery et al., 1996). It has been 
observed that venture capital is associated with increases in ownership, patenting and 
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funding, which provides more innovation opportunities (Kortum & Lerner, 2000; 
Montaguti et al., 2002; Nicol et al., 2014). Regulations have been known to exhibit a 
dual effect on technological processes, as they can impede or accelerate technological 
change (Althouse, Bridgman, & Davis, 2017; Parker, 2000; Wiener, 2004). Network 
support assists in resolving problems during innovation processes to achieve the 
required regulatory objectives. This analysis also explains that the process of 
biotechnology innovation through networks and the influence of networks are well 
understood. 
However, this research study aims to identify the influences and outcomes and how 
these influences and outcomes affect the stages of the BCP. The significant 
involvement of networks during the BCP makes it important to question whether 
networks are crucial for the success of the BCP. Do business networks always benefit 
the process, or do they also act as decelerators, blockages or obstacles for the activities 
that occur during the BCP? Do these network components lead to any shifts in network 
dynamics during the process or do they remain the same throughout the process? 
This analysis identified that the research conducted by Ritter and Gemunden (2003) 
explains that networks developed for commercialisation are a part of the networks 
developed for the innovation process. Interestingly, some examples in the 
commercialisation network literature highlight the strong participation of network 
components throughout the BCP. For example, influences such as network 
configuration and network control exert a negative effect on the commercialisation 
process, leading to delays in the adoption of technologies or prompting control-related 
conflicts (Ballentyne & Williams, 2008; Montaguti, ., Kuester, S., & Robertson 2002). 
Research also shows that certain network relationships influence the process 
positively, such as mitigating risks and uncertainties during the commercialisation 
process and facilitating the design of market entry strategies (Lee, 2009; Zain & Ng, 
2006). TTOs assist the researchers to understand the process and significance of 
commercialisation (Aldrige & Audretsch, 2010). Venture capitalists (VCs) and other 
funding organisations provide funding to progress with the process and occasionally 
act as reference points for developing new relationships with other network members 
that are useful for biotechnology commercialisation (Gertler & Levitte, 2005; Kasch 
& Dowling, 2008; George, Zahra, & Wood. 2002). Some government and legal 
outcomes, such as regulations, patents, licensing, policy changes and reputation of 
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network actors, influence the commercialisation process in its initial stages (Cooke, 
2001; Goldfarb & Henrekson, 2003; Lehrer & Asakawa, 2004). However, this 
information is very limited and does not take into account these network effects on 
the specific stages of the process. Moreover, very few studies conducted on 
biotechnology commercialisation networks (Aaboen, Laage-Hellman, Lind, Öberg, & 
Shih 2016; Fernald & Pennings, & Claassen, 2015, Sandberg, B., & Aarikka-Stenroos 
2014) have considered the network perspective to link the activities of the innovation 
and pre-commercialisation stages of the BCP; most have neglected the understanding 
of the underlying interaction-based mechanisms that may inhibit or promote the 
activities involved in taking new biotechnology innovations to market.  
The research only hints as to the active involvement of biotechnology networks during 
the BCP. Nevertheless, there are still some stimulating aspects and problems regarding 
the involvement of networks during the BCP that need to be addressed. The research 
(Sandberg & Aarikka-Stenroos 2014; Chen & Lin, 2017) calls for studies that attempt 
to identify and analyse networks and ecosystems that facilitate the successful 
commercialisation of biotechnology innovations. 
2.4.2 Integrated biotechnology commercialisation process and network 
involvement model 
The analysis of the literature provided the basis for designing a revised and integrated 
conceptual framework of the BCP and network links. Only a few models in the 
literature consider specific attributes of networks to understand the BCP, such as Lee 
et al. (2010) who linked the role of intermediaries to understand the process of 
innovation and to explore the commercialisation stage as a part of the process. 
Sandberg et al. (2014) provided a conceptual framework to understand the role of 
network actors during the technology commercialisation process; their study also 
pointed towards the limited knowledge regarding the effect of networks on the process 
of technology commercialisation. Another conceptual framework by Lehtimaki 
(2017) was designed to examine the commercialisation capabilities build-up process 
in different domains of the organisation by examining the internal network activities 
during the process. 
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In a recent study, Clayton, Feldman, & Lowe (2018) examined the role of 
intermediaries during the BCP through the concept of entrepreneurship; however, the 
study also highlighted the need for further research to understand the role of 
networking, as the findings showed the involvement of a larger stakeholder network 
in the BCP compared with selective intermediaries. This further indicates that the 
models in previous studies have taken a cross-sectional approach to investigate the 
roles of different network components but have not used the network-based interaction 
perspective to understand the BCP and the issues related to the poor 
commercialisation of biotechnology innovations.  
 
Figure 3: Conceptual model showing different network effects on the 
biotechnology commercialisation process. 
The networked biotechnology commercialisation process model is expected to 
overcome several commercialisation challenges identified in the innovation and 
network management literature, particularly those related to the obstacles faced by 
innovating organisations for taking the product to market. 
The proposed model in Figure 3 illustrates how the concepts of networks, 
biotechnology and the commercialisation process fit together to achieve an integrated 
view of a networked BCP. The model elaborates an understanding of the different 
phases, stages and activities of the BCP and helps depict the established links between 
the different network components and the BCP. This helped in viewing the 
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commercialisation process from a network perspective, which further helped in 
identifying areas of weakness and limited information. The conceptual model in 
Figure 3 shows the commercialisation stage of the innovation process, which has three 
distinct phases (pre-commercialisation, commercialisation and post-
commercialisation). 
2.4.3 Pre-commercialisation phase 
The BCP is iterative. It begins with the first phase of pre-commercialisation activities, 
such as imaging, incubation and demonstration. During this phase, the involvement of 
internal network actors is high compared with the other two phases. The external 
actors, such as customers and market researcher organisations, are also a key part of 
this initial commercialisation network. Through a range of cooperation and 
collaboration activities between internal and external stakeholders, the internal 
network actors, such as R & D support, university scientists and TTOs (Chen & Lin, 
2017; Clayton et al., 2018; Siegel et al., 2004; Siegel, Veuglers, & Wright, 2007), 
derive resources such as information, intellectual capital (Bourelos et al., 2012), 
knowledge (Bourelos et al., 2012; Siegel et al., 2004; Yao, Wadhwa, & Petkova, 2017) 
and new product ideas (Dutta & Hora, 2017) from the external actors. The external 
actors include customers, suppliers, competitors (Laage-Hellman, Landqvist, & Lind 
2017; Vu, 2017) and early-stage VCs (Fielder & Welpe, 2011; Jolly, 1997; Stuart et 
al. 2001). This leads to advances in learning and idea generation (Bullinger, 
Auernhammer, & Gomeringer, 2004). These interdependencies are likely to result in 
a positive or negative outcome for forthcoming processes, such as reputation building 
and enhancing. Grants and capital are the key examples of the type of network 
outcomes that affect the process during the early stages (Datta et al., 2014; Dutta & 
Hora, 2017; Halinen, Salmi, & Havila, 1999). Significant network position allows 
access to isolated information (Bourelos et al., 2008; Laurell, Achtenhagen, & 
Andersson 2017). This broadly shows a strong link between specific network effects 
and the BCP. 
2.4.4 Commercialisation phase 
The progression process follows through the stages of innovation disclosure, market 
assessment and innovation protection, prospecting and resourcing during the middle 
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phase of commercialisation. Each stage in the model is included in a separate box as 
shown in figure 3, to depict that, although the process is overlapping and continuous, 
each stage has its own set of network stakeholders and activities affecting the process 
individually. Researchers have highlighted how networks provide support for 
commercialising complex products (Bullinger, Auernhammer, & Gomeringer, 2004; 
Harrison & Waluszewski, 2008; Ritter & Gemünden, 2003; Ritter, Wilkinson, & 
Johnston, 2004; Laurell et al., 2017). This is particularly visible during the 
commercialisation stages of the process, as government R & D support, VCs (Jolly, 
1997), university scientists, TTOs (Chen & Lin, 2017; Clayton et al., 2018; Siegel et 
al., 2004; Siegel et al., 2007), network champions and relationship promoters 
(Permartin & Sanchez-Marin, 2017; Woodside & Biemans, 2005) assist in the 
innovation disclosure stage by framing and executing market take-off strategies 
(Kentrus, 2017; Woodside & Biemans, 2005). The activities during these stages result 
in technology spillover that further increases the absorptive capacity of a firm. 
Resource exchanges, such as negotiation power, knowledge, competencies 
(Brugmann & Prahlad, 2007; Ozmel, Yavuz, & Reuer, 2017), credibility and social 
networks (Brugmann & Prahlad, 2007) and social capital (Ortiz & Donate, 2018; See, 
2003), assist in building competent relationships and knowledge sharing and transfer. 
Towards the end of this phase, during the resourcing stage, the innovating organisation 
prepares for market entry through different commercialisation pathways. Network 
participation at this stage assists the innovating organisation to access new markets 
and provides new market opportunities (Brugmann & Prahlad, 2007; Maine & Soh, 
& Dos Santos, 2017; Siegel et al., 2004). Social capital gained using multi-firm 
networks facilitates two-way integration; that is, research and market (Ortiz & Donate, 
2018; See, 2003). 
2.4.5 Post-commercialisation phase 
In its last phase, the BCP includes the concluding stages of licensing, adoption, 
diffusion and sustaining. Network activities, such as collaborated marketing efforts 
conducted by suppliers, promote early adoption (Clayton et al., 2018; Vowels et al., 
2011). In addition, the early stages of the diffusion process are influenced by the 
external networks, which may lead to successful adoption (Caiazza & Volpe, 2017; 
Montaguti et al., 2002; Roesler & Broekel, 2017). Network efficiency and network 
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structures ensure the maintenance of confidentiality and safety during the 
commercialisation and post-commercialisation sales and production (Harryson, 
2008). Conversely, the under-commitment of actors and managers downplays the 
importance of patents for protection (Siegel et al., 2004), which act as weak ties that 
are obstacles to a speedy commercialisation process (Harryson, 2008). 
Overall, it has been observed that network involvement is crucial for all stages of the 
biotechnology innovation and commercialisation process. The literature on 
commercialisation networks establishes links between the first category (i.e., 
networks and its three components [actors, resources and activities]) and the stages of 
imagining, incubation, resourcing, innovation disclosure, innovation protection, 
adoption and diffusion. It has also been observed that the third category (i.e., network 
outcomes) is linked with the innovation protection and licensing stage of the 
commercialisation process via regulations, patents, licensing and policy changes. 
However, the network influences (such as relationships, control, interdependency, 
complexity and limitations) and network outcomes (such as ownership, reputation, 
policy development and market intelligence components) have not been clearly linked 
with the stages of the commercialisation process. 
This indicates that the biotechnology commercialisation and networks literature has 
paid particular attention towards understanding the effects of legal network outcomes, 
(patents, copyrights and trademarks), financial (investments and funding 
opportunities) network outcomes and technology transfer strategies for 
commercialising innovations between partners and licensing (Aldridge & Audretsch, 
2010; Allen, 2003; Cooke, 2001; Goldfarb & Henrekson, 2003; Kasch & Dowling, 
2008; Lehrer & Asakawa, 2004).Biotechnology organisations have been more 
concerned with overcoming legal and bureaucratic barriers to obtain patents, 
intellectual property rights and trademarks (Link et al., 2011). In addition, there has 
been an emerging pattern of publication-focused research in research institutes and 
universities that decelerate the process of commercialisation. This is because 
organisations obtain potential benefits from protection (such as competitive advantage 
and control over the innovation), copyrights and further technology development 
(Datta et al., 2014). 
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It has been argued that network alliances are essential for the BCP as they may assist 
with evaluation of the market and/or access to markets; however, this is subject to 
interpretation, as current research is limited. Conversely, it has been observed that 
these networks create barriers because of differences in stakeholder motives and 
behaviours and organisational needs and cultures (Siegel et al., 2004), as well as 
funding issues and limited access to useful resources. The process of network 
formation and network involvement during the innovation and commercialisation 
processes have also been identified as a challenge for innovating organisations (Snow 
et al., 2011) and the full role of networks has not been clearly defined at all stages of 
the process. Therefore, it is important to understand different network effects, such as 
network influences and outcomes, on the different stages of the BCP. 
2.5 Conclusion and Implications 
The commercialisation of biotechnology innovation and the management of the 
process is an emergent issue that interests both industry and academia across a range 
of business, science and manufacturing domains (Cross, 2017; Kirchberger & Pohl, 
2016; Romero, 2018; Tinoco & Ambrose, 2017). By analysing the literature on 
networks, commercialisation and biotechnology, this study integrates the different 
strands of literature into a conceptual model highlighting how biotechnology 
organisations and the involved stakeholders (both internal and external to the 
organisation) can employ network-based interactions to successfully take 
biotechnology innovations to market. This study focuses specifically on the networked 
BCP and extends the knowledge of networked innovation processes that have mainly 
emphasised the development of potentially viable products (Baraldi & Stormsten, 
2009; Bramwell et al., 2012; Dogson et al., 2008; Gertler & Levitte, 2005). Through 
a comprehensive review of the literature, this study analyses how a network approach 
is applied to the BCP, identifies the contributions and effects of different network 
components and how they influence the BCP, and provides an integrated conceptual 
framework showing the links between network components, influences and outcomes 
and the BCP. 
This integrated conceptual framework offers several managerial implications and 
theoretical contributions. Through grounded theory (Denzin & Lincoln, 2005), a BCP 
model with 12 distinct and identifiable stages was developed. Then the network 
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components were studied and interactions between those components were identified 
to understand the network effects, such as influences and outcomes, that seem to play 
an important role in the BCP. All of these concepts were then interlinked with the 
stages of the commercialisation process to identify areas of limited information on 
network effects. Evidence shows that each of these components plays a distinct role 
in the process at different stages. The roles change with different stages of the process, 
resulting in a complex interaction of both internal and external factors in a non-linear 
pattern around the BCP. 
The suggested model is a differentiated approach towards understanding these 
network-based phenomena in comparison with other models. Most models suggested 
in the literature have studied networks in general and a few have studied actors in a 
network and their effects on the commercialisation process (Aarikka-Stenroos & 
Sandberg, 2014; Chen & Lin, 2017; Mattila, 2017). This model provides a more 
holistic approach to understand the network dynamics around the BCP. The analysis 
identified a complex set of network-related effects that might inhibit or promote the 
BCP. It also helped to establish that the morphology of changing networks around the 
BCP may have a positive or negative influence on the stages of the process. Both 
internal and external actors, resources exchanges and activities influence the dynamics 
of these networks around the BCP. The integrated framework has been able to capture 
the key contributions of different network effects during the BCP. This understanding 
will help in modifying strategies for improved commercialisation and in 
understanding the process of formation and distribution of different network-based 
strategies that favour the BCP. Such an understanding of network interactions is 
important if to successfully deal with market resistance regarding new biotechnology 
innovations. 
The findings also suggest that an understanding of intellectual property processes or 
legal frameworks is not enough for implementing useful network strategies for 
successful commercialisation of biotechnology innovations. Further research is 
required to gain a comprehensive understanding of how network and network-related 
frameworks can be devised and implemented to design effective commercialisation 
strategies. Networks currently have a defined influence on innovation disclosure and 
the innovation protection stage of the commercialisation process. The conceptual 
model developed here suggests that networks may exert an influence during specific 
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stages of the commercialisation process. The model also generates questions regarding 
the types of networks involved during the commercialisation process. What types of 
companies do the innovating organisations involve within their network and do these 
networks evolve during the transition from innovation to commercialisation? Overall, 
this study is expected to expand the knowledge of network behaviours and build upon 
the theoretical understanding of the influence of networks on commercialisation. 
The need to understand the process of commercialisation, development of business 
networks for commercialisation and commercialisation management is of interest 
specifically across a different range of Biotechnology-intensive industries, such as 
biotechnology, nanotechnology, bioprocessing, mechanics and bioinformatics. This 
research leads to the generation of new information on how organisations involved in 
the new product development process can extend their network capabilities across the 
different stages of the commercialisation process to successfully take products to 
market. 
Another contribution of this framework is that it would allow an innovating 
organisation to understand the key points of influence during the process of 
commercialisation, specifically when the product is transitioning from the 
commercialisation to post-commercialisation stages (such as adoption, diffusion and 
sustainability) as those are the crucial stages that determine the success rate of an 
innovation. The conceptual framework is capable of guiding the empirical 
examination in future studies and it is expected to be revised and improved during the 
research process. 
Another effective contribution of this framework is the deeper understanding of the 
network relationship as a key network influence on the process. This provides 
information for devising a relationship management strategy to develop resourceful 
network relationships that stimulate the BCP. It also allows the innovating 
organisations to identify the strengths and weaknesses of the different networks or 
networks members, leading to easy deployment of useful networks during different 
stages of the process. Additionally, a detailed understanding of the effects of network 
configuration on the process will assist innovating organisations to select the right 
partners for collaboration and partnering during the process. This will allow access to 
competitive resources, funding and new network connections. 
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The understanding of how network influences, such as network control and network 
position, affect the process will facilitate the design of strategies that improve the 
position of a commercialising organisation within the network. This will also allow 
for easy access to specific and inadequate resources. In addition, the findings of how 
network limitations affect different stages of commercialisation will help in the 
devising of responsive strategies that prevent networks from hurdling the BCP. In 
summary, the contribution to academia and industry is expected to be a model that 
helps high-technology organisations facilitate the innovation process and take 
successful innovations all the way through the commercial success.  
2.5.1 Limitations 
A conceptual framework for a multidisciplinary phenomenon will always change and 
be revised as new concepts, comments, content or literature emerges. There are several 
limitations of this research. The number of articles known to the researcher for this 
discipline was limited; another challenge was to synthesise data from a range of 
disciplines. Future research could be expanded to other disciplines in which 
innovation and networked commercialisation management are covered, such as 
international business, consumer behaviour research and management. The data 
obtained from empirical and theoretical studies are wide-ranging and extensive for 
this domain; narrowing it down to specific context was a tedious task. It was important 
to ensure that the evaluation of data was grounded on quality and that no bias was 
developed towards a specific form of knowledge while developing the findings. 
To develop an in-depth understanding of the effects of individual network components 
on the process of innovation and commercialisation, it was important to understand 
the processes in their typical format and then apply the understanding to observe how 
they changed with respect to biotechnology. This provided a more detailed analysis 
about the morphology of the networks and also formed a clear basis for understanding 
the level of adaptability and how and where it affects the process. Therefore, the 
researcher did not pursue a content analysis in the form conventionally linked with 
biotechnology innovation and commercialisation studies; rather, the evaluation was 
altered based on the aforementioned criteria. In the findings, it can be observed that 
some conclusions identify network components that can be replicated from general 
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innovation commercialisation processes and can be applied to biotechnology-based 
processes, as the initial stages of both types of processes appear to be similar. 
The number of papers in this domain presented some thought-provoking limitations. 
In the first stage, a large number of papers was identified, which was reduced to 122 
papers based on different exclusion and inclusion criteria. It is possible that the 
exclusion criteria might contain errors based on how some abstracts were written or 
perceived by the researcher. However, triangulation and explicit categorising of the 
concepts increased the trustworthiness of the results (Aarikka-Stenroos & Sandberg, 
2014). 
The integrated model that was developed is conceptual and based on qualitative 
research and analysis; this limits the generalisability of this model. In addition, the 
scope of this research is limited to a single country and single innovation industry. 
While the biotechnology industry is vast due to its numerous applications in other 
fields, this research analysed the content by focusing on biotechnology as a whole. 
There is a possibility that the stages of the commercialisation process may vary 
according to the type of technology-based industry under analysis. Further, the 
findings are specific to the biotechnology industry, as each network arrangement is 
condition-specific, thereby limiting the generalisability of this research. The 
knowledge on commercialisation based on the model devised herein is only applicable 
to business-to-business markets. Future studies involving multi-industry or multi-
market designs can solve this issue. 
Despite these limitations, this research opens avenues for future research, as several 
questions remain to be resolved. The analysis showed that the network plays a dual 
role during the process of innovation and commercialisation; combining the dual 
nature of networks with the poor commercialisation capability of the industry, this 
research provides an opportunity to understand if/how networks act as obstacles to the 
BCP. Clearly, further research will be needed to understand how networks evolve and 
terminate during the process. The study also provides the researcher with an 
opportunity to understand how different network structures interchange during the 
BCP. More research into understanding the dynamics of networks around 
commercialisation is still necessary before obtaining a definitive answer as to how 
networks influence the commercialisation of new high-technology innovations. 
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Moreover, applications of a longitudinal approach can assist in understanding the 
linkages and causal relations identified in this study that may facilitate the 
commercialisation process. In summary, the proposed model provides a good 
conceptual framework for understanding the process of taking biotechnology 
innovations to market using an integrated network perspective. It forms the basis for 
future researchers to conduct more comprehensive in-depth studies to understand how 
network integration can be used by innovating organisations to improve other 
management processes. 
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Chapter 3: Network-Based Barriers and Promoters from 
Biotechnology Labs to Australian Markets (Paper 2) 
Abstract: Organisational innovation and commercialisation processes are 
characterised as multi-stage, non-linear and network-dependent. Biotechnology is a 
growing industry with several commercialisation issues. Previous research shows 
strong links between network components and innovation processes and provides 
limited information on how networks influence commercialisation. Some studies on 
biotechnology commercialisation indicate that networks inhibit and promote the 
process of commercialisation. However, they do not provide a detailed analysis of 
how networks inhibit or promote the process and how these interactions influence the 
BCP. This paper reports the findings of an empirical study of 30 biotechnology 
industry experts using a qualitative approach with 30 semi-structured interviews; eight 
key network-based barriers and eight key network-based promoters that affect the 
process of the BCP at different stages are identified. The understanding of the role of 
these network barriers and promoters is expected to facilitate researchers and 
managers in designing methods and strategies to improve the biotechnology 
commercialisation scenario in the Australian biotechnology market. The paper 
concludes with suggestions for future research. 
Keywords: commercialisation, biotechnology, networks, commercialisation barriers 
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3.1 Introduction 
In the past several decades, the commercialisation of biotechnologies and technology 
transfer studies has attracted the attention of stakeholders in industry, academia and 
the government (AusBio Feature, 2016; AusBiotech Snapshot, 2017; Graff, 
Zilberman, D., & Bennett 2010; Leppaaho, Chetty, & Dimitratos 2017; Pandya, 2012; 
Roesler & Broekel, 2017). Since Cooke’s (2002) seminal research on biotechnology 
commercialisation and Vitale’s (2004) report on Australian biotechnology 
commercialisation, the number of studies focusing on this topic has increased 
significantly. These studies have adopted various approaches to examine how the 
process of the commercialisation of biotechnology innovation can be improved 
(Aarikka-Stenroos & Sandberg, 2012; Kim & Madunic, 2014; Kirchberger & Pohl, 
2016; Mattila, 2017; Wang & Liu, 2018). The Australian biotechnology industry is a 
booming sector with amplified innovation activities; however, when it comes to 
commercialisation, the industry is facing multiple issues and is not achieving the same 
success in comparison to innovation activities (AusBiotech Snapshot, 2017; 
Australian Institute for Commercialisation, 2013). A broad understanding of how 
biotechnology innovations can be taken to market, licensed, patented and adopted is 
a key factor in the future development of the biotechnology industry in Australia.  
In the last few years there has been growing interest from both industry and academia 
in identifying the key issues that influence the BCP (AusBio Feature, 2016; Gertler & 
Levitte, 2005; Graff et al., 2010; Grant & Thornton, 2017; Hill, 2016; Pandya, 2012; 
Vitale, 2004; Wang & Liu, 2018). The established literature and industry reports 
suggest the issues are related to intellectual property generation, patent filing, process 
definition, forming start-ups or spin-offs, gaining funds for marketing activities, 
gaining regulatory approvals, finding partners, gaining access to the right partners at 
the time of commercialisation, lack of information, lack of knowledge, lack of skills, 
lack of capital, trade initiatives, government policies, high operational costs and other 
institutional/organisational business restrictions (Australian Institute for 
Commercialisation, 2010; Chiesa & Frattini, 2011; Hill, 2016; Kaarela, 2013; Al 
Natsheh,  Gbadegeshin, Rimpiläinen, , Imamovic-Tokalic, & Zambrano 2015; 
Pellikka, Kajanus, Heinonen, & Eskelinen,2012). 
73 
It has been established that networks play an important role during the BCP, as 
networks provide essential complementary assets in the form of skills, expertise, 
knowledge, funding and several other resources (e.g., see Aarikka-Stenroos & Ritala, 
2017; Datta et al., 2014; Gans & Stern, 2003; Kasch & Dowling, 2008; Odame & 
Alemu, 2018; Strenitzke, 2010; Walsh, 2012). Innovation networks are organizational 
relationships between different actors that are internal and external to an organisation, 
which provide access to different resources and essential assets, which help to develop 
new and improved products and services through the process of collaborated learning 
(Koschatzky et al. 2001). The resources accessed through network collaborations 
assist the Biotechnology organisations at different stages of their innovation and 
commercialisation processes to achieve the innovation goals and objectives.  Despite 
the alliances and collaboration opportunities available to the local biotechnology small 
to medium organisations, Australian Government agencies have identified that the 
absence of specific skills and resources in this industry negatively affects the 
commercialisation of these innovations (AusBiotech Snapshot, 2017; Korporal, 2013; 
Vitale, 2004). One of the key reasons for this is that networks (in the form of actors, 
resources, activities or interactions) occasionally act as barriers during the BCP 
(Aarikka-Stenroos & Sandberg, 2012; Datta Mukherjee, & Jessup, 2015; Goldenberg, 
Han, Lehmann, & Hong 2009; Tinoco & Ambrose, 2017). Evidence from the 
established literature suggests that although many past biotechnology innovation 
projects under the influence of a business network have been successful in developing 
a new innovative product, only a small percentage have achieved commercialisation 
success (Bandarian, 2005; Chen & Lin, 2017; Kirchberger & Pohl, 2016; Stenroos & 
Sandberg, 2012; Khalil Zadeh, Khalilzadeh, Mozafari, Vasei, & Amoei Ojaki 2017). 
This study argues that the way in which the networks contribute to the process of 
biotechnology innovation and commercialisation processes has been widely observed. 
However, identification of different network components and how they inhibit or 
promote the BCP has not received sufficient attention. This paper identifies different 
types of network-based factors that inhibit or promote the commercialisation process. 
Factors that inhibit the commercialisation process are called network barriers that can 
be defined as the outcomes of interactions between different network components 
(network actors, resources and activities) that delay, decelerate or barricade any 
network bound processes. On the other hand, factors that promote the 
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commercialisation process are called network promoters that are defined as outcomes 
of interactions that accelerate, enable or facilitate any network bound process. 
Considering that there is active involvement of networks during commercialisation 
this study emphasises on understanding the differentiated nature of network 
interactions, suggesting that greater attention is needed to the conceptualisation of 
network interactions acting as barriers and promoters and their impact on the BCP. 
Poor commercialisation of biotechnology innovations is a prominent concern for the 
innovating organisations, the findings of this research could be useful in designing a 
solution as it could help in identifying potential barriers, which can be strategically 
eliminated to enhance the rate of Biotechnology commercialisation.  
This research acknowledges the work of Aarikka-Stenroos and Sandberg (2014) who 
view the commercialisation process from a single network perspective by identifying 
how different network actors assist in the technology commercialisation process. 
However, this research agrees with Tinoco and Ambrose (2017) in arguing that high-
technology organisations can have numerous collaborations with different network 
entities that may negatively affect the firm’s technical competence. This study also 
agrees with the research conducted by Zadeh et al. (2017) examining the challenges 
imposed by an industrial business environment on the process of technology 
commercialisation. The analysis of the findings identified several barriers related to 
organisational structure and project management and recognised collaborations with 
stakeholders as one of the key issues affecting the process of technology 
commercialisation. Accordingly, this study focuses on the effect of network-related 
barriers and promoters that influence the BCP; it aims to explore how network-based 
barriers and promoters inhibit or facilitate the BCP. To achieve this, this study draws 
upon a qualitative approach using 30 semi-structured interviews with professionals of 
the biotechnology industry in Australia. 
This research contributes to the network and commercialisation management 
knowledge through a more advanced understanding of network-based factors that 
influence the BCP (Aarikka-Stenroos et al, 2014; Tinoco & Ambrose, 2017). It further 
builds upon the ARA network theory (Hakkanson & Johanson, 1992) by identifying 
network effects in the form of barriers and promoters that emerge as a result of the 
interactions between ARA components. In particular, this research contributes to the 
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body of research on network-based biotechnology commercialisation by offering 
specific information regarding network-specific commercialisation issues by 
providing an integrated conceptual framework. The integrated conceptual model 
reveals areas of the process where network effects inhibit or promote the BCP. This 
study has implications for biotechnology organisations faced with increasing 
expectations from various stakeholders and their own internal organisational goals to 
achieve commercial success for biotechnology innovations. 
The remainder of the study is organised into different sections. The following section 
2 reviews the established literature on the BCP and the role of networks. The section 
following the literature review folds into the discussion of the conceptual model and 
presents the research implications. The research method and analysis have been 
discussed in the next section 3. The following section 4 after that presents the research 
findings and a subsequent section discusses the findings. The last section 5 concludes 
the paper with a discussion of the managerial and theoretical implications, limitations 
and future research opportunities. 
3.2 Theoretical Background 
3.2.1 Network involvement based on ARA theory 
The established literature acknowledges the involvement of business networks during 
biotechnology innovation and commercialisation processes (Aarikka-Stenroos & 
Sandberg, 2014; Kirchberger & Pohl, 2016; Miles, Miles, & Snow 2005; Romero, 
2018; Tinoco & Ambrose, 2017). An organisation’s innovation and 
commercialisation capacity is enhanced when operating within a multiform network 
(Snow, Fjeldstad, Lettl, & Miles 2011). The contribution of a business network to an 
organisation has been studied and well explained by the ARA framework (Hakansson 
& Johanson, 1992). Based on the ARA theory, interactions within the network 
contribute three different layers of outcomes to an organisation (Ford, Gadde, 
Håkansson, Snehota, & Waluszewski 2008) that may influence the organisation’s 
internal and external processes in an integrated manner. The outcomes include actor 
bonds (Ballentyne & Williams, 2008; Ford & Mouzas, 2008; Varey, 2008) where 
members of the network interact individually and mutually benefit each other, the 
activity links (Pelikka & Lauronen, 2007) that have integrated activities and 
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coordination, and resource ties (Aarikka-Stenroos & Sandberg, 2012; Ivens, Pardo, 
Salle, & Cova 2009) where a combination and exchange of tangible and intangible 
products and services materialises whereby each involved actor adapts to the needs of 
the other actor (Ford et al., 2008; Hakansson & Johanson, 1992; Hakansson & 
Senhota, 1995). 
Evidence from the existing literature (Sandberg & Aarikka-Stenroos, 2014; 
Kirchberger & Pohl, 2016; Romero, 2018; Tinoco & Ambrose, 2017) indicates that 
networks play a dual role during the biotechnology innovation and commercialisation 
process. In accordance with Aarikka-Stenroos and Sandberg (2014), the research 
observes the BCP through a network lens using two specific network dimensions—
network-based barriers and network-based promoters—in alignment with the ARA 
network theory (Ford et al., 2008; Hakansson & Snehota, 1995). The interactions 
between the ARA network dimensions at one stage of the BCP may result in effects 
that become antecedents for another stage of the BCP. For example, a collaboration 
between different types of network actors may provide complementary assets that are 
essential for that particular stage of the process; however, the same set of 
collaborations might impede the process at later stages (Bourlos, Magnusson, & 
McKelvey 2012; Datta et al., 2015; Kirchberger & Pohl, 2016; Tinoco & Ambrose, 
2017; Varey, 2008; Vowels, Thirkell, & Sinha 2011; Woodside & Biemens, 2005). 
Such barriers and promoters can rise at any stage of the BCP (Bandarian, 2007). 
Considering the high density of involvement of networks in the commercialisation 
process, it is evident that networks may intermittently promote or inhibit the BCP (for 
examples, see Romero, 2018; Siegel et al., 2004, Zadeh et al., 2017). 
3.2.2 Biotechnology commercialisation process and the dual role of networks 
The established literature on commercialisation processes, biotechnology 
commercialisation networks and industry reports regarding the same led to the 
development of an adapted model (Berbegal-Mirabent, Sabaté, & Cañabate, 2012; 
Jolly, 1997; Kirchberger & Pohl, 2016; Leppaaho et al., 2017; Mattila, 2017; Siegel, 
Waldman, & Link, 2003; Wang & Liu, 2018; Woodside & Biemans, 2005) of the BCP 
(see Figure 4). 
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The conceptual model shows the commercialisation process, which has three distinct 
phases (pre-commercialisation, commercialisation and post-commercialisation) with 
12 overlapping stages (imaging, incubation, demonstration, innovation disclosure, 
market assessment, innovation protection, prospecting, resourcing, licensing, 
adoption, diffusion and sustaining). From the analysis of the innovation and network 
literature (Bourelos et al., 2012; Romero, 2018; Tinoco & Ambrose, 2017), different 
network effects were identified. In the conceptual model, network effects have been 
shown in three different categories: (1) network (ARA) components, which interact 
and generate the second category of network influences; (2) configurations, 
relationships, position, complexity, control, interdependencies and limitations; further 
interactions between network influences then lead to the third category; and (3) 
network outcomes, such as technology transfer strategies, capital, ownership, market 
intelligence, regulations, patents, licensing and policy changes. The established 
literature on commercialisation networks shows some links between the first category 
(networks) and its three components (ARA) and the stages of innovation disclosure, 
innovation protection, adoption and diffusion. It has also been observed that the third 
category (network outcomes) is linked with the innovation protection and licensing 
stage of the commercialisation process via regulations, patents and licences. However, 
the network influences and network outcomes and the technology transfer strategy, 
capital, ownership and market intelligence components have not been clearly linked 
with any stages of the commercialisation process. 
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Figure 4: Conceptual model showing different network effects on the 
biotechnology commercialisation process. 
However, the network influences and network outcomes and the technology transfer 
strategy, capital, ownership and market intelligence components have not been clearly 
linked with any stages of the commercialisation process. 
Network studies related to commercialisation have focused on understanding the legal 
aspects of commercialisation, such as government policies and offices (patents, 
copyrights and trademarks), investments, funding opportunities and transfer strategies 
for commercialising innovations between partners and licensing (Aldridge & 
Audretsch, 2010; Allen, 2003; Kasch & Dowling, 2008). The business focus has 
traditionally been more concerned with overcoming legal and bureaucratic barriers 
(Dorf & Worthington, 1987; Link et al., 2011) because organisations obtained 
potential benefits from protection, such as competitive advantage, and control over 
the innovation, copyrights and further technology development (Datta et al., 2015). 
Based on the existing literature, the conceptual model also shows examples where the 
different network effects (network-based influences and outcomes) could act as 
barriers and promoters during the BCP. In Figure 4, the black circular spots in all three 
network categories symbolise the components of the networks that could act as 
barriers to commercialisation. The black squares marked on different linkages 
represent the network-based barriers and promoters that could interject the BCP at 
different stages. For example, during the pre-commercialisation phase (also known as 
early commercialisation) that consists of imaging, incubating and demonstrating 
(Jolly, 1997; Kutvonen, Torkkeli, & Lin, 2010), the researcher, product developer, 
university, innovating organisation, R & D partners, science parks or the research 
institutes are found to be important network actors that constitute the decision-making 
unit. However, among these actors the lack of entrepreneurial or business knowledge 
and the knowledge regarding the essential prerequisites before commercialisation is 
known to hamper the speed of the BCP (Bandarian, 2007; Martyniuk, Jain, & Stone 
2003; Ndonzuau, Pirnay, & Surlemont, 2002; O’Shea, Allen, Chevalier, & Roche, 
2005). 
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Martyniuk et al. (2003) argued that it is important to assess the technology during the 
early stage of commercialisation because this helps in overcoming future problems. 
Bandarian (2007) further argued that the evaluation of technology at the early 
commercialisation stage will help in augmenting the commercial outcome. Pre-
commercialisation is mainly the research phase and is conducted simultaneously in 
coordination with the new product development process. Network barriers such as 
government organisations affect the speed of the process and influence the project 
timelines at the pre-commercialisation stages by developing strict regulatory policies 
around obtaining licenses and intellectual property rights to access the required 
technology (AusBio Feature, 2016; Ettlie, 1982; Hill, 2016; Johnston, Lewin, & 
Spekman, 1999). Conversely, the strict guidelines regarding the regulatory framework 
also persuade innovating organisations to develop high-quality viable roadmaps for 
dealing with any expected future roadblocks, acting as a network-based promoter. 
As demonstrated in Figure 4, pre-commercialisation leads to the stage of innovation 
disclosure, which is the bridge between the first and second phases of the BCP. The 
innovating organisations disclose the innovations for evaluation and establish market 
assessment. This is to determine if it meets market standards and has the potential to 
be commercially viable (Berbegal-Mirabent et al., 2012; Garbade, Omta, Fortuin, 
Hall, & Leone, 2013; Ismail et al., 2011; Siegel et al., 2003). Institutional 
organisations have TTOs and larger organisations have public–private partnerships 
(PPPs) that assist in taking biotechnology innovations through different 
commercialisation pathways (Davies, Roderick, & Huxtable-Thomas, 2018; Miller, 
McAdam,, & McAdam, 2018; Siegel, Waldman, & Link  2003; Stone & Lane, 2012). 
The TTOs assist and educate the researchers regarding the process and significance of 
technology commercialisation (Aldrige & Audretsch, 2010). Actors in the research 
phase of the process are keen to develop the product further, win grants or gain 
recognition through publication rather than gaining profitable commercial outcomes 
(Blind, Pohlisch, & Zi, 2018; Blind & Gauch, 2009; Gorman, Byrne, & Pandya, 2006; 
Rothaermel & Thursby, 2005). This lack of interest further decelerates the process. 
This is a standard example of how some actors of the university–industry networks 
act as promoters of commercialisation, while others create hurdles to barricade the 
process. 
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The second phase of the BCP as shown in Figure 4, is the commercialisation phase. It 
transpires as a result of the interactions and activities between the network 
components of the pre-commercialisation stage. This phase has the highest level of 
uncertainty due to the increase in the level of network complexity. Risk management, 
finalising marketing strategies and monitoring changes in the later stages are the 
highlights of the commercialisation phase. The phase is divided into four crucial 
stages: market assessment, innovation protection, prospecting and 
resourcing/commercial pathways. The prime focus during this stage is to design the 
strategy for market entry, obtain IPR’s patent protection, partner recruitment and 
selection and finalising the resource requirement for successful adoption (Aarikka-
Stenroos et al., 2014; Siegel et al., 2003; Walsh, 2012; Woodside & Biemens, 2005). 
During this phase, networks act as a source for building new useful relationships 
(Dutta & Hora, 2017; Gronum, Verreynne, & Kastelle, 2012; Lechner, Dowling, & 
Welpe, 2006). These relationships help an organisation recruit the people with the 
right skills for understanding regulatory processes, gaining approvals and developing 
a complete knowledge of patent filing and assessment (Clayton et al., 2018). As these 
activities are based on trustworthiness and commitment, long-term relationships are 
most useful during this phase (Shakeri & Radfar, 2017). 
Conversely, networks can also be the cause of the dissolution of an existing 
relationship (Dutta & Hora, 2017). The dissolution of an existing relationship is 
caused by changing resource requirements, different relationship goals of 
participating network members, evolving expectations and changing market needs or 
business environments. The literature based on network relationships also identifies 
that, despite knowing the benefits of associating with a reputable and credible partner 
in a network, organisations lack the capacity to recognise the value and credibility of 
other network relationships, leading to the development of a fleeting network 
relationship (Anderson, Håkansson, & Johanson, 1994; Gales & Boynton, 1992; 
Pittaway, Robertson, Munir, Denyer, & Neely 2004; Zott & Huy, 2007). The literature 
also indicates that strategic alliances with different network members are not always 
favourable for the BCP (Adams, Khoja, & Kauffman, 2012; Dutta & Hora, 2017). 
The commercialisation phase further merges into the post-commercialisation phase. 
The third phase of the BCP, as shown in Figure 4, involves activities such as 
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negotiation that are usually conducted between partners and other stakeholders, which 
may include the government, research institutes, innovation organisations or 
entrepreneurs. During this phase of the process, the organisations are involved in 
decision-making processes regarding commercialisation pathways for the viable 
biotechnology innovation. This involves preparing legal agreements and defining 
negotiations and business terms. This phase provides an innovating organisation with 
the right to launch, spin-off or market the product or collaborate with other 
organisations with common commercialisation goals. 
The post-commercialisation phase defines the success and failure of the commercially 
viable technology. The four key stages of this phase involve core marketing activities 
in the form of product licensing, adoption, diffusion and sustaining (Berbegal-
Mirabent et al., 2012; Garbade, Omta, , Fortuin, Hall, & Leone 2013; Jolly 1997). 
During the stages of adoption and diffusion, lead actors or network opinion leaders 
have the ability to delay the adoption of an innovation in the market, as their opinion 
about the product has a strong effect on prospective customers (Goldenberg et al., 
2009; Montaguti, Kuester, & Robertson 2002; Woodside & Biemans, 2005). It has 
been suggested that network alliances may assist with the evaluation and/or access to 
markets, but as current research is limited this is subject to interpretation. It has also 
been argued that strong network associations with customers and between customers 
are needed for adoption and diffusion (Aaboen, Dubois, & Lind 2013) and that 
government actors such as federal R & D institutes and regulatory bodies have 
facilitated entrepreneurial development in the technological space (Graff et al., 2010). 
Conversely, it has been observed that these networks have created barriers because of 
differences in stakeholder motives and behaviours and in organisational needs and 
cultures (Siegel et al., 2004). 
The literature on biotechnology commercialisation and investor networks has 
highlighted that funding is an essential resource and activity for all stages of the BCP 
(Gertler & Levitte, 2005; Graff et al., 2010; Hans & Georgia, 2017; Kasch & Dowling, 
2008; Pellikka et al., 2012; Yoon, Rosales, & Talluri, 2017). The network 
infrastructure surrounding venture capital firms is a useful resource for the BCP. The 
VCs provide management proficiency, referrals to experts dealing with regulatory 
procedures and policies and overall business development capability for enhancing 
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commercial success for biotechnology innovation (Cooke, 2001; Kasch & Dowling, 
2008; Reuer & Devarakonda, 2017). Conversely, VCs have indicated that these 
resources are available only for creditable propositions. Industry reports reveal that 
many research projects are unable to commercialise because of such a lack of funding 
(AusBio Feature, 2016; AusBiotech Snapshot, 2017; Vitale, 2004). The poor rate of 
commercialisation evident from the past performance of biotechnology firms is also 
the reason behind the increasing gap between the commercialising organisations and 
funding bodies. Limited access to capital and funding has pushed several 
biotechnology organisations to seek funds from foreign markets, affecting the overall 
commercialisation capability of Australian biotechnology firms (AusBio Feature, 
2016; AusBiotech Snapshot, 2017). Yoon et al. (2017) also identified the lack of 
clarity regarding the understanding of the contractual agreements signed as a result of 
a financial strategic alliance further causing delays to any process related to the 
alliance. 
In recent years, research on the effects of networks on technology commercialisation 
has become prevalent. Aarikka-Stenroos and Sandberg (2012), Goldenberg et al. 
(2009) and Harrington and Srai (2017) have highlighted how network involvement is 
both advantageous and disadvantageous to the technology commercialisation process. 
The commercialisation and network literature provides many examples of network-
based hurdles during the process (Bugge, Hansen, & Klitkou, 2016; Chen & Lin, 
2017; Farrell & Saloner, 1985; Harrington & Srai 2017; Harrison & Waluszewski, 
2008). Hakansson and Johanson (1992) highlighted how activities conducted by one 
set of actors in a network can be useful for them and damaging for other actors 
participating in the same network. This was further confirmed in studies by Borders, 
Jhonston and Rigdon (2001) and Nooteboom (2000); they examined the behaviours 
of participating network members under the influence of network rules and 
regulations, finding that this type of network engagement had a detrimental effect on 
innovation outcomes as it constrained or limited network relationships, which led to 
the failure of commercialisation. The literature also extends towards understanding 
the role of networks as a tool for the promotion of the technology commercialisation 
process (Aarikka-Stenroos et al. 2014; Baglieri, Belussi, & Orsi 2015; Harrington & 
Srai, 2017; Kasch & Dowling, 2008; Wang, Quan, & Huang 2016). The literature 
shows that the commercialisation of technology is impossible without the influence 
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of the surrounding networks in the form of actors, resources and activities. Previous 
research thus suggests that while network interactions are central aspect of technology 
commercialisation process, though little is known about the dual nature of the network 
interactions. There is limited number of studies that have examined the negative 
outcomes of network interactions on the technology commercialisation process in 
comparison to studies that have examined the positive impact of networks on 
commercialisation. Also a holistic approach to understand how the network 
interactions whether acting as inhibitors or promoters influence the BCP as different 
stages has not been theoretically well-grounded.  
In sum, an overview of the literature further underscores the need for research into the 
effects of network-based barriers and promoters on the BCP. There are various lines 
of research that trace different types of network roles concerning the BCP. Studies 
have elucidated advantageous and disadvantageous network interactions and their 
consequences and found evidence of the different roles networks play by 
understanding different types of network phenomena. Nevertheless, there is still 
limited information about the configuration of the networks involved in different 
interactions with specific reference to BCP. Thus, the purpose of this research is to 
assess the dual nature of network-based interactions around BCP, then understand 
their nature as an inhibitor or promoter or both and then understand how those 
characteristics influence the stages of BCP. It is assumed that the preliminary 
framework is capable of linking the different network effects to the BCP and providing 
a holistic view of how and at what stages the network-related barriers and promoters 
affect the BCP. 
The next section empirically examines the specific network-based barriers and 
promoters that influence each stage of the BCP in the form of different network actors, 
resources and activities. 
3.3 Research Methods 
A qualitative study was deemed appropriate for network and commercialisation management 
research as it is a flexible method for understanding the research problem from different 
dimensions of the network (Sandberg, & Aarikka-Stenroos & 2014; Yin, 1994). Specifically, 
a qualitative approach allows interpretation of the data based on the lived experience of 
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individuals, which helps in exploring an under-researched phenomenon (Kumar & Worm, 
2003; Ramstorm, 2008). Another advantage is that the analysis of a qualitatively collected 
data allows the researcher to examine and addresses issues related to social contexts, 
interactional and structural elements of the network (Coviello 2005, Lack 2010). In innovation 
and network-based research some of the network links between actors are indefinable, often 
formed through coincidence rather than an appropriate decision-making process; the network 
boundaries are obscure; actors are usually involved in multiple relationships between different 
networks, networking is not restricted to a specific environment or behavior and all of these 
elements influence the personality of a network actor. Qualitative tools allow researchers to 
explore the network environment from within the network relevant to a specific context and 
also assist in understanding the impact of the network environment on actors (Johannisson 
1986; Lack 2010). Assuming that BCP is a dynamic process due to the interplay of several 
actors, resources and activities, a qualitative approach will allow uncovering of the 
multifaceted and cross-contextual behavior of networks.   
Semi-structured interviews were the chosen method because they provided flexibility, 
the opportunity for self-expression and approachability to the researcher (Qu & 
Dumay, 2011). Within the existing literature related to network and relationship 
analysis and mapping, semi-structured interviews were observed to be the most 
efficient method of data collection (Partenen, Möller, Westerlund, Rajala, & Rajala 
2008; Ramstorm, 2008; Theingi et al., 2008). Because of the semi-structured nature 
of interviews, the process (see Appendix 1 for the interview instrument) was framed 
to confirm uniformity during data collection (Patton, 2002; Theingi, Purchase, and 
Phungphol 2008). The duration of the interviews varied from 30 to 90 minutes. All 
interviews were audio recorded and notes were taken during the interview to identify 
the existing networks in which the participants were involved (Burnard, 1991). The 
researcher provided impromptu probes to the respondents during the interviews to 
extract thorough descriptions (Qu & Dumay, 2011). Unquotable and un-recordable 
information that the respondent insisted on not recording for privacy purposes, was 
noted manually and was only used for reference purposes. Some interviews were 
conducted over the phone because of the schedules of the participating interviewees. 
The interviewer collected information on the following themes: 
1. New product development process 
2. Commercialisation process 
3. Activities conducted and resources provided by the actors 
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4. Issues with the commercialisation process 
5. Recommendations provided by the actors for improvement of the BCP. 
All interviews were transcribed for analysis. All company names and participant 
names have been de-identified (In1–In30) as some of the data collected is confidential. 
The primary data were collected using 30 semi-structured, open-ended and face-to-
face interviews. The participants were key experts from the biotechnology industry 
with various profiles (including CEO, director, executive director, manager of 
industry commercialisation, angel investors, VCs, cooperative research assistants, 
regulatory affairs director, attorneys and commercialisation accelerator). Some 
respondent profiles were not clearly defined or involved multiple activities. For 
example, one of the respondents acted as a CEO and as a consultant (see Table 7). 
This gave the researcher a holistic view of the process with details from different 
member perspectives. 
Table 7: List of Participant Profiles 
Organisation Participant Profile Skill Set 
Government Innovation management Investigating regulatory 
issues 
Policy development 
Agreement design and 
approvals  
Universities Manager industry and 
commercialisation 
Director design institute 
Executive director industry 
Business development 
Research scientists 
Industry engagement 
Networking and 
partnerships 
Regulatory affairs 
Large biotech 
organisation 
Research program leader 
National marketing leader 
National senior marketing 
manager 
Strategic marketing 
Business development 
Project management 
Social media marketing  
SMEs Director 
CEO 
Manufacturing process 
management 
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Organisation Participant Profile Skill Set 
Managing director 
Principal innovation 
design and framework 
Innovation protection 
Reputation building 
Collaboration 
Forums and 
associations 
Expert scientific advisor 
Clinical consultant 
Principal consultant 
innovation and tech 
Pharmacovigilance 
consultant 
Consulting and advisory 
Networking and 
collaboration 
Research management 
Commercialisation 
management 
Funding 
organisations 
Venture capitalists 
Venture capital partner 
Managing director 
Investment director 
Capital development 
Fundraising 
Risk analysis 
Developing the skill set 
A combination of social references, a social media platform (LinkedIn) and snowball 
sampling was used to contact different participants. The participant search began after 
reviewing the roles of key decision makers in the biotechnology market from the 
analysis of various biotechnology industry reports. Initially, the researcher’s existing 
network links were utilised for gathering sample references. Subsequently, a search 
on LinkedIn for Australian biotechnology industry profiles was conducted, providing 
links to specific profiles of prospective participants. The email addresses for the 
selected profiles were collected and maintained in a list organised alphabetically. 
The interviewees were sent an introductory email that stated what their involvement 
would entail and a summary of the research. Participants who responded with interest 
were then interviewed using a pre-designed and semi-structured interview. The 
participating respondents then provided a reference and introduction to a prospective 
participant. The snowball approach helped in further identifying the different types of 
relationships within the biotechnology network. Most of the secondary data were 
obtained using websites, brochures, newspapers, industry reports and magazines. 
The data were initially analysed using open coding and then more elaborate codes 
were developed and linkages identified. The analysis of the interviews led to the 
development of nodes and memos with the help of NVivo software. It was based on 
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the critical evaluation, tagging and assimilation of data from primary and secondary 
sources to generate findings to address the research phenomenon (Glaser & Strauss, 
1967). Coding of the data took place in two stages. First, the data were coded under 
29 different network influences and then under 16 broad themes. Data were analysed 
along the central themes, inclusive of roles of different network actors, 
commercialisation process, identification of various network components and issues 
during the process of commercialisation. This allowed an understanding to be 
developed of the influence of actor roles and activities in the process of 
commercialisation. It also allowed the researcher to study the involvement of the 
organisation across the process and how the development of new connections and 
relationships would possibly hamper the BCP.  
The grounded theory approach allowed to compare the 29 different network influences 
and categories them into 16 key categories, also showing linkages between the 
categories. The data was compared on the basis of different situation of the 
interviewees, their beliefs towards commercialisation processes and their behaviour 
towards the networks that they operate within. Another criterion for comparison was 
the path followed by the interviewees in their career, with almost similar profiles such 
as venture capitalist and angel investors, CEO’s and managing directors against their 
experiences at similar situations during their career. Lastly, the comparison was also 
based on specific characteristics of issues faced by one interviewee in comparison to 
another at similar situations while operating within a Biotechnology network.    
The categorisation process also involved analysing the 16 categories based on the 
number of participants that mentioned a quote directly or indirectly relevant to the 
category (frequency) and also based on the number of times it was mentioned by the 
interviewees across the 30 semi-structured interviews (Inference counts). These 
linkages further allowed the researcher to classify the categories under two broad 
themes network-based barriers and promoters which was then further linked to the 
stages of the BCP. Table 5 outlines the key codes and themes.  
To achieve reliability, the researcher tested the data collection and analysis process at 
multiple stages of the research process. The analysis was conducted alongside the data 
collection and it was regularly referred back to the literature review. The in-depth 
interviews confirmed the existence of the research problem and provided industry 
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experts’ perspectives on why the problem exists and what can be done to facilitate the 
development of a solution. In addition, regular feedback was obtained from the 
participating respondents, thus providing an opportunity to validate the need for 
further data collection. Regular updates were provided to the respondents before and 
after the interviews to check for variability in opinions. All notes and memos written 
during the interviews were utilised for cross-checking of information during the 
process of data transcription to ensure that the transcribed scripts contained accurate 
information. Since the research focused on the biotechnology industry, the note-taking 
activity also ensured that all technical terms were appropriately written and verified 
in the transcribed scripts. The transcribed data were subjected to triangulation to check 
for the emergence of any new information. The analysis was conducted until data 
saturation was achieved and no new information was available. 
3.4 Empirical Findings 
The interview data were used to explore the direct and indirect hurdles and 
opportunities created by the involved business networks during the BCP. The different 
network influences, acting as barriers and promoter are analysed and reported in 
accordance with the different phases and stages of the BCP. The empirical findings 
have been illustrated with the help of quotations from the transcribed interviews. A 
more precise synthesis of specific empirical findings is presented in the tables in 
various parts of this chapter. As highlighted in Table 8, the findings based on the 
analysis identify the key obstacles and opportunities that influence the 
commercialisation of biotechnology innovations in the Australian biotechnology 
market. The eight key network-based barriers are funding, breaking of network chains, 
partner selection and collaboration, conflict of commercial interest, difference in 
perception, time management, de-risking process and consistent barriers and the eight 
key network-based promoters are funding sources, long-term relationships, social 
tools, process cycles, network collators, network heroes, process supporters, and 
diversity. 
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Table 8: The Codes and Frequency of Key Codes from the Data 
Codes Network Aspects Respondents 
(no.) 
Inference 
Frequency 
Barriers 
Funding  30 91 
Cascading resource 
inaccessibility 
Network resources, 
interdependence  
19 35 
Mismanagement of 
funds 
Financial resources, 
Network actor decisions, 
network activities 
23 46 
Unavailability of 
funds 
Network boundaries, actor 
competition 
21 35 
Breaking network chains 21 35 
Changing network 
structures 
Network 
Interdependence, 
Relationships, activities  
19 31 
Companies into 
administration 
Network relationships, 
actor reputation, 
collaborations activities  
5 5 
Partner selection and collaboration  30 158 
Lack of sufficient 
skills 
Network actors, 
resources (skills), links 
30 87 
Demonstration of 
credibility 
Network resources 
(Capability and skills, 
engagement activities  
22 47 
Judgement of 
credibility 
Network Perception, 
strategy, Actor decision-
making, Actor 
performance  
26 83 
Conflict of commercial interest  30 123 
Difference in 
motivation 
Actor motivation, goals, 
perception 
29 100 
Me-first phenomenon Network tier 
composition, Actor 
sensitivity 
18 37 
Difference in perception  30 134 
Cultural conflict Network relationships, 
configuration, Actor 
background 
18 29 
Coordination among 
actors 
Network hierarchy, 
Culture, Actor control 
30 98 
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Perfection over 
progress 
Actor perception, 
knowledge, expectations, 
configuration 
19 31 
Time management 27 105 
Process loops and 
network gates 
Network communication, 
Exchange activities  
18 51 
Time for relationship 
development 
Network compatibly, 
relationships, references, 
reputation, activities  
19 31 
Time zones Actor location, Network 
position 
10 14 
De-risking processes 26 58 
Deal structures Network structures, actor 
and resources 
configuration 
21 39 
Excessive noise Network competition, 
reputation, Management 
activities  
15 19 
Consistent barriers 30 149 
Delay in regulatory 
actions 
Network actor 
experience, skills, 
knowledge, resources – 
funding  
22 54 
Mismanagement of 
capabilities 
Network motivation, 
expectations, productivity  
20 51 
Lack of socialisation Network communication, 
culture, control, Low-
involvement networks  
21 43 
Promoters 
Funding sources  Capital resources, 
Network actor 
management activities  
15 39 
Long-term 
relationships  
Network relationships, 
stability   
14 28 
Social tools  Network configurations, 
channel management 
activities  
16 34 
Process cycles  Network adaptability, 
perception 
9 13 
Network collators  Network structure, 
relationships, actors 
24 53 
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Network heroes  Network (actors) 
champions, 
interdependence 
19 29 
Process supporters  Network relationships, 
actor support 
24 63 
Diversity  Network actor 
background 
Knowledge sharing, 
guidance  
14 43 
3.4.1 Funding 
In Table 8, the empirical findings show that despite the involvement of several 
investing bodies (ranging from government investment, angel investors, VCs and 
other investing associates) during the commercialisation process, several 
commercialisation projects in the biotechnology industry struggle to find sufficient 
investments for the commercialisation of biotechnology innovations. The respondents 
emphasised that the Australian capital system does not effectively support the 
biotechnology market in comparison with the USA or European capital systems. The 
respondent also pointed out that investment or funding is more often directed towards 
other portfolios or industries, such as mining, real estate and banking, which leads to 
a shortage of funding to generate successful commercial outcomes. 
The financial structure that is surrounding the Australian biotechnology market is poor. 
(In9) 
Other noticeable sub-nodes that indicated a lack of funding as the origin of several 
problems that delay the process of commercialisation are illustrated as follows. 
- Cascading into resource inaccessibility 
Some respondents (approximately 63.33%) also noted that the lack of funding further 
influences the availability and accessibility of other complementary assets, which 
cascades into delaying or barricading the commercialisation process at the stages of 
resources, market prospecting and adoption. Specifically, the findings show how 
funding as a key network resource affects scalability, market assessment and supply 
chain management. 
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The other [issue] is lack of right support at the right time. For example, you develop the 
product or invent something, but you do not have the resources to scale that up in the 
market. It could be lack of capital, or the lack of understanding of the market needs 
buyers or supply chains; it could be a range of things that stop you from commercialising 
the technology or bringing a new product to market. (In2) 
It was also evident that funding affects key stages, such as clinical trials, that usually 
occur at the innovation disclosure stages and mainly during the later stages of 
biotechnology innovation process. This finding indicates that commercial planning 
starts alongside clinical trials and it is important to note that poor funding at this stage 
would also affect the BCP, causing process-specific delays. 
- Mismanagement of funds 
Respondents in 76.66% of the interviews indicated that lack of funding at different 
stages of the commercialisation process is due to the inopportune management of 
funds during the process. In particular situations, external investing bodies, such as 
the government and large public and private research institutes, provide considerable 
funds to initiate the process or for the first round of funding, but many companies fail 
to use those funds appropriately. The data also indicates that mismanagement is 
evident in financial management strategies designed by the innovating organisations 
during the stages of marketing (mainly adoption and diffusion). The misallocation of 
funds towards unsuitable promotion and diffusion strategies affects the commercial 
acceptance of the product. One of the innovations and manufacturing experts stated: 
So would we do make a lot of issues that venture capital is weak in Australia but having 
the money [is] just one part of the problem. If you have a lot of money but a bad strategy, 
management and tactics it is just as bad as having a bad technology. (In1) 
- Unavailability of funds 
Interestingly, 21 of 30 respondents suggested a lack of funds during the process could 
be due to both internal and external obstructions faced by the innovating organisation. 
The limited availability of funds not only depended on the type or amount of funding 
but also on the approach employed to generate funds. These issues were also related 
to the design of the organisation’s equity models and financial understanding. Some 
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of the respondents pointed to the ineffective implementation of these business models 
that led to the unavailability of funds. 
One of the difficulties they experienced was where to get funding from. That was the big 
issue. Some knew about angel networks, and some didn’t know how to approach the 
angel networks, what information was required, and we started getting more exposure to 
that network and understanding what they were looking for. (In20) 
3.4.2 The breaking of network chains 
Twenty-one respondents linked the dynamics of dissolving network relationships or 
changes in the nature of those network relationships to various reasons for commercial 
failure. 
You have to remember this in this context: that many new inventions don’t ever find 
their way to products for a whole range of different reasons. Not necessarily because 
there are bad inventions, but maybe because the industrial networks are not available. 
(In2) 
- Changing network structures 
Eighteen respondents identified different types of stimuli affect the commercialisation 
process by morphing the structures of involved networks. 
We ended up a listed company on the stock exchange with all the pressures and changes 
that brings. The company had grown; at that stage, it had about 50 people. I started 
changing it, so we were distributing other people’s stuff from overseas. We became more 
of a sales and marketing company and less and less an engineering and design company. 
Fewer engineers, more salespeople. (In18) 
- Companies into administration 
A dissolving business relationship within a network leads to a continuous shift within 
the network. Although the dissolution of a relationship often has a negative 
reputational effect for all types of organisations, only 13.33% of respondents 
considered that to be a strong barrier. 
Well, they were preclinical and early phase 1 clinical products that they were developing, 
and they may have gone through to product if the company had kept going, but the 
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company went into administration and wound up at around 2008, which was around the 
global financial crisis time. They essentially couldn’t raise enough capital to continue 
operating. (In28) 
3.4.3 Finding the right partners 
Many respondents claimed that finding the right partners was another problematic 
activity during the process of technology commercialisation. All respondents stated 
that resourcing the right partner for the process was an extensive and difficult task. 
- Lack of sufficient skills 
The inefficiency in gaining successful commercial outcomes was linked to the 
inability to find skilled partners for the process. All respondents further confirmed 
this. Many respondents specifically mentioned certain areas where the required skill 
set was often missing. These included activities such as identification of market needs 
and opportunities, lack of experience, lack of expertise and the incapability to design 
the technology transfer strategies. This problem is clearly identified in this 
respondent’s comment: 
We don’t have very strong skills and without those skills you cannot effectively transfer 
technology from a research institute into a company, so we need to try and lift skills from 
both sides. So, technology transfer skills, leadership skills and other skills are important 
to that. (In3) 
- Judgement of credibility 
Judgement of credibility as a barrier was observed to be most prominent during the 
stages of imaging, incubation, market assessment, resourcing, licensing, adoption, 
diffusion and sustainability. Respondents gave various examples regarding the 
selection criteria for selection partners, mainly the one established for selecting 
organisations for collaboration during the later stages of the process. Despite years of 
experience and knowledge in establishing selection criteria for various projects, 
86.66% of the respondents still found it to be an ongoing issue within commercialising 
organisations. 
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The investability of an idea or a company with an idea rests on the people. That’s what 
the VCs look at, who’s on the board, who is in the team. This is because that is the most 
important thing. (In18) 
- Demonstration of credibility 
Conversely, the findings show that demonstration of credibility in order to attract 
partners for collaboration is as important as the judgement of credibility; 73.33% of 
the respondents highlighted reputation, past performance, existing network links and 
skill set of the engaging organisation as important factors likely to influence the 
invited partner organisation’s decision to collaborate. Capability mapping and 
decision-making activities defer the operations during the commercialisation process, 
which further causes delay in the translation of technology from the stage of 
development to market. 
3.4.4 Conflict of commercial interests 
Based on the different profiles of the interviewees, their responses varied when they 
were questioned regarding their expectations concerning commercialisation 
outcomes. It was clear from all of the respondents’ answers that there is some form of 
incongruity in the expectations of the different network members during different 
stages of the commercialisation process. The data specifies that there is a wide gap 
between the motivations and interests of the different network members. Further, 
respondents highlighted how conflicts in commercial understanding also drive 
network actors to follow intemperate activities. The spillover effects of self-serving 
motivations and mismatched expectations result in conflicts that further hinder the 
progression of the process. 
The way [a] researcher sees the product is very different from what the industry sees it 
as. So you will find that there is a mismatch of the expectations. There is one major issue 
with universities—that is, if you want the engagement of a major organisation then they 
need to have the confidence that they are going to get a uniform experience while dealing 
with the different parts of the university. Because if one part judges in one way and 
another part judges in a different way, then it gets confusing and then we might even 
play one but against the other. So that is a big risk, and that is why you have those 
alliances. (In1) 
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- Difference in motivations 
Twenty-nine respondents (96.66%) agreed that the difference in motivation of 
network members is one of the most common reasons for conflicting interests. For 
example, as shown in Table 9, investors (who are involved directly during multiple 
stages of the process) constitute 20% of this particular respondent sample; they are 
interested in gaining reputation, investment gains and developing new network links 
for future collaborations. However, consultants (who constitute the highest percentage 
in this sample) are indirect participants in the process; they expect reputation, 
recognition, business development opportunities and new relationships to be the 
outcome of the process. This issue was further confirmed by another example of a 
conflicting relationship between technology researchers and business development 
teams. One of the industry collaborators pointed out that researchers need to 
collaborate with the marketing teams and understand the importance of identifying 
market needs before progressing deep into the process; conversely, the marketers need 
to be flexible enough to accommodate the perspectives of the researchers during the 
decision-making process. 
I, as a researcher, have absolutely no line of sight to the market and the product. I knew 
that 250 million people die each year of XYZ disease and I did this research, and one 
day this research will save lives, but to actually say how that research will save lives and 
how we will impact patients and what I need to think about in terms of delivering a 
vaccine in a developing world, in a traveller, in a soldier, how much will it cost? All of 
those questions about market and reimbursement and who the customer is and who pays 
for that had never occurred to me as a researcher. (In30) 
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Table 9: Respondent Profiles Showing Differences in Motivation 
Respondent 
Profile 
Motivation Type Respondents 
Chief 
executive 
officer 
Patents, funding, licensing, profitability, market 
reputation 
40% 
Consultants Network connections, business development, 
reputation, recognition 
26.66% 
Government Long-term development, public welfare 20% 
University 
industry 
business dev. 
Network connections, grants, commercial output 20% 
Investors Reputation, investment gains, network 
connections 
20% 
Marketing 
consultants 
Network, brand awareness, financial, reputation, 
business development 
13% 
- Me-first phenomenon 
Many of the respondents candidly expressed the sentiment that researchers, investors 
and the government were responsible for the failures and delays of the BCP. 
Interestingly, 96.66% of respondents criticised the self-seeking behaviour of a few 
participating network actors. In different contexts, there was mention of terms like 
‘researcher’s ego’ and ‘researcher’s view of the world’. In general, most of the 
respondents pointed to a lack of interest in achieving a common goal among a small 
number of participating network actors; these actors preferred individual returns. 
My colleagues were more interested in getting a research project out of it than actually 
fixing the problem. (In10) 
3.4.5 Difference in perception 
Due to the multicultural, inter-organisational and interdependent nature of the 
commercialisation network, actors in the network hold varying interpretations of 
particular situations, such as resource requirements, commercial outcomes or 
management strategies. These different views appear to be useful at certain stages, as 
they provide an open commercialisation platform and assist in brainstorming multiple 
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ways of achieving goals and solving issues. However, conversely, this variety of 
perceptions leads to organisational or individual conflict. Such conflict is based on 
culture, intellect, resource requirements, process pathway selection, outcome 
expectations and simply communicating. These conflicts can arise at both the personal 
and professional levels for the involved actors. Some of these conflicts take much time 
and effort to resolve, which decelerates the process of commercialisation and can lead 
to breaks in the network chain, further hampering commercialisation. All respondents 
were emphatic in highlighting conflicts and delays that emerged as a result of this 
network influence. It was interesting to note that this variation in responses is based 
on several underlying issues related to different perceptions that affect the process. 
For example, an investor’s perspective was that ‘people aren’t interested in 
performance; they just want to get the job done at a good price. They’re not interested 
in the technological fascination’ (In13). Contrasting with the investor’s view, an 
innovating CEO commented, ‘There are people like me in my earlier embodiment, 
who are the biggest danger: the inventing CEO. The person who thinks that because 
he can do medicine and invent something he can, therefore, run a company’ (In18). 
- Cultural differences 
In discussing the different types of network collaborations with the respondents, one 
of the key issues, highlighted by 60% of respondents, was the difference in the cultures 
of the collaborating network members. Culture is used here as a broad term that can 
be employed for understanding conflicts related to organisational culture, work culture 
and cultural background of the actor. This will further assist in understanding the 
effects of cultural beliefs, values, attitudes, norms and behaviours on the network 
collaboration and commercialisation process. These cultural conflicts can arise at an 
individual or organisational level. Some of the common cultural issues are language 
barriers, process pathway development, level of education and information, method 
of delivery, analysis of information, communication styles, the perception of 
importance/priority and the process of relationship development. These issues are 
likely to greatly influence the commercialisation process at various stages as multiple 
teams influence the process with different cultural backgrounds within a 
commercialisation network. 
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The challenges about executing the project management is getting the different cultural 
approaches … In particular, R & D scientists focused on our side can find it difficult to 
conform to the constraints of classic project management. So that’s a big issue for them. 
(In16) 
- Coordination among actors 
The difference in perceptions can lead to issues such as coordination between multiple 
actors. It can complicate the process of commercialisation because actors with 
different perceptions will have their own view of the world, thus preventing the actors 
from forming a common goal. Coordination among actors can be difficult because of 
differences in multiple areas, including values, communication styles, attitude, 
assumptions and expectations. Considering the number of relationships within the 
commercialisation network, the differences can complicate the overall performance 
of the network, which will, at that point, hamper the productivity of the 
commercialisation process. The coordination issues can occur at one stage or multiple 
stages; however, the level of complication increases if it occurs during multiple stages, 
as that can lead to the dissolution of the commercialisation project. These coordination 
issues sometimes also lead to subjective views of the world that foster bias, ineffective 
and unreliable outcomes. 
All 30 respondents noted the existence of cultural differences and pointed to the lack 
of coordination among actors as being directly proportional to the interruption to the 
BCP. It was variously observed that issues of coordination were due to a lack of 
compatibility (94.11%), understanding of the product (29.41%), trust (35.29%), 
commitment (17.64%), availability of a credible team (47.05%), communication 
(23.52%), lack of understanding of the regulatory framework (41.17%) and the fear 
of failure(11.76%). 
- Perfection over progress 
While 63.33% of respondents emphasised compatibility among network members as 
the most prominent problem, another important issue that emerged related specifically 
to the ideology of specific network members—that is, the researcher’s own perception 
of the world. The problem occurred mostly during the stages of imaging, incubation 
and evaluation when the strategy of the researcher became particularly focused 
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towards improving the product—this resulted in a resilient assumption that the product 
was ready for market when it was not or in a fear of failure and further loss of time 
and funds. 
The technology network has defined boundaries within the commercialisation 
network ecosystem. These boundaries divide the technical, research and industrial 
actors into different network communities. This is sometimes referred to as the triple-
helix model (Etzkowitz, 2003), according to which there is a clear difference in the 
perceptions of these three communities regarding the outcomes or activities of the 
commercialisation process. On the commercialisation spectrum, the research network 
community is purely involved in innovation and further development of the product, 
the technical community is involved in perfecting the product as per industry 
standards and the industry end is more interested in commercialising the product and 
taking it to market. There is always a conflict between these teams over perfecting the 
product to their standards of expertise, which raises issues during the 
commercialisation process and further impedes the process. These types of issues lead 
to losses of time, funds and productivity. Such issues are associated mainly with the 
psychology of the network actor and are affected by the actor’s ego, knowledge and 
level of acceptance. 
So sometimes with researchers, the other way I put it is, researchers are always looking 
for perfection over progress and you need that mix with commercially different people—
with a different culture, more of a commercial brain—to look at progress over perfection. 
(In10) 
3.4.6 Time management 
Another issue raised by 33.33% of respondents was management of time during the 
process of commercialisation. All of these respondents had previous experience 
participating in transnational collaborations during the BCP. Time management 
during the process was related to issues like recurrent process loops, network gates, 
time taken for relationship development and different time zones. 
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- Process loops and network gates 
The non-linear nature of the commercialisation process makes it iterative, with several 
feedback loops formed throughout the process based on several factors. One of the 
key factors is communication and exchange activities between the multiple network 
actors. The different types of interactions between network components (actors, 
resources and activities) also act as network-based process gates. A majority of 
respondents (90%) described it as a key issue. Respondents mentioned that to achieve 
increased productivity from a commercialisation network during the BCP, it is 
essential to recruit the right resources. The process of resource recruitment itself is a 
time-consuming activity. They also described ways in which the process of resource 
recruitment is iterative in nature. This iteration affects the sub-activities within the 
network, leading to further delays. 
We try to look at it at the beginning all the way to around C-rounds. C, A, B, and then 
you’d be part of the C round, which is when we look at giving them the funds … When 
you invest, you give the team about 12–18 months’ worth of capital. It’s built into the 
framework. You don’t give them all the capital at once. Each round is just a test to see if 
you can get to the next stage. It’s built into the way you invest. (In13) 
- Time for relationship development 
The commercialisation networks include different types of actor–actor relationships. 
Respondents highlighted that long-term relationships are advantageous for 
commercialisation purposes. These long-term relationships provide strong 
foundational network references and enhance reputation; however, to reach this level 
the commercialising organisation has to cross several levels and gates, which takes 
quite a lot of time. Such relationship development activities delay the process. 
Well, obviously, identifying them first—that takes time—then getting them engaged, so 
getting them interested. If you’re a high profile person, everyone wants your time, so 
you need to approach them in a way that will spike their interest so that you get more 
time to explain what it is you’re doing and get them on the hook basically, get them 
interested. (In15) 
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- Time zones 
One-third (33.33%) respondents faced time management issues that were related to 
the coordination of different activities among network actors located in different 
geographical regions across the globe. The geographical areas that were repeatedly 
mentioned were the USA, Europe and Canada—these were mentioned as the most 
popular markets for biotechnology innovations. The lack of coordination was a result 
of the alternating business hours which made it difficult to complete operations like 
approvals, discussions and documentation. Two-thirds (66.66%) of the respondents 
dealing with the issues of time management referred that the delays in the process 
were related to the lack of understanding of the regulatory processes or the changing 
policies of regulatory processes, which deviate the process from the expected timeline. 
Other issues included management of time with respect to funding, selection of skilled 
partners and presentation of ideas. Some respondents also indicated that 
mismanagement of time during the process eventually results in failure to reach 
market. 
Time zones are challenging, but in this industry everyone deals with it. Most of my 
clients are on the phone at all hours of night and morning because you just have to be. If 
you need that person that happens to live in Toronto and they’re the best person for the 
job, then … they’re the best person for the job. (In11) 
Mismanagement of time also limits opportunities for collaboration, as it affects 
selection criteria. The problem extenuates when multiple networks are operating at 
the same time. This also raises concerns regarding increased competition and 
competitors reaching the market before the innovating organisation. 
One other criterion was Australians working in the local time zone. It wasn’t an absolute 
criterion, but it was a preference. (In9) 
3.4.7 De-risking processes 
The capability to manage risks is required for the successful commercialisation of 
biotechnology products and was highlighted as an important skill by 26 respondents. 
A successful commercialisation approach is to maximise the outcomes of the process 
and minimise the risk during process management. This approach is known as de-
risking. De-risking itself is a multi-staged process, which involves crucial activities 
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such as exchanges, information transfers, approvals and permissions. As important as 
this activity is for any technology-based companies, it is also one of the most time-
consuming processes. 
It’s a lot less risk there, the risk in that type of product is whether or not it works clinically 
and whether it will outdo the current products that are on the market that you are trying 
to compete against. That’s … in terms of the product development side of things, most 
of that risk is taken out. You have longer development times in doing that, but you have 
less risk about the product itself. It’s more about how it will perform clinically and in the 
market in terms of pricing. (In28) 
The changing deal structures and excessive competition—such as multiple suppliers 
for different products and services in the market—are the key underlying network 
issues that influence the de-risking process, which then influences the BCP. 
- Deal structures 
The actors involved in minimising risks are a part of the commercialisation network. 
A combination of risk-minimising actors with diverse backgrounds and experiences 
form a complex network structure by collaborating in different ways. The different 
types of collaboration processes are risk bound. The increased level of complexity of 
the network structure complicates the process of de-risking. However, the actors 
involved in the process of de-risking try to design streamlined and simplified risk 
management processes, but these sometimes fail or are delayed when encountering 
the risk because of the increased complexity. If the de-risking process is delayed, this 
influences the commercialisation process by delaying it or impeding it at some stage. 
The risks really are obligated by the deal structure. So, the deal that we didn’t proceed 
with—we weren’t going to get enough money out of it to justify taking it off the table 
and not having any other ability to shop it around. (In24) 
- Excessive noise 
The competitors are a key set of actors in a commercialisation network. These 
competitors contribute by providing indirect motivation and sometimes access to 
limited resources. However, conversely, these competitors contest for resources (such 
as patents, regulatory approvals, technology designs, tools for technology 
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development and ideas), in speed to market and in accessing important network actors 
(such as key suppliers, experts and experienced skilled labour). Half of the 
respondents indicated that activities related to minimising and managing the risk 
associated with competitor activities created further complexities for the 
commercialising organisation. 
There were two X & Y distributors at the back of the room who saw that it was a good 
idea. The company, to their credit, got to the US before us, with product A. Because I 
had to constrain the patent so tightly to get it, they were able to go around it. They started 
building the market. You can’t imagine my shock when I was in the states and went, 
‘Hang on, that’s my Product A!’ (In18) 
3.4.8 Consistent barriers 
Between 65–77% of the respondents frequently spoke about common issues that affect 
the BCP, such as delays in regulatory actions (73.33%), mismanagement of 
capabilities (66.66%) and lack of socialisation (70%). It is worth noting that the 
excerpts for these themes were very direct, which signifies that these issues are 
consistently occurring and have a direct and concrete effect on the BCP. 
- Delay in regulatory actions 
The Australian regulatory system was highlighted by the respondents as a strong 
system with global recognition; however, the regulatory processes and the involved 
actors occasionally delay the BCP at various stages. 
There were two key failure areas. Very rarely was it the technology; it was mostly 
inability to run a business and failure to engage, preferably day 1, with the regulatory 
environment. (In18) 
- Mismanagement of capabilities 
The mismanagement of capabilities is a prominent issue. The BCP consists of multiple 
teams and each team consists of multiple actors. The skills for task management are 
essential for developing teams for commercialisation purposes. However, because of 
lack of experience, capabilities, funds, motivation and common goals and different 
perceptions and personal influences, the management capabilities of certain network 
actors are affected, causing delays during the BCP. 
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When it comes to clinical strategy, regulatory strategy, manufacturing strategy, and 
actually how you got the product on to the shelf and sold—the marketing side—that in 
the past … I don’t know exactly what it’s like with going through the various programs 
now, but companies seem to always come up against brick walls again and again and 
again. (In11) 
- Lack of socialisation 
Lack of socialisation is an unusual finding in a network-based study, as the foundation 
of network building is dependent on the socialisation capability of a network actor. 
However, the respondents indicated several factors that lead to a lack of socialisation, 
which influences the network building capability and in turn affects the development 
of a resourceful commercialisation network. 
We spent some time going overseas and looking at the ecosystems overseas and spent 
some time in health thinking, and also started communicating with ecosystems in Silicon 
Valley, looking at their business models, and from there really decided that while 
Australia is starting to form a cohesive network around the ecosystem, we still have a 
long way to go. We aren’t going to fix the problem; it’s a collaborative, open system that 
needs to happen. (In20) 
Network effects as promoters for BCP 
The contributing role of networks during the commercialisation process is evident in 
the established literature. The findings from this study also show the steady occurrence 
of network contributions during the BCP. All respondents emphasised the importance 
of working in a network-bound environment and how this accelerates the 
commercialisation process. 
Business networks are dichotomous in nature (Aldridge & Audretsch, 2010; Bernstein 
& Singh, 2006; Brugmann & Prahlad, 2007; Chiesa & Frattini, 2011; Epting, Gatling, 
& Zimmer, 2011; Rothwell, 1994; Vitale, 2004; Vowels et al., 2011; Woodside & 
Biemens, 2005). One aspect of their nature is to act as a promoter to facilitate 
innovation and commercialisation activities. 
This whole industry—there’s only one science which is truly enabling for all of this 
outcome success, and that’s the study of collaboration and networks. It’s the most 
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important thing. Because it’s universally enabling; we can’t do anything on our own. 
(In17) 
The findings show eight key network-based promoters, covering the advantages of the 
diverse nature of networks, the financial network support, effective network 
relationships and the socialisation capability of the network. The classification of 
these network promoters is based on time and their role in the network in accessing 
resources. 
3.4.9 Network-based funding sources 
The key network actors that provide funds and capital as a key resource include seed 
funding bodies, VCs, angel investors, government grants, university scholarships and 
crowdfunding. These are the key sources of funding that help in the progression of 
commercialisation activities (Lerner, 2002; Samila & Sorenson, 2010). Half of the 
respondents agreed that funding sources are essential to network promoters. 
And so, over the course of 17 years, we probably did about 10 to 12 million dollars in 
licensing deals like that, and we raised probably close to 20 million dollars in public 
listing, probably another 5 or 10 million in private rounds. So it was quite a substantial 
amount of money that went into the company … in Europe. (In17) 
3.4.10 Long-term relationships 
Relationships are developed between different network actors to access the required 
resources for the commercialisation processes. Some of these exchanges are 
transactional and some of these lead to long-term relationships. These relationships 
can be unidirectional, bi-directional, incidental or planned, though most relationships 
are transactional due to constantly changing network structures. However, in the 
Australian biotechnology industry, relationships have been rigid, as agreed by 46.22% 
of the respondents. 
I guess it’s about having a big enough network that you can pick and choose the people 
that you want to work with for different pieces of work that you need. At the same time, 
they’re growing their own little networks so that can be useful as well. In the early days 
they may not have had links to other groups or people that can help you, but over time 
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when they realise the need they might build their network out in a way that will 
ultimately help you as well. (In14) 
3.4.11 Social tools 
The business networks have been used as social tools for customer engagement, 
community building and relationship development and marketing activities during the 
new product development process (Kietzmann et al., 2011; Lam, 2016; Mislove et al., 
2007). The use of networks as social tools for innovation and commercialisation 
processes was highlighted by 53.33% of the respondents. The social tools for 
recruitment, investor search, supplier search, background verification, distribution and 
marketing of innovations were key advantages that assisted in the commercialisation 
of biotechnology innovations. 
We are just going to be a facilitator and supporter. We just provide online infrastructure 
… around that space; we then allow groups and communities involved around 
inventions, disruption and commercialisation to come together and be able to build 
networks, build groups, build communities and either work within or outside their own 
community and own teams. (In20) 
3.4.12 Process cycles 
It was further found that within a business network surrounding an innovation and 
commercialisation process, several processes run simultaneously. If efficiently 
operated, these processes assist in promoting the process of technology 
commercialisation. 
I then went to raise the money; initial seed funding was captured to get the initial concept 
to clinical trials, then on the back of that a number of other pieces of commercialisation 
were put in place. Then I went out and raised more money to then take the business from 
what I would call a basic business platform … It’s being sold to X … It has a team of 
people around it that can build and grow the business, and it has all the resources that it 
needs to grow. That was effectively the journey over the last 10 years. (In27) 
This analysis also allowed us to classify the type of network actor based on the nature 
of the activities from their experience. These network actors were classified as 
network collators, process supporters and network heroes. These different types of 
actors directly or indirectly assist in moving the process from one stage to another. 
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3.4.13 Network collators 
The role of such actors appears to emerge with the process from the beginning or, 
sometimes, at crucial stages of the commercialisation process. These actors perform a 
key activity: generating awareness and developing relationships to build a network 
structure around the process. 
Often that expertise is very hands-on but is also not just our own expertise but involves 
having the knowledge and the networks to bring in the right expertise, whether it’s from 
here or overseas. So that fund now has over 50 research organisations as members, so 
it’s truly a collaboration. It has been very successful as an investment fund—we’ve now 
raised our third fund, which is a $200 million fund. We’ve spat out 24 companies and 
some have been very successful, with lots still in very early stages. (In15) 
3.4.14 Network heroes 
These types of network champions are characterised as key influencers, occasional 
opinion leaders or promoters (Howell & Boies, 2004; Shane, 1995). They are usually 
available by reference, unless they are in a pioneering position. 
You have to have some hook to want to work with them and it’s hard to know what that 
is, but personal recommendation by someone who’s done a similar thing to what you’re 
trying to do who says this person is good goes a long way. (In14) 
3.4.15 Process supporters 
The supporting actor relationships may emerge at any time required, and it is not 
necessary for these relationships to last until the end of the process. These supporting 
relationships can be transactional, long-term, transient or intransigent. 
My role is to manage the regulatory piece, which is dealing with the FDA and the 
European regulatory authority and, where we need to, the Australian regulatory group, 
TGA, as well. So as you imagine, there are a whole lot of different documents that are 
needed—filings, communications and paperwork—so making sure all of those things 
happen in a timely manner. (In14) 
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3.4.16 Diversity 
The term ‘diversity’ was found to be broadly mentioned during the data collection 
process; 14 respondents highlighted the role of a diverse environment as a key for 
successful commercialisation. Diversity relates to actors and resources and their 
backgrounds, knowledge, skill sets and capacity to adapt to diverse situations as well 
as develop diverse solutions for problem-solving. The level of diversity in these 
network components was indicated to be a very useful parameter for the success of 
the BCP. 
I think they offer a lot of key ingredients. They can offer money, they can offer supply 
chains, they can international presence, they can offer marketing strategy, they can offer 
a lot of specific things. They offer support of the right time. They can actually provide 
guidance about timing the new products and how to get those to market. (In2) 
3.5 Discussion 
The main purpose of this paper was to draw attention to the network-related issues 
that act as barriers to the BCP and to identify how networks promote the process. This 
paper has highlighted eight key network-based barriers (Funding, breaking of network 
chains, partner selection and collaboration, conflict of commercial interest, difference 
in perception, time management, de-risking process and consistent barriers) and eight 
key network-based promoters (funding sources, long-term relationships, social tools, 
process cycles, network collators, network heroes, process supporters, and diversity) 
that emerge as a result of various network interactions and which may directly or 
indirectly influence the BCP. Figure 5 shows the different underlying mechanisms 
that act as network-based barriers and promoters that influence the process at different 
stages. 
A central theme in this paper has been the investigation of the dual role of the 
networks. The existing literature showed evidence of a few network interactions—in 
the form of barriers and promoters—that were affecting the process (Bandarian, 2007; 
Boehlje, 2004; Epting et al., 2011; Tahvanainen & Nikulainen, 2011). In a similar 
manner, the results in this paper (shown in Figure 5) have identified and examined the 
consequences of those network interactions, which affect the speed of the 
commercialisation process. The in-depth analysis not only testified the research 
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problem but also has resulted in a clear understanding of the adverse effects of network 
influences that affect the process at specific stages. It was also observed that some of 
the issues are common among different stages of the BCP, as shown in Figure 5. A 
strong reflection of the interdependent nature of the network components is visible 
during the BCP, as there are causal links between the findings that show some of the 
issues are interdependent. 
 
Figure 5: Revised framework showing network barriers and promoters during 
different stages of the biotechnology commercialisation process. 
Lack of funding has been a prominent issue in the industry, evident in the literature 
(AusBio Feature, 2016; Australian Institute of Commercialisation, 2010; Hill, 2016) 
and repetitively stressed by the respondents. As shown in Figure 5, it is a key 
underlying network mechanisms  all stages of the BCP. Financial aid in the form of 
research capital, funding, scholarships, grants and R & D tax incentives is provided to 
the commercialising organisations through various types of investors, including VCs, 
angel investors, crowdsourcing, government bodies, universities and large 
organisations, based on set criteria. This helps funding bodies to scrutinise the 
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organisations according to their intellectual capital, past performance score, reputation 
in the network, recognition, value creation capability, strategies for fund management 
and the expected commercial outcome. Organisations that fail to fulfil the criteria fail 
to gain funding. The finding shows that the lack of understanding of the process, lack 
of interest of the participating members or absence of the right skills for fund 
management is the reason for failure. Another critical component is the capability of 
the organisation to identify the right financial support opportunities at the right time. 
From the perspective of SMEs, the opportunity to gain funds is decreasing because of 
increasing competition. The speed to access a funding opportunity is influenced not 
only by the decadent regulatory and administrative tasks but also by the strength of 
the existing network relationships that dominate the Australian biotechnology market. 
This further leads to the development of firm boundaries that make it difficult for 
SMEs or new start-ups to penetrate the network to access the required resources. 
The empirical findings suggest that there is a lack of understanding of the difference 
between a definite commercial outcome (DCO) and an expected commercial outcome 
(ECO). Based on the respondents’ identification of different commercialisation 
outcomes, the DCO can be defined as a consequence by default for the commercial 
investment, whereas the ECO is the anticipated consequence of the commercial 
investment. This lack of understanding leads to an incoherent process of funding. 
Investors need to assess the commercial projects in terms of DCOs rather than ECOs. 
This would further enhance the quality and strength of the network relationships 
between the investors and the fund-seeking organisations. It would also reinforce the 
trust components and allow secure transactions between the two actors. It would have 
a positive effect on the BCP, enhancing the overall process.  
The analysis of the data identified several barriers related to the breaking of the 
network chains because of changing network structures and companies going into 
administration, leading to delays in the BCP. Network structures change because of 
different types of stimulus from internal and external components of the network 
(Halinen et al., 1999). The stimuli can be resource-based, activity-based or actor-
based. These stimuli may lead to the building of new network relationships or to the 
breaking of existing relationships. These stimuli may be induced or generated 
internally, depending on the requirement of the process. The key areas where 
112 
morphing network structures have a major effect are the pre-commercialisation and 
commercialisation stages of the process, as shown in Figure 5. 
One of the key reasons for the dissolution of a network is the innovating organisation 
shutting down because of managerial mistakes, financial instabilities, liquidations, 
bankruptcy or companies being sold, which is mainly the case with small 
organisations. These changes then lead to the breaking of internal and external 
networks (tier 1) of the organisation. This then replicates into the breaking of the tier 
2 networks. These networks may or may not form relationships with other connecting 
networks. In such cases, these organisations are usually acquired by or merged with 
larger organisations, resulting in profitable collaborations. Such factors indicate that 
changing network interdependencies have unpredictable effects based on different 
actor motivations. 
The selection of the right partner for commercialisation was identified as a dominant 
barrier across all stages of the BCP, as shown in Figure 5. Selection is based on the 
identification of skills and credibility. The literature frequently mentions lack of skills 
as one of the prominent network-related issues during the BCP. In agreement with 
this, this study’s empirical findings pointed to the consequences of inappropriate 
decision-making concerning partner selection. This influences the activities of 
resourcing, strategy design, communicating, process mapping, coordinating and 
planning. This indicates that establishing judgement criteria before different activities 
during the process should be a streamlined and transparent process. Failing to achieve 
the required standards also affects activities related to investment decisions, partner 
selection, team identification, sponsor selection, disclosure of product and the idea (as 
it may affect confidentiality). 
A wide range of collaborations occur during the BCP and each exchange between 
these network actors is based on specific criteria. The criteria established for such 
exchanges vary from rigorous to lenient. For example, guidelines provided by 
authoritative bodies to the innovating or commercialising organisations is an 
obligation that has to be followed; conversely, the partnerships based on verbal 
commitments are flexible until organisations have reached the stage of establishment 
and commitment in the relationship development process (Broch, Maniscalco, & 
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Brinberg, 2003). In both situations, the ability of the organisation to prove its potential 
plays a key role in the BCP. 
The efficient yet stress-free access to funding will allow SMEs and other 
commercialising organisations to develop separate departments and recruit skilled 
experts in each department. This further allows for the distinction of roles and easy 
collaboration of multiple teams, with each team focusing on specific tasks during the 
different stages of the BCP. Collaboration of expertise also allows effective 
information and knowledge exchange. It is important to acknowledge that the 
collaboration capability would also be advantageous for building a reputation and 
increasing recognition among the networks. Having different levels of expertise on-
board will allow network relationships to develop. 
It was found that motivational conflicts between network actors lead to the generation 
of poor or limited commercial outcomes. This paper has been able to identify the key 
reasons for this network influence: lack of trust, lack of commitment, lack of 
acknowledgement sharing and differences in perspective. Organisational culture and 
hierarchy, organisational rivalry, mismatched expectations and the race for 
recognition form the basis of differences in motivation. Research interests, the 
competition of ideas, miscommunication and the incapability to collaborate also 
influence the decision-making power of the individual network members and the 
organisation. 
It was found that the perception of the value of the commercial outcome has an 
encumbering effect on the BCP. Some network members, specifically researchers or 
developers and universities, tend to generate value through research and development 
activities. Only a few actors in that category show an affinity for achieving 
commercial value from commercially viable technology. On the post-
commercialisation end of the process, the marketing, resourcing, prospecting and 
investing teams perceive value in terms of IP, licensing, patenting, start-ups, sales and 
profits. There is a need to find common ground for collaboration among 
interdisciplinary teams. This aligns with the results of other studies (Gorman et al., 
2006; O’Shea, Allen, Chevalier, & Roche, 2005). This friction in perception raises 
cultural conflicts that further inhibit commercialisation. 
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This research finding also draws upon the cultural differences that arise during 
collaboration between multiple organisations during the BCP. Cultural conflicts arise 
at all levels of the organisational relationship hierarchy. Collaborators from overseas 
markets or international collaborators in the Australian market occasionally fall into 
the cultural misfit category based on the way they conduct business. The cultural 
challenges are not limited to inter-organisational collaboration with external 
stakeholders; they also extend to intra-organisational stakeholder relationships. 
Considering the benefits that the multicultural Australian biotechnology market 
provides to the commercialising organisations (in terms of access to wider networks 
and limited resources and the wide customer base), the organisations tend to 
undermine the challenges that accompany these cultural collaborations. The bases of 
cultural conflicts include inappropriate communication and information exchange 
strategies and lack of understanding of needs and requirements of different network 
members, such as industrial needs and technical capabilities. 
It was also found that time management and coordination of activities based on 
different time zones is an underestimated problem that leads to the mismanagement 
of the commercialisation process. Timely management of resources, skills, capital and 
practices can prevent process delays and help in the design and delivery of a cost-
effective commercialisation strategy. The time taken to manage and develop 
relationships for accessing other useful partners might not align well with the timeline 
of a commercialisation process. Time taken for reference checks, accessing the right 
network partners and judging compatibility based on the capabilities of the other actor 
delays the relationship development process. This could lead to further delays in 
taking actions necessary for commercialisation. Therefore, respondents indicated that 
management of time is important for dealing with such issues and for identifying the 
right opportunity to hit the market. This confirmed the notion that before initiating the 
process of innovation and commercialisation an important step is understanding 
market need. 
Another key barrier in the BCP is de-risking. Different types of risk are associated 
with managing the commercialisation processes; for example, trial management, 
financial, regulatory, competition, technical and project management risks. The 
network around the process includes specialised actors and resources that assist in 
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minimising or eliminating these risks. This process assists network actors involved in 
the commercialisation process to secure investments, gain trust, build and maintain 
reputations and protect against potential future liabilities. During this elimination 
process, the actors encounter issues—such as rapidly changing deal structures and 
increasing competition in the market—that are likely to hamper the process of de-
risking and hamper the commercialisation process. Therefore, a strategic approach is 
required by organisations that are commercialising biotechnology innovations to 
progress through the de-risking process with less time-consuming and more effective 
processes. 
Some key barriers that consistently create hurdles for commercialising organisations 
include delays in regulatory approvals, the mismanagement of capabilities and the 
lack of socialisation. The technology commercialisation process operates within the 
tight boundaries of the regulatory framework. These regulatory frameworks are 
guidelines provided by the government or different regulatory authorities that direct 
the innovating or commercialising organisations throughout the process. These 
regulatory actions act as hurdles or gates that all involved actors are required to cross 
or pass through to reach the next stage of the process. Delays are mainly caused by 
issues of time management, lack of knowledge of regulatory frameworks, limited 
availability of regulatory resources and high costs, along with several other factors. 
This sometimes also leads to a complete shutdown of the commercialisation process. 
The mismanagement of capabilities is a prominent network activity related issue 
during the BCP. The consequence of such mismanagement can lead to the selection 
of the wrong partners—thus building less productive teams and resulting in poor 
communication that can negatively affect the process of technology 
commercialisation. For example, in certain circumstances, mismanagement of skills 
affects the innovating SMEs at the pre-commercialisation and post-commercialisation 
stages, as can be observed in Figure 5. Due to the limited availability of the required 
resources, the SMEs have to licence viable innovations to big pharmaceuticals that 
otherwise have the potential to be directly diffused into the market. In this process, 
the SMEs suffer through financial losses and the issues related to organisational 
disintegration. Mismanagement of skills leads to an incapacitated BCP by affecting 
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the stages of the process during the activities of reimbursement, regulatory approvals, 
adoption and diffusion. 
Lastly, a lack of socialisation was another consistent barrier. It is based on multiple 
factors, such as limited communication, lack of certainty of the idea, language issues, 
misjudgment of the useful network activities, actor egos, level of control in the 
network, lack of knowledge about the importance of socialisation and use of incorrect 
platforms for socialisation. One of the key issues was the age gap between younger 
network actors and older generations and their preferences regarding communication 
channels and content. Limited socialisation leads to the formation of weak network 
structures that decelerate the BCP at all stages. 
This study also advances network management knowledge by demonstrating the 
advantages of commercialising within a network. It aligns with the work of Sandberg 
and Aarikka-Stenroos (2014), Chen and Lin (2017), Rampersad et al. (2010) and 
Stuart, Ozdemir and Ding (2007). It shows the diverse nature of networks in terms of 
interdependencies, configurations of networks, position and complexity and how they 
affect key stages of the commercialisation process. Diverse actors add a variety of 
skills and resources, personal capacities, alliance formation opportunities, guidance 
and regulatory understanding. The network actors also facilitate learning during the 
process through knowledge exchange and experience. Diversity leads to a range of 
challenges, while also providing various solutions for those challenges. 
As shown in Figure 5, lack of funding has been highlighted as a key challenge across 
all stages. However, the availability of funding resources is also a significant 
contribution of network components at all stages of the process. Some promoters in 
the form of various actors (individual or organisational), such as VCs, government 
bodies, angel investors, financial aid and university grant offices, provide capital, 
monetary deal structures and financial benefits that support the BCP at various stages 
(Chen, 2009; Hsu, 2006; Powell et al., 2002). Funding bodies raise different types of 
funds specific to the stages of the process. The planning involved in fund management 
processes includes different network activities, such as process pathway identification, 
process team identification and process approach identification. Fundraising activities 
drive the network members to select better teams and develop reimbursable products. 
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The advantages of network relationships have been widely highlighted in the network, 
innovation, business, organisational and industrial literature (Ceci & Lubatti, 2012; 
Hakkanson & Ford, 2002; Jackson, 2011; Symeonidou, Bruneel, & Autio, 2017; 
Varey, 2008). This study has also demonstrated that network interdependencies and 
configurations, when coupled with long-term relationships, lead to the formation of a 
potential commercialisation pathway. It shows that access to advantageous network 
resources and exploration and exploitation of those resources within a 
commercialisation network needs a comprehensive, reliable and dependable network 
structure with multiple webs of stable relationships. 
In figure 5, the role of social tools and process cycles as a network promoter can be 
observed to affect multiple stages of the process. There is a debate within the literature 
concerning the effect of social tools in business-to-business markets (Berthon et al., 
2012; Kaplan & Haenlein, 2010); however, the literature fails to specifically identify 
the application of social media platforms and the support gained from collaborative 
social networks, social events for conducting various types of innovation and 
commercialisation activities. Thus, it is important to understand how these tools and 
their components can be utilised for facilitating the BCP. Some of these tools will be 
related to the innovation activities; however, those activities appear to be foundations 
for future commercialisation activities. Although this study has identified  few areas 
of social media application during the BCP, it is a key area for future research, as more 
understanding is needed to identify the specific social channels and their application. 
Innovation and commercialisation processes are non-linear and iterative (Chen & Lin, 
2017; Harmon et al., 1997; Wright, Birley, & Mosey, 2004). With the increasing 
interest in lean models (Bicen & Johnson, 2015; Grohn et al., 2015; Thakur, Cabrera, 
DeCarolis, & Boni, 2018) for biotechnology innovation, these processes assist in 
taking into account the perception of various network actors before innovation and 
commercialising the technology to meet market needs. Further, such processes are a 
result of multiple interactions within the ARA components of the network. These 
processes assist in building agile and apt technology transfer pathways and generate 
dynamics within business networks that affect the process at multiple stages. 
The roles of different network actors have been analysed and classified to be very 
important based on the types of activities of the network members. The role of network 
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champions (Bridge, 2017; Howell & Boies, 2004; Walter et al., 2011) has been 
positively highlighted in the established innovation literature—individuals that 
emerge and promote the process of product/service innovation through the innovation 
process and assist in the implementation of the innovation. However, the role of such 
champions is not clear during the commercialisation process. The data show that one 
type of network champion is an actor who is a network collator. They gather all the 
essential resources that would facilitate the process and the execution of 
commercialisation activities at various stages of the process. These activities vary 
depending on the requirements of the process. 
One useful role of a network champion is to act as a spontaneous problem solver 
(Bridge, 2017; Howell & Boies, 2004; Shane, 1995). These network heroes are actors 
who can solve a problem by pioneering the method to solve the issue in a particular 
situation or by emerging spontaneously only during a specific situation. These are 
adaptable actors and sometimes they have multiple types of expertise. Such network 
promoters are usually highly experienced and have a known reputation within the 
network. They usually have strong relationships within a network and have a 
capability and experience of connecting several networks together. 
The literature has introduced and somewhat elaborated the concept of network 
dynamism, strategic flexibility and the benefits of relationship adaptability within a 
network structure (Koka et al., 2006; Madhvan, Koka, & Prescott, 1998; Ritter & 
Gemünden, 2003). Another way of understanding network adaptability is by 
understanding the effects of flexible relationships on the process of technology 
commercialisation. A useful adaptable network relationship is the type that occurs 
between network actors and the process supporters. These supporters can be different 
network actors who provide resources that support activities during different stages of 
the process. These actors may or may not: be present at the beginning of the process, 
be an official part of the process (legally bound or in the contract), obtain expected 
outcomes from the process or obtain any benefits from their involvement. 
Adopting a qualitative methodology and a semi-structured interview approach 
provided an in-depth and comprehensive understanding of this network-based 
phenomena. The findings assist in understanding the network-related barriers and 
promoters and their influences on the BCP. 
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3.6 Contribution 
An important gap in the existing literature regarding the understanding of a network-
bounded BCP and its success was identified. The gap was addressed through a 
framework based on commercialisation and network theories and partly based on 
innovation theories that assist in the better understanding of the necessary network-
based conditions for exploration in the context of biotechnology commercialisation in 
Australia. It was then aligned with the empirical findings that identified the network-
related barriers and promoters. 
The key theoretical contribution of this research is that it provides new information 
and understandings of how networks operate during commercialisation. It also adds 
new evidence to the existing literature about the types of barriers that block the BCP 
and, simultaneously, act as promoters of successful commercialisation. The findings 
suggest that vertical or horizontal network chains around the BCP require strong 
network management. Network chains should be managed equally at both individual 
and organisational levels in the network structures. Due to the dynamic nature of 
network structures, this would further help in identifying the network-related factors 
that lead to morphological changes in network structures when networks move from 
one stage of the commercialisation process to another. These findings also suggest 
that individual-psychological factors, such as personal interests and perceptions, play 
a dominant role in technology development and commercialisation. Although 
networks are mainly known for individually contributing to knowledge-sharing 
activities and the acquisition of required skills and capabilities, understanding 
perception-based behaviours of network actors during such process-based studies can 
help in identifying and employing effective network management and team training 
techniques. 
Theoretical funding models rarely view the BCP from a network lens. The findings of 
this study assist in identifying the areas of strong network influence that will allow 
future researchers to conceptualise and examine funding models around the BCP to 
develop improved understandings of intra-organisational and inter-organisational 
funding processes. This will further assist in the exploration of funding-related issues 
caused by the negative interactions between different network components. It can be 
achieved by establishing causal links between different network components; for 
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example, the strength of actor relationships and personal perceptions of the involved 
actors. This particular causal link explains the influence of network interactions on the 
funding processes from the early stages of the commercialisation process, where 
investors (network actors) who provide seed funding or entrepreneurial start-up funds 
(resources) seek projects mainly based on personal interests (perceptions) and strong 
references (long-term relationships). Understanding such causal links will assist 
researchers in suggesting methods to counter issues that emerge as a result of different 
types of network barriers. 
The emerging literature on social tools, social capital and socialisation has generated 
awareness in the academic community of the effect of such tools during the process 
of technology development and management. The findings of this study suggest that 
network-based interactions are the key components for the development of social 
instruments that affect various stages of biotechnology commercialisation. However, 
the limited understanding of how these tools can be implemented has proven to be a 
major obstacle for several organisations in commercialising successfully. These 
findings indicate that these tools are important particularly during the later stages of 
the process. However, more research is needed on how these tools can be employed 
in existing network structures or how new network structures can be generated using 
social tools as an important network component. 
Another academic contribution is the model that will allow researchers to map 
networks around the process of commercialisation and is expected to expand 
knowledge on network behaviours and build upon the theoretical aspects of 
understanding the influence of networks on commercialisation. This will also allow 
the expansion of theoretical understandings of network-related gates during the BCP. 
The findings of this study align with the stage-gate models that are popular in the 
innovation management literature. However, these network gates are based on 
blockages that are generated from network-based activities. This research contributes 
to understanding the different types of network gates, the bases on which they are 
generated and the stages of the BCP where they exert an influence. However, further 
research is needed to understand how barriers can be managed and eliminated as the 
process progresses. 
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This research has managerial implications. Managers and executives of R & D firms, 
financial firms and university commercialisation departments can apply this research 
to successfully design solutions to facilitate the commercialisation of biotechnology 
innovations. The identified stages and phases of the BCP and the network links will 
help managers assess each stage of the process and identify the resources and network 
capabilities required for that particular stage. The research findings based on the 
interview data from 30 biotechnology experts will assist start-ups and entrepreneurial 
leaders in understanding the prerequisites of the innovation and commercialisation 
processes. 
The results of the study can be used for making various investment decisions, such as 
fund-seeking organisations seeking to identify the right funding resources and to 
design effective fundraising strategies. It also provides investors with an 
understanding of the difference between types of commercial outcomes, which is 
likely to influence their investment decisions. This also provides the managers with 
an opportunity to develop selection criteria for collaboration purposes. Further, this 
framework provides the basis for well-coordinated team management. It provides an 
understanding of different types of network-based conflicts and suggests several ways 
to resolve such conflicts. Conflict dissolution strategies can be designed based on 
these findings as the data provides an understanding of the different perceptions of 
network members. This also encourages managers to develop collaborative 
environments and identify the common grounds for collaboration. 
The study also provides information on how to identify ways to strengthen or improve 
relationships with relevant partners at all stages of the commercialisation process. 
Information regarding the development and management of network-based 
relationships during the BCP can also be applied to university–industry 
collaborations, where network-related issues around collaboration and technology 
transfer can be resolved. The framework for identifying individual network-related 
barriers and promoters illustrates the important network-related dimensions of the 
innovation and commercialisation process and depicts how business networks can be 
integrated into cross-collaborated commercialisation processes all the way from the 
pre-commercialisation phase to the post-commercialisation process during the stages 
of licensing, adoption and diffusion. 
122 
3.7 Limitations 
This framework draws upon extensive theoretical research and empirical research 
from 30 biotechnology industry experts from organisations representing different 
actors of the network. However, only one or two members represent each type of 
organisation, which contributes to increasing the generalisability of the findings 
within the context of Biotechnology industry. To further enhance the generalisability 
of the findings, another quantitative study could focus on understanding how network-
related components/variables change during the different stages of the 
commercialisation process: 
• number of actors that increase or decrease from one stage to another 
• number of factors affecting changing network structures 
• level of interdependency between actors, scaled between strong and weak at the initial 
and later stages of the commercialisation process 
• number of network-related factors that inhibit or promote each stage of the process. 
This type of quantitative study is likely to contribute knowledge and insights to the 
existing literature about networked commercialisation. 
In addition, this study observes the biotechnology commercialisation network in 
Australia. As such, it cannot be assumed that these findings apply to biotechnology 
industries in other geographical areas. It is possible, however, that these findings may 
be generalised to other industries while differing significantly among specific 
technology-based industries. This study has been conducted from a network 
perspective; however, it is expected that the findings can be used as a reference and 
combined with a different perspective to resolve the issue of biotechnology 
commercialisation. These limitations also identify relevant opportunities for future 
research. It is hoped that this research will guide future researchers to understand the 
links between network dynamics and commercialisation. 
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Chapter 4: Ecosystem Mechanics and Their Effects on the 
Process of Biotechnology Commercialisation (Paper 3) 
Abstract: The purpose of this paper is to reframe the perspective of network influence 
on commercialisation to include levels of adaptation and dynamic involvement. The 
established literature emphasises understanding ecosystem dynamics from a 
conceptual perspective and in the context of the new product development process. 
However, the literature has limited information about the effects of underlying 
interactions in the process of biotechnology commercialisation. This empirical study 
was conducted using 30 semi-structured interviews with biotechnology innovators. 
This research led to the identification of key network interactions for the 
commercialisation process where the networks’ influence and adaptation have the 
greatest effect. A conceptual model of network interactions to improve commercial 
outcomes is proposed. 
Keywords: networks, commercialisation, commercialisation process, network 
dynamics, biotechnology 
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4.1 Introduction 
In the network and innovation literature, network dynamics have recently gained a lot 
of attention (Andersen & Medlin, 2016; Freytag & Ritter, 2005; Gadde, 2014; Garnsey 
& Leong, 2008; Geiger & Finch, 2010; Hakansson & Henders, 1995; Kinnunen, 
Sahlman, Harkonen, & Haapasalo, 2013). Interactions and change are constant within 
a network environment (Andersen & Medlin, 2016; Elo, Halinen, & Törnroos, 2010; 
Ford & Håkansson, 2006; Iansiti & Levien, 2004). This observation is particularly 
relevant for interactive network dynamics revolving around the process of technology 
commercialisation. The importance of understanding network dynamics in the context 
of the process of technology development and commercialisation has been recognised 
in various studies conducted on commercialisation business ecosystems (Aarikka-
Stenroos et al., 2014; Abrahamsen, Henneberg, & Naude, 2012; Adner, 2006; Ford & 
Redwood, 2005; Garnsey & Leong, 2008; Halinen et al., 1999; Huang, Farrukh, & 
Shi, 2018; Kinnunen, Sahlman, Harkonen & Haapasalo, 2013; Peltoniemi & Vuori, 
2004; Zahra & Nambisan, 2012). 
Studies related to the business ecosystem from the network dynamics perspective are 
of particular importance when new product development processes result in the 
development of new business models or important stakeholder relationships 
(Kinnunen Sahlman, Harkonen, & Haapasalo 2013; Lewis, Hayward, & Baxter, 
2017). Ecosystem dynamics studies have been helpful in identifying challenging areas 
within an ecosystem, which has helped innovating organisations to improve value-
creation strategies for both upstream and downstream partners involved in the process 
(Adner, 2006; Kapoor & Ardner, 2010; Jacobides, Knudsen, & Augier, 2006; Pisano 
& Teece, 2007). Evidence suggests that business ecosystems have been very useful 
for individual network actors, especially when the actor lacks the capability of 
commercialising a product or service by relying on its competencies (Ahuja, 2000; 
Baptista, 2000; Clarysse, Wright, Bruneel & Mahajan, 2014; Zahra & Nambisan, 
2012). The commercialisation process relies heavily on network contributions to gain 
an edge and to successfully diffuse new technologies through their desired 
commercialisation outcomes. Thus, it is important to extend the understanding of 
network-based dynamics beyond the existing knowledge of network ecosystems in 
the context of the commercialisation process. 
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An empirical study was conducted using 30 semi-structured interviews with CEOs, 
commercialisation managers, researchers, consultants and investors from the 
biotechnology field to understand the mechanisms related to business ecosystems and 
with relevance to the BCP. This allowed the researcher to explore the key interactions 
related to the network dynamics that affect the BCP. Earlier studies on business 
ecosystems focused on understanding the evolution of different network interactions 
that emerge as a result of the interplay between the key dimensions of a business 
ecosystem (Adner, 2006; Moller & Halinen, 2017; Peltoniemi & Vuori, 2004; Teece, 
2007). These studies specifically focused on understanding innovation, business 
ecosystems and network dynamics, which only partially contributes to understanding 
the effects of such on the network character of the BCP. So although the analytical 
approach in the industrial marketing and research management literature is not new, 
there is limited research that seeks to understand the effects of network dynamics on 
the BCP. This study offers an alternative perspective for viewing the network 
structures underlying the commercialisation ecosystem, which will help in identifying 
the positive and negative influences of the emerging network dynamic interactions on 
the commercialisation process. By using an ecosystem dynamic view to examine the 
underlying interactions of the commercialisation process, this study expands the scope 
of the investigation beyond its existing focus by identifying the underpinning 
mechanisms that help deal with uncertainty during the process and provide a 
competitive advantage (Iansiti & Levien, 2004; Kapoor & Ardner, 2010; Lieberman 
& Montgomery, 1998; Moller & Halinen, 2017). 
This study aims to address this important topic by analysing the different types of 
network influences occurring within a commercialisation business ecosystem. The 
biotechnology industry was selected because it is an important knowledge and 
technology-based industry with a widespread network. It consists of a combination of 
divergent actors that are involved from the stage of new product development all the 
way through to commercialisation. The main purpose of this study is to understand 
the motives and the manifestations of the network exchanges and their role in 
generating network dynamics during the BCP. Specifically, the intent is to explore the 
effects of network dynamics on the BCP. 
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This paper is organised into six sections. The first section introduces the aim and 
purpose of the study. The following section discusses the theoretical foundations and 
key concepts, explaining the definition and role of business ecosystems and network 
dynamics in the context of the BCP. The third section discusses a preliminary 
conceptual framework for analysing the different interactions that generate network 
dynamics and their link with the BCP. The next section discusses the research 
methodology and design. The fifth section discusses the findings through a table of 
analysis showing the revised framework and a table of the analysis. The final section 
discusses the managerial and theoretical contributions and the limitations of this study. 
4.2 Theoretical Background 
This study draws on the literature on inter-organisational network components, 
network ecosystems and the BCP. This section explores the concept of network 
ecosystems and its components and studies their dynamics. 
4.2.1 Business ecosystem 
Business ecosystems are a key source of all the required resources, competitive 
advantages, skills and capabilities during the BCP. This increasingly popular concept 
has been defined in the literature by several researchers (Adner & Kapoor, 2010; 
Clarysse et al., 2014; Corallo, Passiante, & Prencipe, 2007; Cowan, 1994; Iansiti & 
Levien, 2004; Kinnunen et al., 2013; Moller & Halinen, 2017; Moore, 1996; 
Peltoniemi & Vuori, 2004; Rong, Hu, Hou, Ma, & Shi, 2013; Weiller & Neely, 2013). 
In their broad studies, Iansiti and Levien (2004) and Peltoniemi and Vuori (2004) 
mentioned different analogies of the business ecosystem and identified its key 
characteristics. Several other studies have been conducted to understand innovation 
ecosystems and have clarified how interrelated networks within a business ecosystem 
influence the process of product innovation (Ardner, 2006; Auserwald & Dani, 2017; 
Baden-Fuller & Haefliger 2013; Chesbrough & Appleyard, 2007; Iansisti & Levien, 
2004; Xiaoren, Ling, & Xiangdong, 2014; Zahra & Nambisan, 2012). 
Business ecosystems are the interrelated ‘network of networks’ with multiple 
organisations in an individual relationship within a focal organisation (Corallo, 
Passiante, & Prencipe 2007). Based on the ARA theory provided by Hakansson and 
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Johanson (1992), networks contribute three layers of network components that 
influence different organisational processes. Business ecosystems achieve their goals 
through multiple dynamic interactions between different network structures, which 
are the permutations and combinations of different actors, resources and activities 
(Adner, 2017; Gertler & Levitte, 2005; Gilsing & Nooteboom, 2005; Marra, 
Antonelli, Pozzi, & Sarra 2017; Smith & Powell, 2004). Biotechnology networks 
commonly refer to the collaboration of interdependent and interconnected network 
entities (individual or inter-organisational), such as universities, government bodies, 
funding organisations, commercialisation agents, TTOs, research institutes, 
incubation facilities, suppliers, customers, patent attorneys and customers. The main 
goal of an interrelated network is the development and commercialisation of new 
technologies and knowledge. 
Business ecosystems are heterogeneous; this affects the entire network structure of the 
ecosystem (Iansisti & Levien, 2004). The interwoven dynamics of the network 
ecosystem are a consequence of the interplay of several ecosystem dimensions. Based 
on this view, the key dimensions of the network ecosystems that create value for the 
commercialisation process are interdependence (Adner, 2006; Peltoniemi & Vuori, 
2004; Teece, 2007), transition (Andersen & Medlin, 2016), relationship development 
(Hakansson & Ford, 2002; Teece, 2007; Varey, 2008), complexity (Moore, 1996; 
Peltoniemi & Vuori, 2004; Teece, 2007), openness (Iansiti & Levien, 2004; 
Peltoniemi & Vuori, 2004; Teece, 2007) and adaptation and flexibility (Moore, 1998; 
Xiaoren et al., 2014). The involvement of networks during the commercialisation 
process (Bnadarian, 2007; Chevalier & Roche, 2005; Goldenberg et al., 2009; 
Harrison & Waluszewski, 2008; Martyniuk et al., 2002; Woodside & Biemans, 2005) 
provides an understanding that effectively managed commercialisation ecosystem 
dynamics leads to the transmission of higher value across the network, which 
facilitates the successful commercialisation of viable innovations (Adner, 2006; Hearn 
& Pace, 2006; Kinnunen et al., 2013; Valkokari, 2015). 
The literature on commercialisation networks further supports the view that network 
components within a business ecosystem play a dual role—that is, they can influence 
the BCP both positively (Bourlos, Magnusson & McKelvey 2012; Brugmann & 
Prahlad, 2007; Datta, Avimanyu, Mukherjee, Debmalya, Jessup & Len 2014; Fielder 
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& Welpe, 2011; Siegel, Waldman, Atwater & Link, 2004; Varey, 2008; Vowels, 
Thirkell & Sinha 2011; Woodside & Biemens, 2005) and negatively (Farrell & 
Saloner, 1985; Goldenberg, 2009; Harrison & Waluszewski, 2008; Nooteboom, 2000; 
Woodside & Biemans, 2005). Studies that focus on understanding ecosystem 
dynamics (Andersen & Medlin, 2016; Halinen, Medlin, & Tornroos, 2012; Medlin & 
Tornroos, 2015) suggest that network structures and individual actors or organisations 
are in a state of continuous flux and this movement induces a shift that is a result of a 
continuous exchange between these network structures. Therefore, the positive and 
negative influence of these interactions can transmit from one structure, individual or 
organisational entity within the network to another. 
The significance of embedded network dynamics, specifically in the context of the 
BCP, is an imperious extension to the industrial network approach. Broadly several 
studies suggest that network dynamic studies play a crucial role in developing 
network-based strategies (Andersen & Medlin, 2016; Ford & Redwood, 2005; Freytag 
& Ritter, 2005; Gadde, 2014; Garnsey & Leong, 2008; Geiger & Finch, 2010; Halinen 
et al., 1999; Iansisti & Levien, 2004; Kinnunen et al., 2013), which further influences 
the process of commercialisation. Dynamic interactions facilitate the understanding 
of marketing and distribution systems (Halinen & Tornroos, 1998; Stern & El-Ansary, 
1977). Studying network dynamics also helps in understanding the roles and 
perceptions of network actors; this in turn helps in designing strategies to resolve 
conflicts in an inter-organisational environment (Freytag & Ritter, 2005). 
Understanding the dynamics behind the confined and connected changes within the 
network ecosystem improves the management of networks involved in the process 
(Halinen & Tornroos, 1998). 
4.3 Development of the Conceptual Framework 
The literature provides the basis for building up a preliminary framework for 
establishing the links between different network ecosystem components, their 
resulting dynamic interactions and the BCP (see Figure 6). First, the actor, resource 
and activity components of the network ecosystem were considered based on the ARA 
network framework laid by Hakansson and Johanson (1992). The literature on 
biotechnology networks, innovation and commercialisation processes helps in 
identifying the key actors, resources and activities involved during the process 
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(Aarikka-Stenroos & Sandberg, 2014; Datta et al., 2014; Fielder & Welpe, 2011; Jolly, 
1997; Siegel, Waldman, & Link, 2003; Vowles et al., 2011; Woodside & Biemans, 
2005), as outlined in Figure 6. 
 
 
Figure 6: Preliminary framework showing the effects of network dynamics on 
the process of biotechnology commercialisation. 
The network ecosystem literature identifies that components within a network 
ecosystem interact in various patterns to generate network dynamics. Actors interact 
individually, as an organisation, as a community or as a cluster (Iansiti & Levien, 
2004; Moore, 1993, 1996; Peltoniemi, 2004; Peltoniemi & Vuori, 2004). These actors 
interact intentionally, incidentally, continuously and discontinuously to support the 
commercialisation process at various stages (Clarysse et al., 2014; Moore, 1996; 
Peltoniemi & Vuori, 2004; Pucci, Runfola, Guercini, & Zanni, 2018). Hence, the 
different types of ARA interactions between different individuals and inter-
organisational entities that form different network structures around each stage of the 
BCP were taken into account. The interactions referred to here were drawn from the 
literature (e.g., Chetty & Campbell-Hunt, 2003; Colombo & Delmastro, 2002; Kilduff 
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& Krackhardt, 1994; Lechner & Dowling, 2003; Partenan, Möller, Westerlund, 
Rajala, & Rajala,  2008; Song & Thieme, 2009). 
Business network dynamics is an interesting domain, as it involves examining 
different types of interactions around each stage of the commercialisation process. 
Taking all these into account in the research framework, this study addresses the role 
of business ecosystems and its components during the BCP. This study considers four 
key network dynamics influences that result from interactions among the ARA 
components: (1) network movements (2) network relationships (3) network structure 
and (4) network acuity. These different types of network dynamic influences are a 
result of rotation, evolution and termination of actor roles, resource requirements and 
activities concerning different stages of the BCP. However, how these network 
patterns change and emerge has not been clearly defined. 
4.3.1 Types of network movements 
As demonstrated in Figure 6, commercialisation network movements are the result of 
the path commenced by participating organisational actors from one stage of the 
commercialisation process to another. The nature of resource exchanges and the 
activities during the process of technology commercialisation can vary with respect to 
the timing of the resource requirement during the process (Aarikka-Stenroos & 
Sandberg, 2014; Bidault, Despres, & Butler, 1998; Palmberg, 2004; Song & Thieme, 
2009; Wasti & Liker, 1997; Wynstra, Weggeman, & van Weele, 2003). This 
phenomenon further instigates the movement of different actors within the network 
that influence the BCP at various stages. 
The established literature facilitates the identification and classification of the network 
movements that influence the process of technology commercialisation into different 
types (Chen, 2009; Colombo & Delmastro, 2002; Dröge, Jayaram, & Vickery, 2004; 
Palmberg, 2004; Schiele, 2010; Song & Thieme, 2008). These movements are mainly 
generated during the process as a result of interactions between the network actors, 
the resources and the activities involved during the BCP. 
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4.3.1.1 Jumping actor phenomenon 
The jumping actor influence can be defined as the symmetrical and asymmetrical 
movement of the entities, mainly in the form of an individual actor or as an 
organisation, from one stage of the commercialisation process to another. This type of 
network movement involves various activities that may or may not be favourable to 
the commercialisation process. For example, previous studies (Bidault, Despres, & 
Butler, 1998; Palmberg, 2004; Song & Thieme, 2008; Wasti & Liker, 1997; Wynstra 
et al., 2003) identified the role of suppliers during the process of technology 
commercialisation. Collaboration with suppliers is known to provide technological 
opportunities, operational facilities, higher quality capabilities and increased 
capacities especially during the time of technological advances. The literature 
indicates that suppliers are partly embedded in the network mostly during the pre-
commercialisation and post-commercialisation stages (Dröge et al., 2004; Harrington 
& Srai, 2017; Schiele, 2010). One of the key reasons for increased supplier integration 
during the process is the need of supplier-specific resources, which changes from stage 
to stage (Harrington & Srai, 2017; Schiele, 2010). 
Similarly, financial organisations and investors are a valuable part of the BCP at 
various stages. VCs facilitate start-ups by providing them with capital, management 
skills and several value-adding services (Chen, 2009; Fleming, 2015; Von Burg & 
Kenney, 2000). These VCs and other financial investors are prominent mainly during 
the commercialisation and post-commercialisation phases of the commercialisation 
process. Incubators, universities and research institutes are involved during the pre-
commercialisation and commercialisation stages. Several incubator services provide 
reputation, laboratory facilities and human resources, thus adding value to innovation 
projects (Chen, 2009; Colombo & Delmastro, 2002). These actors, resources and 
activities move in either a continuous or discontinuous pattern from one stage/phase 
to another. This further leads to the evolution and termination of small network 
structures around each stage of the commercialisation process. 
4.3.1.2 Resource iteration 
Based on previous research, resource iteration can be defined as a discontinuous 
movement of organisational resources, both internal and external, from one end of the 
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BCP to another. The literature on biotechnology commercialisation and innovation 
highlights that during the pre-commercialisation of the BCP, different entities are 
involved in various activities, such as communication through feedback and 
knowledge/data/information exchange about market needs and selection of the right 
commercialisation partners (Aarikka-Stenroos et al., 2014; Ballentyne & Williams, 
2008; Cooke, 2001; Gertler & Levitte, 2005; Kapoor & Lee, 2013; Kasch & Dowling, 
2008; Montaguti, Kuester, & Robertson 2002; Niosi, 2000; Powell, Koput, Bowie & 
Smith-Doerr, 2002; Walsh, 2012; Woodside & Biemens, 2005; Zucker, Darby, & 
Brewer, 1994). At each stage the information is assessed, evaluated and delivered 
through activities such as learning, strategic thinking, partnering and resource 
utilisation (Gadde, Huemer, & Håkansson 2003). This allows the selection of an 
accurate commercial pathway for successful commercialisation of the viable 
innovation. 
During the post-commercialisation stages, the evaluated information is iterated 
through previous stages for further evaluation and for generating value during the 
process for gaining successful commercial outcomes. This evaluation process leads to 
non-linearity that further instigates the formation of different network structures in the 
commercialisation ecosystem. Based on these factors, network structures 
continuously evolve and change with the organisations involved in the network. 
4.3.1.3 Interdependent relationships 
One of the key characteristics of the network ecosystem is interdependency among 
different network entities at the individual and organisational levels. The 
interdependency is visible at a dyadic level or an inter-organisational cross-functional 
level (Ballentyne & Williams, 2008; Kapoor & Lee, 2013; Montaguti et al., 2002). 
The established literature highlights that the interdependent relationships between 
upstream and downstream partners of the network ecosystems are important for value 
creation and in overcoming challenges that affect the technology commercialisation 
process (Ander & Kapoor, 2010). There is a considerable body of literature identifying 
the role of university–industry relationships in understanding the BCP. 
The key network actors involved in such relationships are the TTOs and 
commercialisation offices. It has been suggested that there is strong interdependence 
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shown by universities and TTOs during the stages of innovation disclosure, market 
assessment, patenting for facilitating industry partnerships, data collection, promotion 
of university research and navigating regulatory processes (Bercovitz, Feldman, 
Fellar, & Burton, 2001; Friedman & Silberman, 2003; Kristinawati & Aprianingsih, 
2016; O’Shea et al., 2005). Conversely, industry bodies are dependent on TTOs/TCOs 
during the stages of licensing, negotiation, adoption and diffusion for activities such 
as submitting applications, processing legal protections, identifying complementing 
technology incubators and identifying useful investment opportunities (Balasingham, 
2014; Kristinawati & Aprianingsih, 2016; Siegel, Waldman, Atwater, & Link, 2005). 
Different levels of network ecosystems are interconnected and change in one level 
induces change in the other level. These changes are responsible for evolution and 
termination of different interactions, which generate complex network dynamics 
around the BCP. The effects of these interdependent dynamic interactions can be 
positive or negative based on the source and motive of the evolution of an 
interdependent relationship. 
4.3.2 Types of network relationships 
Commercialisation network relationships are continuous and productive exchange 
activities between two or more organisations involved in a value-generating business 
network (Gadde & Mattsson, 1987; Hakansson & Ford, 2002; Varey, 2008). A strong 
ecosystem provides an organisation with the capability to develop relationships and 
other intangible resources with the different network actors (Jackson, 2011). The 
literature on network relationships (Allen, 2003; Ballentyne & Williams, 2008; 
Brugmann & Prahalad, 2007; Gebauer & Friedli, 2005; Johnston, Lewin & Spekman, 
1999; Lee, 2009; Lenney & Easton, 2009; McLoughlin & Horan, 2000; Montaguti et 
al., 2002; Oliva & Kallenberg, 2003; Varey, 2008; Vowles et al., 2011) reveals a 
variety of approaches to understand the influence of relationships on the process of 
biotechnology innovation and commercialisation. Companies develop new 
relationships with other network actors to use their resources and to link themselves 
with different networks. 
Ceci and Lubatti (2012) highlighted the role of personal relationships in innovation 
diffusion using a business network. Other researchers have highlighted the roles of 
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distributors, suppliers and customer relationships within a business ecosystem for 
exploitation and exploration of high-technology innovations (Amara, Landry, 
Becheikh & Ouimet, 2008; Bierly, Damanpour, & Santoro 2009; Hernandez-
Espallardo, Sanchez-Perez, & Segovia-Lopez, 2011). 
4.3.2.1 Rigid relationships 
Based on the established literature (Ford & Redwood, 2005; Halinen et al., 1999; 
Orsenigo, Pammolli, & Riccaboni, 2001; O’Shea, Allen, Chevalier, & Roche, 2005; 
Teece, 1977), rigid networks can be characterised as a mesh of strong, consistent inter-
organisational relationships that are an outcome of the multiple, repetitive exchange 
activities among different organisations that provide the essential complementary 
assets required for developing a new product. 
Rigid relationships are strong pre-existing interactions within a business ecosystem. 
It has been observed that during the technology exploitation stages, SMEs prefer to 
enter into strong relationships with suppliers, other SMEs and large firms in the form 
of joint agreements, outsourcing agreements or alliances (Edward, Delbridge, & 
Munday 2005; Luukkonen, 2005). Such relationships maintain stability within a 
network ecosystem (Easton, 1992; Halinen et al., 1999) and act as a source to generate 
new interactions that affect the progression of the commercialisation process. 
In rigid relationships, the strength of connections, reassurance, utilisation of consistent 
resources (in the form of skills, expertise, experience, knowledge and understanding 
of licensing policies and procedures) and increased frequency of exchanges among 
the similar actors indicate that there is a probability of existence of rigid nets around 
the stages of the commercialisation process (Hakansson & Snehota, 1995; Halinen et 
al., 1999; Nicolaou & Birley, 2002). This also indicates that the relationships at these 
stages are capable of acting as reference points for new relationship development as 
the network evolves during the process. For example, funding bodies such as VCs are 
more inclined to invest in companies that they know or have been referred to by trusted 
resources because this facilitates access to information (Sorenson & Stuart, 2001). 
Networks have been known to act as a source of recommendations that lead to 
feedback effects and that provide validity in commercial actions (Nicolaou & Birley, 
2002). 
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4.3.2.2 Fluid relationships 
Rigid structures gradually become fluid due to the change in the focal organisation’s 
external and internal relationships. As the parts of the network are linked, the change 
may result in a continuous shift within different parts of the network structure (Halinen 
et al., 1999). In their study, Ceci and Lubatti (2012: p.565) argued that ‘multiple 
relationships lead to the existence of multidimensional links’. This type of a network 
dynamic influence is a mesh of constantly changing inter-organisational relationships 
which are a result of changing network actor configuration within a network 
ecosystem that perform diverse exchanges to provide the required complementary 
assets for new product development. 
Network fluidity has been a prominent characteristic of the innovation and 
commercialisation processes based on the fact that such processes rely on 
interdependent relationships (Ballentyne & Williams, 2008; Kapoor & Lee, 2013; 
Montaguti et al., 2002). The ‘domino effect’ theory proposed by Hertz (1999) explains 
how a change in one-business relationship affects the other interdependent 
relationships. Similarly, the fluidity of commercialisation dynamics can also be 
related to the consistently changing network environment. 
All network relationships are reciprocal (Moller & Halinen, 2000). The level of 
iteration and frequency of iterative interactions leads to changes in interdependent 
relationships, generating fluidity. Commercialisation processes incorporate consistent 
feedback loops based around the process (Roosenberg, 1994; Woodside & Biemans, 
2005). This indicates that fluid relationships have an important role in the process of 
commercialisation. Fluid relationships generate several interactions and such 
mechanisms influence the process of commercialisation at several stages. 
Table 10: Characteristics of Rigid and Fluid Structures 
ARA Network 
Components 
Rigid 
Networks 
Fluid 
Networks 
Network actors 
(Halinen et al., 1999; 
Orsenigo et al., 
2001) 
Consistent 
relationships 
Repetitive skills, 
expertise and 
experience 
Altering relationships 
Emerging skills, expertise 
and experience 
Shifting position within the 
network 
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Centralised position in 
the network 
Analogous 
configuration 
Difficult network 
penetration 
Mutable configuration 
Easy network penetration 
Network resources 
(Shea et al., 2005; 
Teece, 1977) 
Consistent sources 
Mostly resources 
incremental, 
continuous, closed 
innovation 
Limited resources 
Altering sources 
Mostly resources 
disruptive, discontinuous, 
experimental, open 
innovation 
Simultaneous resource 
requirement 
Network activities 
(Ford & Redwood, 
2005) 
Consistent 
communication formats 
Limited interaction 
Consistent learning 
Altering communication 
Formats 
Increased interaction 
Simultaneous learning 
through new developments 
4.3.3 Components of network structure 
The formation of a network ecosystem starts as a web of loosely connected 
organisations and relationships, which then convert into different network structures 
(Corallo et al., 2007). For several years, great effort has been devoted to the study of 
network structures (Burt, 2000; Cowan & Jonard, 2004; Reagans & McEvily, 2003; 
Reagans & Zuckerman, 2001; Rodan & Galunic, 2004; Schilling & Phelps, 2007; 
Hagberg, Swart & Schult, 2008), investigating their effects on innovation processes. 
The role of network structures has been considered important during the post-
commercialisation stages, such as adoption and diffusion (Midgley, Morrison, & 
Roberts, 1991). Structural cooperation among research scientists and external linkages 
assist in bridging network gaps, which facilitates easy access to resources and 
convenient knowledge transfer to improve commercialisation efficiency (Burt, 2000). 
Inter-firm network structures are strong competitive tools, as they provide 
collaboration opportunities for exploration and exploitation activities (Capaldo, 
2007). 
Ford and Redwood (2005) suggested that individual moves made by involved 
organisations lead to considerable changes in the entire network structure, such as 
shifts that result from mergers, alliances or ventures with new organisations to gain 
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resources during the new product development or commercialisation process. As the 
components within a network are interlinked, any change may result in a continuous 
shift within different parts of the network structure (Halinen et al., 1999). Thus, 
understanding the role of network structures and the related interactions is important. 
Considering the diversity of network actors and resources within the 
commercialisation ecosystem, the network structures within the ecosystem vary based 
on the position of the actor within the network, the level of network complexity and 
the type of network. 
4.3.3.1 Network position 
The locus of an organisation within an ecosystem relative to the locus of other 
organisations within an ecosystem defines the position of an organisation within the 
network (Mattsson, & Johanson 1992). The position and needs of an organisation 
within an ecosystem are in continuous transition; within the commercialisation 
ecosystem, this is a result of several interactions. The transition is based on the 
organisations financial and operational capabilities (Kinnunen et al., 2013). Changing 
network position within a knowledge-based ecosystem also influences the 
performance of the individual organisation within the ecosystem (Tsai, 2009). Given 
that one of the key resource transfers in the biotechnology commercialisation 
ecosystem is knowledge, it is likely that the resulting interactions have a major effect 
on the process. 
Additionally, issues and changes in network position affect the processes of value 
generation and value resonation within the ecosystem. Considering the interdependent 
nature of the biotechnology commercialisation ecosystem, the change in network 
position is capable of creating a positive or negative domino effect of interactions that 
may influence the process at different stages. Another way in which the existing 
literature identifies the position of an organisation within an ecosystem is through the 
type of exchange relationships the organisation possesses (Mattsson, & Johanson 
1992; Tsai, 2009). As we know that commercialisation strategies are network 
dependent, the interactions related to position-based dynamics are of strategic 
importance. 
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4.3.3.2 Network configuration 
Network involvement is prominent in the literature on biotechnology 
commercialisation (Bandarian, 2007; O'shea,.Allen, Chevalier & Roche, 2005; 
Goldenberg et al., 2009; Harrison & Waluszewski, 2008; Martyniuk et al., 2003; 
Nooteboom, 2000; Woodside & Biemans, 2005). Based on the network literature 
(Aarikka-Stenroos et al., 2014; Ballentyne & Williams, 2008; Corsaro, Cantù, & 
Tunisini 2012; Kasch & Dowling, 2008; Lee, 2009; Montaguti et al., 2002; Stenroos 
et al., 2012;), the configuration of a network is defined as an interwoven pattern of 
actors, resources and activities in an arrangement that is compatible with the 
requirements of an organisational process. Aarikka-Stenroos et al. (2014) suggested 
that different network actors contribute different resources for the successful 
commercialisation of innovations. However, the source and type of innovation 
determine the commercialisation pathway, which in turn determines the configuration 
pattern for the network structure. 
4.3.3.3 Network types 
The literature discusses ecosystems as a combination of several networks in 
continuous interactions (Adner, 2006; Baden-Fuller & Haefliger, 2013; Chesbrough 
& Appleyard, 2007; Iansiti & Levien, 2004; Xiaoren et al., 2014; Zahra & Nambisan, 
2012). These networks can be classified in several ways, such as based on the type of 
resource exchanges, type of actors (e.g., supplier networks, distributor networks, R & 
D networks, investor networks and university networks), type of network relationships 
and exchange activities. Networks have also been classified on the basis of the number 
of actors and the type of value generated. The classification of networks can be viewed 
from multiple perspectives; however, each approach depicts different types of 
underlying network interactions. These network interactions within an ecosystem can 
be a result of individual exchanges or a combination of different capabilities within a 
network. 
The difference in network types has also been acknowledged as a source of 
collaborative activities that influence the commercialisation process at various stages. 
However, the effect of network types and their capability to morph into different types 
of networks during the commercialisation process may or may not be useful for the 
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BCP because interactions raise uncertainties during the process, creating high-risk 
situations and requiring additional efforts for risk identification and management. 
4.3.4 Components of network acuity 
Network acuity can be defined as a combined output of interpretations of individual 
actors based on their ability to co-exist within the multidimensional and intricate 
environment of a business ecosystem. The literature suggests that network acuity adds 
intangible value to a commercialisation ecosystem, as the source for such interactions 
are cognitive in nature and are capable of inducing interdependent, sensitive and 
continuous transitions within the ecosystem. For example, Kilduff and Krackhardt 
(1994) suggested that an actor’s patterns of interactions within a social environment 
based on their perceptions of the social environment influence the attitudes and 
behaviours of other actors within the same environment. Interestingly, interaction-
based change is parallel to, yet associated with, the actual structure of the social 
environment. The literature on network psychology and behaviour has also placed 
emphasis on the relationship between cognitive manipulation and the decision-making 
capabilities and adjudication of actors (Goodhew et al., 2005; Hodgkinson, Bown, 
Maule, 1999; Walsh, 1995). 
In a similar context, network acuity also influences interaction dynamics at an 
organisational level. Nadkarni and Barr (2008) described organisations as 
‘interpretative systems’ in which organisational decisions are based on stimuli 
received from the embedding environment. While the importance of interaction-based 
acuity generated by actors at different levels of an ecosystem is understood, the effects 
of such dynamics have not been explored in detail. Several levels and dimensions need 
to be further explored to understand the relationship between cognition structures 
within an ecosystem and their effects on the BCP. 
4.3.4.1 Actor control 
The influence an actor has on another actor or cluster of actors within an ecosystem is 
defined as actor control (Baraldi & Stromsten, 2009). The level and method of 
establishing actor control within a commercial ecosystem vary depending upon the 
size of the organisation. For example, large pharmaceuticals or government 
organisations are capable of establishing control independently, using their capability 
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for resource provision and management. Conversely, SMEs establish control over 
their external network environment through collaborations and regular relationship 
exchanges of different types. 
One of the key characteristics of a business ecosystem is decentralised control, which 
provides a sturdy structure to the ecosystem (Peltoniemi, 2004). Decentralised actor 
control raises issues regarding organisational authority, conflicting actor goals and 
network management approaches (Håkansson & Ford, 2002; Peltoniemi, 2004). As 
the control characteristic increases inter-dependability and provides flexibility to the 
organisations to adapt to sudden changes that occur simultaneously within a 
commercialisation ecosystem, it is likely that actor control interaction dynamics will 
affect the BCP. 
4.3.4.2 Network complexity 
Complexity is a key characteristic of business ecosystems. The literature defines 
network complexity as a mesh of interdependent relationships that are interconnected 
and highly interactive (Cowan, 1994; Peltoniemi & Vuori, 2004). The level of 
interdependency between network actors influences coordination activities and 
mechanisms, which also specifies the roles of network entities around the stages of 
the commercialisation process (Munksgaard, 2010). 
For example, the commercialisation process requires generous funding; universities, 
in particular, rely heavily on federal organisations to gain funds for public research. 
However, universities have to undergo rigorous processes and demonstrate the social 
and economic effects of their research to obtain funds. Further, there appears to be 
constant conflict between the two network actors to gain authority in such situations, 
which influences the performance and capability of the involved actors (Rasmussen, 
Moen, & Gulbrandsen, 2006). In his research for innovation ecosystems, Jackson 
(2011) explained the wide gap between the innovation development and market 
acceptance stages of the process. The lack of resource availability and evaluation of 
associated risks leads to the failure of commercialisation. In both cases, the dynamic 
interaction among actors and implemented resources increases complexity, which 
influences the commercialisation of viable innovations. 
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4.3.4.3 Actor perception 
Actor perception is defined as an individual’s or organisational entity’s subjective 
interpretation of the surrounding network relationships, organisation and 
interdependencies (Abrahamsen et al., 2012; Henneberg, Rohrmus, & Ramos, 2006; 
Henneberg, Naudé, & Mouzas, 2010). For example, during the post-
commercialisation stages, selective network actors (specifically research institutes 
and universities) perceive commercial value in the form of continuous research 
activities and publications. Conversely, entrepreneurs, TTOs and government 
organisations perceive commercial value in the form of developing spin-offs, 
licensing deals, gaining patents or converting technologies into on-the-shelf products 
(O’Gorman, Byrne, O., & Pandya 2006; O’Shea et al., 2005). Many actors from start-
up organisations depend on perception-based sensitivity for making business 
decisions (Abrahamsen et al., 2012; Zahra & Nambisan, 2012). The perception-based 
decisions of many network actors are also based on the non-commercial environments 
from which they emanate (Siegel, et al, 2003). 
An actor’s perception influences their decision-making capability concerning their 
role during the commercialisation process, their level of participation and their 
relationship-forming ability. Individual and organisational actor perceptions also 
influence the management and behaviour of other participating actors involved during 
the BCP (Chakrabarti, Ramos, & Henneberg, 2013; Ford, Gadde, Hakansson, & 
Snehota, 2003). Several network changes are translated across the network to different 
stages of the BCP based on the interdependent behaviours of the network actors. Their 
reactions to the changing network environment generate dynamic network 
interactions within the commercialisation ecosystem. 
In their analysis of business ecosystems in the value-based network context, Clarysse 
et al. (2014) emphasised the difference between value generated by knowledge 
ecosystems as opposed to business ecosystems and the useful implications of 
understanding the difference for policymakers in the commercialisation area. A large 
proportion of the emerging research on business ecosystems focuses mainly on 
understanding the dynamic chemistry of business ecosystems during the technology 
innovation processes (Adner, 2006; Iansiti & Levien, 2004; Nambisan & Sawhney, 
2007; Zahra & Nambisan, 2012) or understanding the implementation of business 
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ecosystems for entrepreneurial business models for new product development 
(Fetters, Greene, & Rice, 2010; Muegge, 2013; Rong, Hu, Hou, Ma, & Shi 2013; 
Rong, Lin, Shi, & Yu, 2013; Tsvetkova & Gustafsson, 2011; Weiller & Neely, 2013). 
In general, the discussion of dynamic interactions in a business ecosystem has focused 
on understanding the effects of such network interactions, relationships and structures 
on the innovation processes or in a generalised manner. Therefore, the research has 
failed to examine the effects of different network dynamic interactions on the process 
of commercialisation, especially in the context of the BCP. 
While different types of network dynamic interactions in the technology 
commercialisation business ecosystem have been emphasised, for this research it was 
purposely considered that the commercialisation process can begin with the new 
product development process (Jolly, 1997) or it can begin at the end of the new product 
development process (Cooper, 1983; Cooper & Kleinschmidt, 1986; Rochford & 
Rudelius, 1997; Woodside & Biemens, 2005). The basis for this decision arises from 
the fact that the interplay of network dynamics within a business ecosystem is 
important for every type of technology commercialisation process; however, there is 
limited information regarding the effects of such network dynamic interactions on the 
BCP. 
This study supports the view that different network events result in interactions 
between the different network ecosystem components; it is argued that the dynamics 
behind these components and how they influence the process of BCP has not been 
explored in depth. The existing literature has been successful in exploring the roles of 
these network ecosystem components around the commercialisation process. Earlier 
research attempted to understand the dual role of networks in the process of 
technology commercialisation. However, the established literature does not fully 
explain the evolution of these network dynamic influences during the BCP. Thus, it is 
important to identify the different types of dynamic influences around the process of 
the BCP and to understand the effects of such dynamic influences on the BCP. 
It is expected that the analysis of the data collected from semi-structured interviews 
and the development of the preliminary framework can link the network ecosystem 
components through their dynamic influences with the BCP. The next section 
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empirically analyses the different dimensions of these influences that generate 
dynamics during the BCP. 
4.4 Methodology 
4.4.1 The research problem 
The analysis of different types of network interactions should provide a detailed view 
of the different network dynamic interactions that transpire during the process. This 
study investigated how those network dynamic interactions influence the different 
stages of the BCP. A qualitative approach was selected for data collection and 
analysis. The semi-structured interview method was adopted, as suggested by Yin 
(2009), because of the lack of prior knowledge in this area of research (Patton, 2005). 
A qualitative approach is a well-established research approach for industrial 
marketing, management and network-based research (Filieri, McNally, & O'Dwyer, 
2014), which plays a significant role in theory building within industrial marketing 
and network-based studies. This approach allowed the researchers to gain a 
comprehensive view of the multifaceted phenomena. It allows for in-depth exploration 
of the BCP by applying a theoretical lens to network-based dynamics and how those 
dynamics affect the BCP. It also helps to explain ‘the how’ of the phenomenon under 
investigation. In addition to this, semi-structured interviews allow for generalised 
conclusions based on the findings. 
The interview instrument was designed with open-ended questions. The instrument 
was based on the following themes: (1) the BCP, (2) level of network involvement, 
(3) issues related to commercialisation and (4) types of interactions within the 
commercialisation network. This instrument was designed based on three main 
principles: necessity, transparency and collecting information (Alreck & Settle, 1995; 
Neuman, 1994). All the important questions were based only on the included themes. 
Repetitive practice runs were conducted with colleagues with similar data analysis 
expertise to ensure the validity of the questions. The question content was based on 
the specified theme to ensure that the participant understood the objective of the study 
and provided the related information. 
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The primary data were collected using 30 semi-structured, open-ended, face-to-face 
interviews. The participants were key experts from the biotechnology industry with 
various profiles (CEO, director, executive director, manager of industry 
commercialisation, angel investors, VCs, cooperative research assistants, regulatory 
affairs director, attorneys and commercialisation accelerator) and other selected 
industry experts, as outlined in Table 11. Some respondent profiles were not clearly 
defined and their roles covered multiple activities. For example, one of the 
respondents acted as a CEO and as a consultant, this gave a holistic view of the 
process, with details from different member perspectives. 
Table 11: Overview of Interview Participant Profiles 
Organisation Participant Profile Skill Set 
Government Innovation management Investigating regulatory 
issues 
Policy development 
Agreement design and 
approvals  
Universities Manager industry and 
commercialisation 
Director design institute 
Executive director 
industry business dev. 
Research scientists 
Industry engagement 
Networking and 
partnerships 
Regulatory affairs 
Large biotech 
organisation 
Research program leader 
National marketing 
leader 
National senior 
marketing manager 
Strategic marketing 
Business development 
Project Management 
Social media marketing  
SMEs Director 
CEO 
Managing director 
Principal innovation 
design and framework 
Manufacturing process 
management 
Innovation protection 
Reputation building 
Collaboration 
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Organisation Participant Profile Skill Set 
Forums and 
associations 
Expert scientific advisor 
Clinical consultant 
Principal consultant 
innovation and tech. 
Pharmacovigilance 
consultant 
Consulting and advisory 
Networking and 
collaboration 
Research management 
Commercialisation 
management 
Funding 
organisations 
Venture capitalists 
Venture capital partner 
Managing director 
Investment director 
Capital development 
Fundraising 
Risk analysis 
Developing the skill set 
A combination of social references, social media platform (LinkedIn) and snowball 
sampling was used to contact different participants. The participant search began after 
reviewing the roles of key decision makers in the biotechnology market from the 
analysis of various biotechnology industry reports. Initially, the researcher’s existing 
network links were utilised to gather sample references, then a search for Australian 
biotechnology industry on LinkedIn was conducted. This provided the links to specific 
profiles of prospective participants. Email addresses for the selected profiles were 
collected and maintained in a list that was organised alphabetically. The interviewees 
were sent an introductory email stating what their involvement would entail. 
Participants who responded with interest were then interviewed using a pre-designed 
and semi-structured interview. The participating respondents then provided a 
reference and introduction to a prospective participant. This led to the identification 
of the different types of relationships within the biotechnology network. 
Semi-structured interviews were the chosen method, as they provided flexibility, 
clarity and approachability to the researcher (Qu & Dumay, 2011). Semi-structured 
interviews were observed to be the most efficient method of data collection in the 
existing studies related to network and relationship analysis and mapping (Partanen et 
al., 2008; Ramstorm, 2008; Theingi, Purchase, & Phungphol 2008). As different 
researchers were involved, the interview process was framed to confirm uniformity 
during data collection (Patton, 2002; Theingi et al., 2008). The duration of the 
interviews varied from 30 to 90 minutes. 
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All interviews were audio recorded and note were taken during the interviews to 
identify the existing network in which the participants were involved (Burnard, 1991). 
The researcher provided impromptu probes to the respondent during the interview to 
extract thorough descriptions (Qu & Dumay, 2011). Unquotable and non-recordable 
information was noted manually and was only used for reference purposes. Some 
interviews were conducted over the phone to fit the schedules of the participating 
interviewees. Most of the secondary data were collected using websites, brochures, 
newspapers, industry reports and magazines. 
All interviews were transcribed for analysis. All company names and participant 
names were de-identified (In1–In30), as some of the data collected are confidential. 
Data were analysed along the main themes. To analyse the perceptions of different 
network members concerning specific activities that occur during BCP, the data were 
divided into a set of actor profiles (investors, CEOs, consultants, patents attorneys, 
research associates, government officials and commercialisation experts) based on the 
job descriptions of the respondents. The classification also allowed the researcher to 
study the involvement of the organisation across the process and how the development 
of new connections and relationships would possibly generate different network 
effects that influence the BCP. 
The analysis of the key interviews led to the development of nodes and memos with 
the help of NVivo software. The analysis was based on the critical evaluation, tagging 
and assimilation of data from primary and secondary sources to generate findings for 
addressing the research phenomenon (Glaser & Strauss, 1967). The analysis was 
conducted alongside the data collection and the literature review was referred back to 
the regularly during this process. 
To achieve reliability and validity, the researcher tested the data collection and 
analysis process at multiple stages of the research process. Regular feedback was 
obtained from the participating respondents and organisations, which provided an 
opportunity to validate the need for further data collection. Regular updates were 
provided to the respondents before and after the interviews to check for variability in 
opinions. 
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The notes and memos written during the interviews were utilised for crosschecking 
the information during the process of data transcription to ensure the transcribed script 
was accurate. Since this research is focused on the biotechnology industry, the note-
taking activity also ensured that all technical terms were appropriately written and 
verified in the transcribed scripts. For data validity, the data were initially analysed 
using open coding, then more elaborate codes were developed and linkages were 
identified. The transcribed data were repeatedly analysed and subjected to 
triangulation to check for the emergence of any new information. The analyses were 
conducted until data saturation was achieved and no new information was available. 
4.5 Key Findings 
In this section, the data from the interviews were used to explore the aspects of 
network dynamics that influence the BCP. The different network dynamics 
interactions concerning different dynamic influences have been analysed and reported 
in the revised framework. The empirical findings have been illustrated with quotations 
from the transcribed interviews. The findings based on the analysis highlight the key 
network interactions that positively or negatively affect the process of the BCP. 
The analysis of the interview data concerning network dynamics in the context of the 
commercialisation process revealed that substantial interactions between different 
aspects of network morphology—such as movements, relationships, structures and 
acuity—were responsible for the changing network dynamics. Table 12 provides an 
overview of the network interactions identified during the commercialisation process 
and their links with the network ecosystem components. The analysis revealed a need 
for an in-depth understanding of the individual effects these interactions have on the 
individual and multiple stages of the process. The data were classified based on the 
interaction that generated dynamics leading to changing network movements, 
relationships, structures and acuity, as shown in Table 12. 
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Table 12: Outcomes of Thematic Analysis of the Interview Data 
Main 
Category 
Subcategories Nodes Node Names 
Network 
movements 
Jumping actor 
phenomenon 
2 Background changes 
Time of interaction 
Resource iteration 2 Innovation type 
Feedback network 
Interdependent 
relationships 
2 Outcome dependability 
Process pathway 
Network 
relationships 
Rigid relationships 3 Distressed relationships 
Network reference points 
Individual interactions 
Fluid relationships 3 Evolving relationships 
Relationship life cycles 
Dyadic interactions 
Hybrid relationships 2 Adaptation 
Cross-functional 
integration 
Network 
structure 
Network positions 2 Centralisation vs. 
decentralisation 
Large vs. small 
organisations 
Network 
configurations 
3 Actor selection process 
Resource development 
Network boundaries 
Network types 3 Capability combinations 
Value-based networks 
Clustering/community 
Network 
acuity 
Actor control 2 Domain interests 
Degree of influence 
Network complexity 3 Stability 
Environment 
Channels of 
communication 
Actor sensitivity 3 Opportunity 
identification 
Innovation strategy 
Outcome expectation 
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4.5.1 Interactions leading to network movements 
The established literature led to the classification of network movements based on the 
roles of actors, activities and resources around the process. However, building upon 
that knowledge, the analysis allowed for the identification of key network interactions 
specific to each type of movement within the commercialisation ecosystem. As shown 
in Table 12, simple interactions such as background changes and time of interaction 
assist in generating strong dynamics around the process. 
Background changes were mainly due to individual’s personal mindset, availability 
of a lucrative opportunity, consistent failure, unhealthy work environment or lack of 
compatibility with the existing position. These changes mainly related to educational 
and professional growth of individual actors. Some changes were induced by 
organisational pressure and others were acquired based on the availability of a 
valuable opportunity for growth. These interactions led to actors jumping from 
organisation to organisation. Mainly in the biotechnology industry, these changes 
were of an extreme nature especially with reference to time. Such as some changes 
were observed at the beginning of the process and some were observed at the end of 
the process based on the outcome of the commercialisation process. 
So my background, my undergrad’, was in medical science. I worked in an XY 
laboratory for two years. Then I moved into the commercial realm … Then I moved 
into marketing pharmaceuticals … I’m now working in XY company doing ABC 
technology, commercialising a product. (In28) 
The iteration of resources occurs from one stage to another, one actor to another and 
one form to another (e.g., a service combining with a specific product to form another 
product). The interactions were related to the specific type of innovation and the 
entities that were required to be involved in developing and commercialising that 
specific innovation determined the level of iteration of resources during the process. 
The determination as to whether the innovation was a result of an entrepreneurial 
venture or a university-based research outcome formed the basis for identifying the 
potential collaborations and the important resources for commercialisation. The 
resource pathways were determined based on the abovementioned conditions. The 
distinction between different types of innovation and their relationship with the 
commercialisation strategy was found to be important. 
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The XY university was providing expertise on AB product to make the cup. The XYZ 
institute was the originator for the technology and was doing all of the microsurgery in 
OPQ models. And ZXY hospital was the partner doing it in humans. We had another 
company … reviewing the market—so speaking to the clinicians about how to shape the 
product, what it truly looked like in order for them to be happy to use it. And then there 
was another company which was an expert in ABC technology. So we had the ability 
[XYZ activities] all in one project. (In17) 
It was expected that a network involving multiple actors around a process was bound 
to have feedback loops that form a small web of an interdependent network within the 
ecosystem. Within these loops, the interactions were related to information transfer, 
data management and gathering, regulatory process management, trial and error 
methods, bi-directional communication from multiple stakeholders, screening and 
scanning processes, reconnecting or extending network chains and management of 
multiple activities at the same time. Many experts pointed out the importance of these 
types of networks and how these interactions lead to better commercialisation. 
We had to backtrack and discuss the problem with the chemists and they came up with 
this new modification of the technology that allowed a much greater shelf life. It was 
basically missing three compounds … The way that happened was the company that 
were almost ready to shelve the whole project because it didn’t have enough shelf life. 
We went back and innovated again and this all led to a better product. (In6) 
The findings reveal that the outcome of a commercialisation process and the pathway 
selected for achieving the desired outcome are the key factors that influence the 
selection of partners and resources during BCP. However, as the respondents 
emphasised that due to the high levels of uncertainty during the BCP, the outcomes 
are sometimes unexpected. This type of variation in commercialisation outcomes is 
possible if the network chain is strongly interconnected. The level of interdependence 
and the strength of network bonds within a commercialisation network chain define 
the rate at which a network responds to the change within a network. 
With clusters, you can do different things … Some of those clusters are there to adopt 
technology, some … for product development. So you can shape it any way you like … 
However, you do have to be careful about what is the intended outcome. You need to 
know the unintended consequences, or you can create conflict in disguise. (In1) 
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4.5.2 Interactions leading to network relationships 
Relationship building and maintaining was a common topic—it was mentioned by all 
respondents. Most respondents highlighted the interactions for relationship building 
as the most important activity. However, relationship dissolution was also one of the 
most common activities related to relationship development. That is, the dissolution 
of existing relationships not only had negative effects but also positive effects, as they 
became a reference point for the formation of new and potential relationships during 
the process. Respondents gave examples of internal and external dissolution of 
relationships. The analysis showed that dissolution of internal and external 
relationships could sometimes lead to the enhancement of the company’s innovation 
and commercialisation portfolio by providing opportunities for building new 
advantageous relationships. 
And actually, the projects got smaller with time and financial basis … So, the company 
has downsized to … science. It has gone through many changes … getting rid of XYZs 
and so on … Moreover, now they are focused in three areas … and have a impressive 
patterns portfolio around an area of biology that is yet to have its day, I think, medically. 
(In5) 
Table 12 shows that interactions related to distressed relationships, relationships 
acting as reference points and individual development interactions all indicated the 
rigid  nature of the biotechnology network. Respondents indicated that network 
boundaries were tight and the networks were highly interrelated. They also pointed 
out how a lack of trust and commitment leads to the development of strict selection 
criteria that limit the entry of new entrants and internal collaborators or, conversely, 
helped in selecting the most appropriate and result-oriented skill set. 
Interactions such as maintaining confidentiality, secure process pathways and 
screening gates lead to the development of inflexible relationships. Due to limited 
capabilities to build trust, most of the involved actors were limited to individual 
interactions that were transactional. Respondents suggested that such transactions 
were not very advantageous to commercialisation. Through the analysis, it was easy 
to gauge that actors were unknowingly biased towards selecting partners from 
available options. Most selections were based on references provided by other existing 
relationships, bureaucratic pressure or personal intent. 
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It is a pilot[ … ]We are doing it by introduction only—personal introduction through 
our network, because[ … ]we need to show[ …. ]what we have built [..] give us your 
feedback. (In20) 
Despite the inflexible nature of the networks, some respondents pointed towards the 
flexible and adaptive nature of relationships. The network interactions related to 
fluidity include constantly evolving relationships, changing relationship structures 
based on the stage of the relationship cycle and dyadic interactions between network 
actors. The projects were mainly based on co-development strategies and teaming 
capabilities. Respondents mentioned different ways that contributed to the evolution 
of new relationships, such as organising events that led to the development of 
relationships with VCs and international investors to raise funds for new and existing 
projects. 
There is some sort of a fluidity involved where, okay this is how we start, then these are 
the decision makers, then they go back but they involve some new people, whether it’s 
from the external market area or whether internally. And they again go back to … once 
it’s finalised then it goes back again to the decision makers. Then there are some stages 
where they go back. (In) 
The ability to adapt and collaborate through cross-functional integration was another 
key characteristic of network relationships. The interactions related to adaptation and 
cross-functional integration included the development of hybrid relationships based 
on terms agreeable to all actors, acclimatising to the communication styles and 
methods of the client organisation, dealing with a diverse range of internal actors and 
their skill sets, all of which were based upon a common motive between participating 
actors. Respondents specified that adaptation strategies change with different types of 
organisations at different stages of the process. Some organisations integrate with 
other organisations by forming a separate team of different individuals from each 
organisation (rather than integrating directly); this type of adaptive collaboration 
during the commercialisation process was termed as ‘translation channels’ by the 
respondents. 
This big scale of relationship allows the company to work with different parts of the 
organisation. So these relationships open up the range of projects that you can do. So 
these relationships provide guidance on how to conduct this or how to draw on 
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commercial terms and so on. On the other hand, some of my people also built up in 
consortiums that bring groups of companies together on a common technology 
platform. So there are many different models that you can use. (In1) 
Interactions such as limited identification of partnering capabilities/opportunities lead 
to lack of adaptation and cross-functional integration. This was highlighted as a 
common issue that leads to failure of commercialisation. Some of these adaptation 
and cross-functional integration strategies were also important for interactions on one-
to-one bases, as it was expected that these would affect the overall network 
relationships. The relationship types and development process was identified as the 
most important dynamic influence affecting the process. 
Our need to take that science and discovery and then partner that with the business and 
commercial element—I think that’s where a lot of the products that I saw earlier in the 
R & D space weren’t successful. They just stayed in that realm of being scientific and 
academic and not partnering with commercialisation. (In23) 
4.5.3 Interactions leading to network structure 
The findings in Table 12 show that the position of an individual or organisation, the 
configuration of network components and the types of networks around the process of 
commercialisation are the key elements of network structure. 
The interactions leading to change in network position within a commercialisation 
network relate to centralised versus decentralised structures, both internally within an 
organisation and externally within the network. Respondents emphasised that the 
management of operations around the process within a centralised network 
configuration leads to streamlined delivery of outcomes. It was easy to identify areas 
of improvement within a centralised network. Some respondents also identified that a 
centralised network position helps predict market orientation and trends faster than a 
decentralised network configuration. However, network centralisation showed strong 
links with interactions related to actor control. The process of knowledge sharing 
involves the transfer of knowledge from experienced teams to new or existing network 
members, which may lead to displays of authority by experienced actors. In such 
cases, a decentralised network position is useful to maintain collaborative control over 
commercialisation outcomes. 
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We demonstrate the product and give them a trial of the product. We also talk to them 
and provide references for other key clinics that are using the product as well … We also 
build advisory boards as well in each region. There will be a group of key opinion leaders 
that we can then reference back … Getting them to do a trial of the product and see the 
benefits themselves, and then making sure that we follow up. A very strong support 
network is needed at that point in time to make sure they have had a good experience 
with the product. (In23) 
The interactions related to actor selection processes, resource development and 
creating and maintaining network boundaries influence the configuration of the 
network. The actor selection process is related to interactions such as judgement of 
skills (specifically patenting of technologies, development of prototypes, fundraising 
and capital development), uniting a range of skill sets, recruitment capabilities (such 
as recruitment of patients for clinical testing), target market estimation, dealing with 
government agencies and authorities for regulatory approvals, management of media 
personnel and public relations specialists for marketing, identification of key opinion 
leaders and process champions, identification of key influencers and reference points. 
Modification in the morphology of any of the abovementioned interactions could alter 
configuration, which can positively or negatively influence the commercialisation 
process at any stage. 
Resource development relates to interactions occurring during supply chain 
management, such as assessing suppliers, substitution of suppliers and other actors in 
the supply chain, identifying geographical locations of actors, building relationships 
through networking events and any interaction that led to the acquisition of resources 
for commercialisation purposes. This resource development process involves different 
actors and activities, which further adds complexity and changes the density of the 
network. It was found that the types of resources that were acquired and the process 
by which they were acquired determined the level of interconnectedness of the 
network. 
The formation of network boundaries plays a key role in configuring the network 
during the process. The psychological and physical network boundaries were 
established during the process. In the biotechnology industry, trust is a main 
component of establishing a new relationship, which makes it difficult for 
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organisations to build and maintain relationships; therefore, it was observed that 
network boundaries were tight and limited the actors to only sporadic collaborations. 
These limitations were due to actor knowledge and perception, actor ego, process 
requirement, fund availability, understanding of the need for collaboration, fear of 
cannibalisation, personal interests and motivations. Such interactions altered the 
configuration at several stages. 
But if you are trying to organise a horizontal supply chain where you are trying to group 
the companies together so that they can work on the same thing, then you do not want 
the big ones to swallow the small ones because the big ones we learn faster because they 
have the skills and the distribution and all of that. (In1) 
Some respondents pointed out that interactions that involve combining different 
capabilities of individual and organisational actors, building valuable networks and 
developing clusters and communities assist in determining the types of networks that 
operate during the commercialisation process. The interactions include identifying the 
skill sets for a particular activity; adding or eliminating actors, resources and activities 
that increase the overall value of the network; and the formation of sub-units or 
clusters of organisations with similar interests to contribute to the process of taking 
products to market. For example, respondents highlighted the importance of selecting 
the right composition for clustering and associated it with strategic intent. The 
respondents also revealed that combining different capabilities alters the morphology 
of a network, as usually the networks and collaborations are customised for specific 
types of innovations, depending upon specifications provided by the supporting 
actors. 
4.5.4 Interactions leading to network acuity 
The classification of interactions under network acuity (see Table 12) is based on the 
activities related to thinking, judgement, decision-making and intangible resource 
exchanges (such as ideas, diligence, personal intellectual skills, experiences and 
information). 
Respondents highlighted that decision-making during the commercialisation process 
is influenced by an actor’s position in the network, interests and expectations for the 
project. Opinion-based interactions relate to different types of individual and 
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organisational choices that managers make during the process, which may or may not 
be favourable for the progression of the process or for the health of the inter-
organisational network. The choices involve decision-making regarding specific 
situations, such as the type of collaboration, the type of collaboration partner, 
departments for collaborations (ranging from entrepreneurial to R & D activities), the 
sequence of activities, the selection of target markets and judgements of proficiency. 
Because if one part judges in one way and another part judges in a different way, then 
it gets confusing and then we might even play one but against the other. (In1) 
The analysis in Table 12 demonstrates that network acuity is also based on the level 
of complexity of the network. A combination of different types of interactions related 
to stability, the types of factors influencing network environments and the types of 
selected or preferred channels of communication between the actors lead to the 
formation of denser networks. This further affects the sensitivity of the network as a 
whole or at an individual level. 
The stability of a network can be challenged based on actors’ past experiences, their 
level of involvement or isolation in the network, their level of bias towards other 
actors, the availability of resources in a network and the layout of different types of 
exchange activities. Further stability is also related to the views of the involved actors 
and the responses they have to different situations based on those views. The empirical 
data indicated that some actors migrated to competing organisations for personal gain 
and some actors limited resource exchanges to within the existing collaborations based 
on different types of conflicts. The stability-based interactions also affected the overall 
value generated by the network. It was observed that in some cases the value increased 
and in other cases the value decreased, which influenced the BCP at different stages. 
Several respondents confirmed that the changes they made during the course of their 
career were based on a situation being advantageous for professional growth and its 
effect on the network and other actors in the network. 
I finished my XYZ [degree] and decided I wanted to do full-time job, so I joined a 
company that I later became CEO of, changed the name and moved it from X city to Y 
city with various degrees of success. I moved to another company … that went into 
administration. At the same time, I moved based on the fact that one of the people at 
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the XY institution supported my research … I brought to IJK that experience of setting 
up public companies … but the rest have various degrees of lack of success. (In24) 
Interpretation of information and the channels through which information is 
transferred was also one of the key selection criteria for collaborations for several 
organisations and individuals. A strong relationship between the type of 
communication process within a network and the reputation of the actors involved in 
the communication process was evident. This further had an influence on the level of 
sensitivity of the collaborating actors regarding their level of participation in the 
process. 
I am too old for that. It is true. It is not of my generation, social media. I don’t post and 
use it at all. I don’t post a tweet; I don’t do any of that. I am not interested. For me, it is 
about face-to-face or picking up the telephone and initially, sure. But in the end, if you 
are going to do business with someone, you have to be able to meet them, I think. 
(In29) 
The data also showed that interactions related to opportunity identification by 
organisations, the selection of an innovation strategy and expectations related to 
commercialisation outcomes were related to the perceptions of the actors within the 
commercialisation network. The perception-based difference was noted when the 
respondents (key actors of the commercialisation network) explained their views 
about commercialisation and methods of commercialisation. A CEO of a technology-
based company (In8) emphasised that his expectation for a ‘technology-driven 
innovation’ is successful sales profits from the products and that only the best quality 
products lead to guaranteed sales. Conversely, a university-based business 
development director (commercialisation) explained that commercialisation means 
making an ‘innovation accessible for business exploitation’ (In21). A global 
marketing coordinator (In23) also indicated that actors in the R & D and regulatory 
teams have limited commercial understanding and have to be introduced to the 
commercialisation strategy in the early stages of the process rather than later for 
successful evaluation of outcomes. This indicates that the perception-based 
interactions related to commercialising technology are strongly influenced by the 
motives, knowledge and expectations of the involved actors. 
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4.6 Discussion 
This study aimed to explore the dynamic interactions that influence the BCP and 
understand the network-based mechanisms in the commercialisation ecosystem. The 
relevant literature discusses various findings related to ecosystem mechanics 
concerning the innovation process (Iansiti & Livien, 2004; Segers, 2017; Xiaoren et 
al., 2014; Zahra & Nabisan, 2012). It provides a broad view of different types of 
network interactions around the innovation process. It also includes specific details 
about ecosystem mechanics in the context of the commercialisation process (Andersen 
& Medlin, 2016; Goldenberg et al., 2009; Kinnunen et al., 2013; Teece, 2007). This 
study supports the view that network dynamics play a crucial role during the BCP and 
explores how different types of network-based interactions related to movements, 
relationships, structure and acuity affect the process at various stages. 
The adoption of a network lens to examine the types of interactions within the 
biotechnology network in Australia involving academia and different actors of the 
industry has provided interesting insights regarding different types of interactions and 
their positive and negative influences on the stages of the BCP. This research 
emphasises that studying these interactions can assist in the development of successful 
commercialisation strategies. 
As shown in the revised framework in Figure 7, the conceptual model included the 
ARA network components based on the framework provided by Hakansson and 
Johanson (1992) and links it to the network dynamic influences related to network 
movements, relationships, structure and acuity, which are the result of interactions 
between the ARA components. The findings from the empirical data assisted in 
identifying the individual interactions that generate dynamic influences that affect the 
BCP. As demonstrated in figure 7, the first category of network movements was based 
on interactions such as background changes, time of interaction, innovation type, 
feedback networks, outcome dependability and process pathways, which are classified 
under the jumping actor phenomenon, resource iteration and interdependent 
relationships, respectively. The second category, which is network relationships, was 
highlighted as the most important influence. The network relationship category was 
linked to interactions that included distressed relationships, network reference points, 
individual interactions, evolving relationships, relationship lifecycle, dyadic 
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interactions, adaptations and cross-functional integration, further categorised into 
rigid relationships, fluid relationships and hybrid relationships, respectively. 
Interactions related to the third category of network structure included centralised vs. 
decentralised positions, large vs. small organisations, actor selection processes, 
resource development, network boundaries, capability combinations, value-based 
network and cluster/community, further classified into network position, network 
configuration and network type. Lastly, the fourth category of network acuity was 
based on interactions that included subjective interests, the degree of influence, 
stability, network environment, channels of communication, opportunity 
identification, innovation strategy and outcome expectations, classified under actor 
control, network complexity and actor perception. 
These interactions, listed in Table 12, were found to positively and negatively affect 
different stages of the commercialisation process. The in-depth analysis of the 
empirical data clarifies how the underlying interactions generate dynamic influences 
and then how it impacts the stages of the BCP. Interestingly, the findings were 
interrelated, establishing causal links between the interactions. 
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Figure 7: Revised framework showing the interactions related to the effects of 
network dynamics. 
The literature discusses different types of network movements based on resource 
exchanges, resource pathways and actor associations (Chen, 2009; Schiele, 2010; 
Song & Thieme, 2009). It also explains the types of network movements—such as 
symmetrical, asymmetrical, spasmodic, incessant and interconnected (Ander & 
Kapoor, 2010; Kapoor & Lee, 2013; Schiele, 2010)—that occur during the process of 
technology commercialisation. In alignment with this, the research highlights how 
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interactions such as background changes, time, type of innovation, process pathways 
and outcome dependability positively influence the process by providing different 
types of resources at different stages. As the movements can be individual, in a cluster 
or the result of alliances, mergers and acquisitions, they add various skills to the 
organisations, including new methods, technologies, people and skills. These 
unexpected movements can lead to unexpected outcomes that are favourable to the 
commercialising organisations. The movements also lead to enhanced reputation and 
quick access to limited and restricted resources based on the reach and capability of 
the moving actors. These movements also allow rotation of resources and prediction 
of successful commercialisation pathways by reducing levels of uncertainty. 
Conversely, these movements also have a negative effect during the process, such as 
loss of reputation (specifically if the movement involves changing leadership roles), 
decreases in financial capacity and reduced resource accessibility. It also hinders the 
process of long-term relationship development. 
The importance of network relationships has been thoroughly highlighted in the 
network, innovation, commercialisation and ecosystem literature (Aarikka-Stenroosa 
& Ritalab, 2017; Ceci & Lubatti 2012; Hernandez-Espallardo et al., 2011; Varey, 
2008). Further to this, the study provides insights into how network-based interactions 
around the BCP form the basis for classification of network-based relationships in 
rigid, fluid and hybrid forms and their impact on the process. It was identified that 
relationships that are rigid in nature act as points of reference for the development of 
new resources or relationships that promote the commercialisation process. Rigid 
relationships also provides experience in process management and handling. Fluid 
relationships are more important for technology transfer activities and lead to 
exposure to new platforms for communication and sharing. The speed of the process 
is hampered if the relationships lead to the development of negative word of mouth, 
or if they act as network gates that transfer only limited information from one end to 
another. 
In further alignment with the literature that highlights the importance of network 
structure and configuration within an innovation and commercialisation ecosystem 
(Chesbrough & Appleyard, 2007; Corallo et al., 2007; Iansisti & Levien, 2004; Swart 
& Schult, 2008; Xiaoren et al., 2014), this study demonstrates that interactions related 
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to network structure influence the BCP. The influence of these interactions is based 
on the size of the organisation, the internal operational structure of the organisation 
and its position in the external network hierarchy in the ecosystem. 
This study found that large companies were passionate about being one hundred per 
cent involved with their projects from start to end by employing only experienced 
individuals, as it is advantageous for organisations to use their experience for 
commercialisation. However, the disadvantage of this type of employment is that it 
limits the idea of open commercialisation within the network. In addition, larger size 
of the organisation adds a higher level of complexity to the process because of the 
large number of internal sub-units and internal actors within the intra-organisational 
network. Conversely, smaller organisations require more time and resources for 
operating, which increases the level of interdependency in the commercialisation 
ecosystem. 
The flexible and fluid structure of a network and its capacity to modify its morphology 
according to changing needs and requirements of the process allow it to access specific 
skill sets that are rare or limited in the industry. This also assists in gathering funds 
for investing in technology purchasing. Interactions that help in classifying the types 
of networks also assist in understanding the overall value that is generated from 
operating within that specific network. Clustering and community-based networks 
favour the process by establishing common goals that facilitate efficient management 
of resources. 
Lastly, this study adds to the plethora of knowledge available in the established 
literature about the significance of network perceptions during the innovation and 
commercialisation process (Abrahamsen et al., 2012; Chakrabarti, Ramos, & 
Henneberg, 2013; Nadkarni & Barr, 2008). The interactions around actor control, 
network complexity and actor perception influence the process by explaining how 
biased decision-making occurs during the process, which may or may not be 
advantageous. The study also provides a better understanding of the types of 
communication patterns that revolve around the process and the reach of the 
communication channels during the process. It highlights how bureaucratic decision-
making and authorities interfere with the process, which limits the decision-making 
power of other collaborating actors. 
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Interactions based on improved network position help develop leadership capabilities 
and promote improved and experienced process management. However, actor 
perceptions may lead to misjudgements, such as the development and nurturing of 
unproductive relationships that lead to the inefficient exploitation of organisational 
and network resources, thus hampering the speed of the process. Nonetheless, a 
perception-based understanding of the process helps build lean commercialisation 
models and allows collaboration with customers for successful commercialisation. 
Overall, this study identifies how different network interactions generate network-
based dynamic influences that result in ecosystems mechanics that affect the BCP. 
4.7 Conclusions and Implications 
4.7.1 Theoretical implications and contributions 
Biotechnology innovation and commercialisation ecosystem management is an 
emerging issue of interest to universities, researchers and the biotechnology industry. 
By examining the established literature on biotechnology network ecosystems and 
commercialisation processes (Fujiwara, 2014; Kinnunen, Sahlman, Harkonen & 
Haapasalo, 2013; Philp & Winickoff, 2017; Segers 2015; Rong et al., 2013; Viitanen, 
2016), this study develops new knowledge regarding how understanding the different 
types of network interactions and the resulting network dynamics can facilitate the 
BCP. Through a comprehensive literature review and qualitative semi-structured 
interview-based approach, this study analysed how different network components 
generate dynamic interactions and identified relevant network dynamics that affect 
the BCP. This study also developed a conceptual framework depicting the links 
between individual network components, the resulting influences and the different 
dynamic interactions. 
The first important contribution of this study relates to the analysis of network 
influences and how they affect the commercialisation process. In the framework, these 
influences are linked to individual network components (i.e., actors, activities and 
resources); this framework depicts the effect each component is likely to have on the 
BCP. Several permutations and combinations of these individual components result 
in influences that may affect one or several stages of the process. The analysis 
emphasised how network activities originate as a result of network interactions among 
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individual actors, organisational actors or organisational clusters and influence the 
process at one stage or at multiple stages simultaneously, which is likely to generate 
and increase complexity. These interactions can be a result of collaboration, alliance 
formation, mergers or acquisitions, both inter-organisationally and intra-
organisationally. These types of network dynamics may accelerate or decelerate the 
BCP. The understanding of these dynamics provides the opportunity to unfold 
strategies that allow easy identification of the necessary network components and 
predict interactions that may be beneficial for the commercialisation of biotechnology 
innovations. Outlining the foundations of such interactions may lead to the 
development of tactics for building credibility, gaining market reputation, increasing 
technology adoption, building beneficial relationships and reducing network conflicts. 
Considering the commercialisation lag that the biotechnology industry is currently 
dealing with, these tactics need to be learned and applied to strategise against market 
resistance, educate the involved actors and successfully manage innovation. 
Second, these findings provide new evidence regarding the roles of different actors 
based on their movements (individually, as an organisation and as clusters), 
relationship-forming capabilities and the effects of different dimensions of the 
relationship. The identification of dimensions that influence the relationship-forming 
capabilities of actors within an ecosystem will assist in the designing of applicable 
strategies for penetrating stiff networks, accessing new opportunities for tie-ups and 
for designing communication models based on relationship mapping. This will also 
facilitate the conducting of comparison studies that seek to understand relationship 
structures. It will further assist in comparing different dimensions of network 
dynamics and the perceptions of different network stakeholders related to network 
structures, movements, relationships and acuity, and the study of their effects on 
various processes from a network or ecosystem perspective. However, these findings 
will be applicable only when the phenomenon observed is within a technology-based 
context. 
Lastly, the study of dynamic interactions related to network structures will assist in 
defining parameters to develop new network structures and help in understanding the 
evolution and termination of network structures related to technology-based 
processes. It will also help establish methods for skill mapping, designing 
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performance capability metrics and differentiating types of networks based on the 
same set of metrics. It is expected that these findings will further assist in identifying 
engagement tactics for network actors and also resource mapping techniques. It will 
assist researchers in conducting network behavioural studies based on the 
understanding of network acuity patterns in alignment with different network 
structures. The analysis of the reviewed literature indicates that there is a definite need 
for future research on the commercialisation process using different network-based 
approaches, as each component of the dynamic dimension can be viewed from diverse 
perspectives. This would assist in accruing further knowledge and strengthening the 
academic basis of this field of research. 
4.7.2 Implications for stakeholders 
This study has several implications for industry stakeholders. Considering the 
growing gap between universities and industry (Melese, Lin, Chang, & Cohen, 2009; 
Sauremann & Stephan, 2012; Tralau-Stewart, Wyatt, Kleyn, & Ayad, 2009; 
Whittington & Smith-Doerr, 2008), this study will help draw attention to the areas 
that can facilitate a closing of that gap. 
This study encourages commercialisation managers to identify and understand 
relevant interactions underlying the process. Such an understanding would help 
resolve inter-organisational and intra-organisational conflicts. It would also facilitate 
the development of strategies to achieve common adoption and diffusion goals. 
Further, such knowledge would assist in the mapping of resource pathways and 
understanding perceptions would assist in collaboration. Mapping relationship 
development pathways would help in the development of relationship management 
strategies to improve the level of confidentiality, develop long-term relationships and 
trust, and customise communication platforms better suited to commercialisation. 
Identifying the patterns and frequency of interactions will assist managers in 
identifying contributions and in exploiting competences of each network stakeholder 
at the end of the process, which would help in further strategising relationships. It 
would also assist in understanding the process of information flow and in the cross-
fertilisation of ideas at each stage of the process. The process of interaction mapping 
will enhance efficient cost and time management. 
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4.7.3 Limitations 
The literature discussed in this paper was sourced using limited database resources. 
However, it is assumed that the selected databases provide an extensive account of the 
current situation of how commercialisation networks interact. The inclusion of other 
databases could have been used for reaching further saturation; however, this would 
not have changed the current explanation of the literature. 
This study focused on understanding interactions based on four influences 
(movement, relationships, structure and acuity) that broadly cover all aspects of 
understanding network dynamics. However, if observed from a different perspective, 
there may be more ways of interpreting dynamics. Studying interaction-based 
dynamics involves a multidisciplinary approach; therefore, the work of several authors 
was positioned in a specific way, using relevant links to ecosystem dynamics, which 
may be viewed by the respective authors in a different way. 
The triangulation techniques applied to reliability and validity testing establishes the 
trustworthiness of the findings. Although the study focuses on the commercialisation 
of a technology-based industry (biotechnology), the results of this analysis are only 
restrictively generalisable. However, it is expected that these findings will help 
develop foundations for future research in a similar area. 
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Chapter 5: Discussion and Conclusion 
5.1 Purpose of the Study 
Recent research has called for a further understanding of the BCP and the 
identification of the reasons why the biotechnology industry in Australia is dealing 
with the issue of poor commercialisation (Aarikka-Stenroos & Sandberg, 2012, 2014; 
AusBiotech Snapshot, 2017). In particular, there is a need for a more network-based 
approach to understand the role of key network components and how they affect the 
BCP at different stages (Sandberg & Aarikka-Stenroos , 2014; Chen & Lin, 2017; 
Clayton Feldman & Howes, 2018; Nabulsi, 2017). While acknowledging that the 
commercialisation process transpires as a result of the interactions between different 
network components (Aarikka-Stenroos & Sandberg, 2014; Hagedoorn, Lokshin, & 
Malo 2018; Heirati & O’Cass, 2016; Leppaaho, Chetty, & Dimitratos 2017), 
researchers and industry practitioners are still probing for knowledge concerning the 
role of network-based interactions during the BCP. This includes an understanding of 
the different network actors, activities and resources, the interactions between those 
components and their effects during the BCP (Aarikka-Stenroos & Sandberg, 2014; 
Baraldi & Stromsten, 2009; Clayton, Feldman, & Lowe, 2018; Dutta & Hora, 2017; 
Snow, Fjeldstad, Lettl, & Miles 2010; Terziovski & Morgan, 2006; Thompson & 
Hermann, 2018; Vitale, 2004). 
In this context, the research aimed to answer the following overarching questions: 
RQ1. How do networks influence the commercialisation of new biotechnologies? 
RQ2. How does the network configuration inhibit or promote the BCP? 
RQ3. How do the network dynamics interactions affect the BCP? 
Three interrelated studies were conducted to answer these questions. Each study 
included sections on theoretical positioning, methodology, findings, contributions and 
limitations. Study 1 was conceptual and was conducted using the content analysis 
method. Studies 2 and 3 were empirical and were conducted using a qualitative 
approach using 30 semi-structured interviews. Research Question 1 was answered in 
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Chapter 2 (Study 1), Research Question 2 was answered in Chapter 3 (Study 2) and 
Research Question 3 was answered in Chapter 4 (Study 3). These studies provide 
insights into the BCP, network effects and their influence on the process, the issues 
related to network effects and the dynamics of those network effects around the 
process. The findings from all three studies combined generated several academic and 
managerial contributions that managers and practitioners can apply to design useful 
strategies and policies for management, research and organisational purposes. 
This discussions chapter provides a summary of the three studies, discussing the key 
highlights. A section explaining the key theoretical contributions and managerial 
implications of this research follows this. The last section discusses limitations and 
concludes with areas of future research and final comments. 
Study 1 consolidates and clarifies the understanding of the biotechnology innovation 
and commercialisation processes. The concept of networked biotechnology 
commercialisation is explained as a process of taking new biotechnology innovations 
to market within an integrated environment consisting of multiple configurations of 
actors, resources and activities to achieve successful and profitable commercial 
outcomes. The conceptualisation of the networked BCP provides an in-depth 
theoretical understanding of the units of analysis, network effects (influences and 
outcomes), the 12 stages of the commercialisation process and the existing links 
between the process and the network effects (around which standard managerial 
contributions can be drawn). The lack of clarity and limited conceptual understanding 
of network effects that specifically relate to the 12 stages of biotechnology 
commercialisation has made it difficult to generate integrated theoretical frameworks. 
Therefore, viewing the process from a network perspective and reconsidering 
network-based interactions in the context of the BCP provides researchers with the 
theoretical basis for conducting future industrial marketing research and process-
based research. This significant understanding of the concepts also attempts to 
highlight the key problem areas within the context of the Australian biotechnology 
industry and the commercialisation domain. 
The in-depth content analysis of the existing literature and the application of the ARA 
theory support the conceptual framework and the subsequent research propositions. It 
also emphasises the contextual conditions and the network effects within the 
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biotechnology ecosystem that influence the BCP and assist in developing an improved 
understanding of the managerial issues and outcomes related to the process. 
Building on the integrated conceptual framework provided by the theoretical 
understanding and research propositions in Study 1, Study 2 aimed to examine the 
dual nature of network effects that may act as barriers or promoters during the BCP. 
In addressing this question, Study 2 builds upon theoretical knowledge by providing 
empirical data regarding the role of networks (actors, activities and resource-based 
interactions) within the BCP. The method selected for this study was semi-structured 
in-depth interviews with 30 biotechnology experts with different profiles from the 
Australian biotechnology industry. Study 2 further builds upon the existing literature 
by identifying eight network-based barriers: lack of capital and funding, breaking 
network chains, finding the right partners, conflicts of commercial interest, differences 
in perception, time management, the de-risking process and consistent barriers (delays 
in regulatory actions, mismanagement of capabilities and lack of socialisation). The 
data further confirmed the dual nature of networks—that is, the networks 
simultaneously act as process promoters. Eight network-based promoters were 
identified: diversity, funding sources, long-term relationship sources, network 
collators, network heroes, process cycles, process supporters and acting as social tools. 
These network barriers and promoters were linked to different stages of the 
commercialisation process. Broadly, the findings showed that eight network-based 
promoters influenced all stages of the process; however, the level of influence varied 
from stage to stage. Conversely, the eight network-based barriers had different effects 
at different stages of the process. Another interesting finding concerned the causal 
links between barriers and promoters, such as certain network interactions that act as 
a barrier for one stage but as a promoter for another. This demonstrates the variation 
in the effects of networks on the BCP. This study provides an integrated model 
showing the effects of network barriers and promoters on the BCP. The model 
provides the basis for studying complex network behaviour using the interaction-
based network patterns around the process. Such network patterns can also be used 
for conducting comparison-based studies that examine different network phenomena. 
From a managerial perspective, Australian biotechnology firms have been 
successfully innovating biotechnology products from different domains. However, the 
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industry has struggled to achieve a higher rate of commercialisation for over a decade 
(Bio-Savvy, 2016; Cross, 2017; Vitale, 2004). Strategic implications relate to how 
managers should organise network-based interactions to facilitate positive 
commercialisation outcomes. The existing literature highlights that consequences of 
a network interaction cannot be pre-determined; however, this study will help 
managers design selection criteria based on identified patterns of interaction to 
eliminate the interactions that could lead to the formation of barriers. As such, these 
findings present a useful and potential application to the industry by providing rich 
insights into the issues that have delayed or barricaded the process and how these 
issues can be turned into favourable commercial outcomes. 
Study 3 builds upon the insights from Study 2 to investigate the interaction-based 
network dynamics that affect the BCP within a commercialisation ecosystem. This 
study involved the analysis of the same 30 semi-structured interviews with 
biotechnology experts, as study 2. However, the data for this study were analysed with 
a view to understanding the underlying network interaction mechanisms that generate 
different types of network influences that affect the BCP at different stages. In 
addressing this, Study 3 builds upon theoretical knowledge by providing empirical 
data on 30 different types of network dynamic interactions: background changes, 
times of interaction, innovation type, feedback network, outcome dependability, 
process pathway, distressed relationships, network reference points, individual 
interactions, evolving relationships, relationship life cycles, dyadic interactions, 
adaptations, cross-functional integration, centralisation vs. decentralisation, large vs. 
small firms, actor selection process, resource development, network boundaries, 
capability combinations, value-based networks, clustering, domain interests, degree 
of influence, stability, environment, channels of communication and opportunity 
identification, innovation strategy, and outcome expectation. These interactions were 
grouped into higher-order subcategories and main categories based on the nature of 
the network interaction, the type of activities and how these interactions influenced 
the process: jumping actor phenomenon, resource iteration, interdependent 
relationships (network movements), rigid relationships, fluid relationships, hybrid 
relationships (network relationships), network position, network configuration, 
network types (network structure), actor control, network complexity, and actor 
perception (network acuity). 
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Study 3 reveals how the 12 dynamic network influences positively and negatively 
affect the BCP. It influences the process at micro, macro, individual, organisational, 
inter-organisational and intra-organisational levels. This study suggests guidance for 
and managers towards an understanding of interaction-based network patterns. These 
patterns can help in the development of frameworks and in reshaping network-related 
practices, which will enable biotechnology organisations to regulate network 
behaviours to generate potential commercialisation outcomes. The study provides 
empirical evidence of how the interactions between ARA network components 
generate network influences capable of altering the morphology, relationships, 
movements and perception of networks within a commercialisation ecosystem, which 
in turn influences the success of the commercialisation process. 
From a managerial point of view, the findings offer insights that will help managers 
develop a proactive approach to resolve organisational conflicts and implement 
strategies leading to common commercialisation goals. The study of interaction 
patterns will also help in measuring the contributions of network actors and taking 
commercialisation network-based decisions based on the results of those 
measurements. 
Collectively, the three studies address the problem of how business networks 
influence the BCP. The findings contribute to understanding the process and how it 
operates in a commercialisation ecosystem. In particular, the findings reveal issues 
where the involvement of both researchers and the industry play an important role and 
they point to areas for future research that will help better understand other aspects of 
biotechnology commercialisation issues, thus developing a deeper understanding that 
leads to successful commercialisation pathways. The following sections highlight the 
contributions of this study in academia and industry. 
5.2 Theoretical Contribution 
This thesis identifies and examines the problem through a network lens using three 
different network perspectives; it draws on the work of Aarikka-Stenroos and 
Sandberg (2014), Chen and Lin (2017), Hakansson and Johanson (1992), Hansen and 
Klitkou (2016), Harrington and Srai (2017), Kirchberger and Pohl (2016), Romero 
(2018) and Tinoco and Ambrose (2017), as shown in Table 13. The first objective 
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using the network perspective was to conduct a qualitative analysis of the established 
literature to understand how network components can be classified and linked with 
the stages of the commercialisation process. The second objective was to classify 
those network components as barriers and promoters that accelerate or delay the 
process of the BCP. The third perspective was to understand the ecosystem 
mechanism that operates around the BCP and influences the progression of the 
process. These objectives address different research questions and yielded different 
outcomes, each leading to diverse contributions to theory. This research makes three 
contributions to the key theoretical domains of networks, commercialisation and 
biotechnology. 
Table 13: Showing Theoretical Contributions for Study 1 
Research 
Questions Literature Theoretical Contribution 
How do 
networks 
influence the 
commercialisati
on of 
biotechnology 
innovations? 
Innovation and 
commercialisation process 
is network supported 
(Aarikka-Stenroos & 
Sandberg, 2014; 
Kirchberger & Pohl, 2016; 
Romero, 2018; Siegel et al., 
2004; Tinoco & Ambrose, 
2017) 
Networks have a strong 
effect on the legal 
processes associated with 
the BCP (Datta et al., 2014, 
Dorf & Worthington, 1987; 
Kim, 2018; Link et al., 
2011) 
ARA theory highlights the 
effect of network 
components on relationship 
building and accessing 
resources within 
organisational networks 
(Hakansson & Johanson, 
1992) 
Abundance of information 
on network interactions and 
their effects on the 
An adapted model of the BCP 
An improved and integrated 
understanding of the network 
links and key points of network 
influence during the BCP through 
an integrated conceptual 
framework 
Identification and understanding 
of different types of network 
effects in the form of network 
influences (network 
configurations, relationships, 
position, complexity, control, 
interdependence and limitations) 
and outcomes (technology 
transfer, capital, ownership, 
market intelligence, regulations, 
patents and licenses) around the 
BCP. This provides a holistic 
approach to understand the 
effects of networks on the BCP 
An improved foundational 
paradigm for conducting 
network-based comparison 
studies around technology 
commercialisation processes 
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biotechnology innovation 
process. Limited 
information on the effects 
of networks on the BCP 
Advances the application and 
implementation of the ARA 
network theory as an analytical 
tool for analysing network 
interactions and contributions 
around the BCP 
5.2.1 Contribution 1: an integrated conceptual framework that shows strong 
links between network effects (influences and outcomes) and the BCP 
Study 1 contributes by providing an integrated framework (see Figure 3) for 
researchers that examines the links between different types of network components 
and the stages of the BCP. It also expands on the ARA network theory (Hakansson & 
Johanson, 1992) by understanding how interactions between actors, resources and 
activities generate different network-based influences and outcomes that affect the 
stages of the BCP. This model is different from more general sequential 
commercialisation processes as it takes a holistic approach to investigate the 
significance of the network-bounded commercialisation process. It identifies a more 
complex set of network-based interactions that facilitate new networked pathways to 
transfer innovations from one stage of the commercialisation process to another. 
The literature has studied network configurations, relationships, position, complexity, 
control, interdependence and limitations as individual components; it has also studied 
the effects of these components on innovation and several aspects of 
commercialisation (Edwards, 2007; Cullen, Bradford,., Zilberman, & Bennett, 2003; 
Kirchberger & Pohl, 2016; Mireles, 2004; Romero, 2018; Tinoco & Ambrose, 2017; 
Van der Bij, Michael Song, & Weggeman 2003). This study further explored how the 
interaction between these components generates network outcomes—such as 
technology transfer, capital, ownership, market intelligence, regulations, patents and 
licenses—that affect the stages of the BCP. The integrated framework (see Figure 3) 
contributes in different ways. First, the model will allow researchers to understand the 
networked commercialisation process and how it can be conceptually defined in the 
industrial marketing, networking and innovation management literature. Secondly, it 
is expected that the framework will allow academic researchers to conduct more 
insightful network-based comparison studies by examining the different types of 
network influences and measure their influence in different contexts. Thirdly, the 
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model will allow academic researchers to conduct quantitative studies to measure 
network effects and outcomes at different stages of the process. For example, 
researchers can measure the effects of different inter- and intra-organisational factors 
that may lead to the generation of different network influences and outcomes. A 
measure of the accurate estimates of such network effects will allow managers and 
industry practitioners to make strategic decisions that accelerate the BCP. 
5.2.2 Contribution 2: evidence of the dual nature of commercialisation networks 
by identifying eight network-based barriers and eight network-based promoters 
that inhibit and accelerate the BCP, respectively, that have been empirically 
justified 
Study 2 built upon the indications from Study 1 and identified the network interactions 
that inhibit and accelerate the process of technology commercialisation. Study 2 is an 
in-depth qualitative study that contributes towards the commercialisation management 
literature by further understanding the dual role of business networks (Bandarian, 
2007; Gatling & Zimmer, 2011; Kirchberger & Pohl, 2016; Romero, 2018; 
Tahvanainen & Nikulainen, 2011; Tinoco & Ambrose, 2017), as outlined in Table 14. 
It identified eight key barriers: lack of funding, breaking of network chains, finding 
the right partners, conflicts of commercial interests, the difference in perceptions, time 
management, de-risking processes and consistent issues (such as lack of socialisation, 
delay in regulatory actions and mismanagement of capabilities). It identified complex 
network behaviours by studying individual physical and psychological interactions 
between different network actors, which transpire into the biotechnology 
commercialisation process. 
The current network literature highlights the role of the network as a facilitator (Datta 
et al., 2014; Kirchberger & Pohl, 2016; Romero, 2018; Tinoco & Ambrose, 2017). 
This study further identified eight network-based promoters (network diversity, 
funding sources, long-term relationships, process cycles, social tools, network 
collators, network heroes and process supporters) that assist the BCP at different 
stages. It builds upon the ARA theory by identifying network interactions that support 
the process of relationship development. The network ARA theory (Hakansson & 
Johanson, 1992) uses the actor, resources and activity components to study how 
network relationships are formed to access resources. Although several network-based 
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studies (Batt, 2008; Harrison & Prenkert, 2009) have utilised the ARA network theory 
as a theoretical and analytical lens in different domains of business and marketing 
literature, this study shows a distinctive approach towards the theory’s application by 
using the ARA network theory as the basis for the analysis of network effects and as 
a guide for understanding the network interactions that occur during the BCP. 
The ARA theory has usually been used to understand and analyse the bases of 
relationship development and management (Glinska-Newes, Escher, Brzustewicz, 
Szostek, & Petrykowska, 2018; Gummesson & Mele, 2010; Huemer, 2006). This 
study further builds upon the ARA literature by identifying how ARA components 
can lead to network interactions that may dissolve a relationship, prevent the process 
of relationship development or limit access to resources. 
Table 14: Showing Theoretical Contributions of Study  
Research Questions Literature 
Theoretical 
Contribution 
How does the network 
configuration inhibit or 
promote the BCP? 
Network plays a dual role 
during the biotechnology 
innovation and 
commercialisation 
processes (Aarikka-
Stenroos & Sandberg, 
2014; Kirchberger & 
Pohl, 2016; Romero, 
2018; Tinoco & Ambrose, 
2017) 
Limited information on 
influence of network-
based inhibitors and 
promoters on all stages of 
the BCP (Bugge et al., 
2016; Chen & Lin, 2017; 
Harrington & Srai, 2017; 
Torkkeli & Lin, 2010) 
Identification of 
eight key barriers: 
lack of funding, 
breaking of 
network chains, 
finding the right 
partners, conflicts 
of commercial 
interests, the 
difference in 
perceptions, time 
management, de-
risking processes 
and consistent 
issues (such as lack 
of socialisation, 
delay in regulatory 
actions and 
mismanagement of 
capabilities) 
Identified eight 
network-based 
promoters: network 
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Funding was highlighted as a key network barrier during the BCP, as mentioned in 
Study 2 (see Chapter 3). The lack of funding has been due to the lack of appropriate 
collaboration strategies (Beaudry & Levasseur, 2017; Hurst & Lusardi, 2004). This 
study contributes by providing a deeper understanding of network-based barriers 
related to the funding issues around the BCP. It identifies causal links between 
different network interactions that can lead to a lack of funding for commercialisation. 
Study 2 also provides empirical evidence for the development of two new concepts to 
understand the commercialisation process outcomes. Based on the evidence, this study 
diversity, funding 
sources, long-term 
relationships, 
process cycles, 
social tools, 
network collators, 
network heroes and 
process supporters 
An improved 
understanding of 
network behaviour 
and perception 
around the BCP in 
the form of network 
barriers and 
promoters by 
linking the barriers 
and promoters to 
the different stages 
of the BCP 
Two new concepts 
related to the 
understanding of 
commercialisation 
outcomes—the 
ECO and the DCO 
Improved 
understanding of 
stage-gate models 
by identifying 
network barriers 
that act as network 
gates during the 
BCP 
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classified the perceptions of network actors regarding commercialisation outcomes 
into the ECO and the DCO. The DCO is defined as the dependable consequence of 
the commercial investment; the ECO is defined as the desired consequence of the 
commercial investment. An understanding of these concepts can assist in designing 
studies that will examine the perception-based behaviours of network actors. It will 
also assist in gathering a measure of different psychosomatic factors that affect access 
to funding, the expectations of investing bodies regarding fund provision and the 
conflicts that can arise during the process of fundraising based on the expectations of 
the involved network actors. Future studies utilising these concepts can be conducted 
with the goal of designing solutions that lead to faster commercialisation. 
A range of traditional stage-gate models and new, lean and agile stage-gate models 
have been developed for innovation and commercialisation processes (Cooper, 2017; 
Kundu, Bhar, & Pandurangan, 2015). These models have identified the importance of 
gates during the commercialisation process. The gates establish the benchmarks for 
measuring the progress of the processes. Similarly, since the network barriers inhibit 
the process at several stages, they can also act as network gates. The conceptual 
framework (see Figure 4) provided in Study 2 (see Chapter 3) highlights the network 
interactions that act as inhibitors and promoters of the BCP. The analysis of the 
empirical data also led to the identification of key barriers and promoters that have 
been linked to the revised conceptual framework in Figure 5. This framework further 
contribute to the understanding of stage-gate models for innovation and 
commercialisation processes (Cooper, 2017; Kundu , Bhar, & Pandurangan 2015; 
Soenksen & Yazdi, 2017). Research academics can use the framework with identified 
barriers to develop new stage-gate models for an improved understanding of the 
commercialisation process. The identified network interactions can also be used by 
researchers as parameters to measure the value generated at each stage of a process 
through the application of quantitative methods. 
5.2.3 Contribution 3: 31 empirically supported network interactions, grouped as 
network movements, structure, relationships and acuity, that generate the 
network dynamics during the BCP 
Study 3 built upon the findings of Study 2 to identify the types of network interactions 
that act as underpinning mechanisms that result in the dynamic nature of the network 
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ecosystem surrounding the commercialisation process. The qualitative approach for 
Study 3 contributes to the network and ecosystem management and technology 
commercialisation literature (Adner, 2006; Auserwald & Dani, 2017; Baden-Fuller & 
Haefliger, 2013; Chesbrough & Appleyard, 2007; Iansiti & Levien, 2004; Xiaoren, 
Ling, & Xiangdong 2014; Zahra & Nambisan, 2012) by identifying 31 network-based 
interactions that generate 12 different types of network influences, as outlined in Table 
15. The 12 influences have been classified under network movements, structure, 
relationship and acuity based on the motive and consequence of the related 
interactions. 
This study in building ARA theory, as the ARA network components have been used 
as an analytical tool to develop an integrated understanding of the interplay between 
individual external, internal, inter- and intra-organisational network-based 
interactions that occur during the BCP. The integrated model in Figure 7 shows the 
links between the network-based ARA components and provides an improved 
understanding of how the interactions between those ARA components generate 
network movements, build network structures, develop and manage network 
relationships and generate network acuity. The understanding of these interactions is 
then taken into consideration to interpret dynamic network behaviours during the 
BCP. 
The literature has identified how one network interaction can influence the 
performance of other network interactions, owing to the interdependent nature of 
networks (Johnston, Peters, & Gassenheimer, 2006). In addition, understanding the 
nature and timing of interactions have been used as important factors to study the 
process of building business relationships (Medlin, 2004). Further, the ARA network 
theory explains the role of ARA components in the organisational relationship 
management process. This study advances the understanding of the ARA theory and 
the relationship building process during the BCP by identifying the patterns of 
interaction around the process that are important for relationship development. It also 
helps in understanding relationship-based factors that may have a positive or negative 
influence on the BCP. Patterns of interaction can be examined using the findings from 
Study 3 by taking as a frame of reference factors such as time, motivation, culture and 
perceptions. This will also assist in estimating the probabilities of the outcomes related 
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to these interactions. This will further help organisations increase their awareness 
levels and thus make better strategic decisions while operating within a network. 
Table 15: Showing Theoretical Contributions of Study 3 
Research Question Literature 
Theoretical 
Contribution 
How do the network 
dynamics 
interactions affect 
the BCP? 
The business ecosystems 
achieve their goals 
through multiple dynamic 
interactions between 
different network 
structures, which are the 
permutations and 
combinations of different 
actors, resources and 
activities (Auserwald & 
Dani, 2017; Baden-Fuller 
& Haefliger, 2013; Gertler 
& Levitte, 2005; Gilsing 
& Nooteboom, 2005; 
Smith & Powell, 2004; 
Zahra & Nambisan, 2012) 
The dynamic interactions 
among the ARA 
components of the 
network lead to the 
development of four key 
network dynamic 
influences: (1) network 
movements (2) network 
relationships (3) network 
structure (4) network 
acuity (Abrahamsen et al., 
2012; Chen, 2009; Corallo 
et al., 2007; Dröge et al., 
2004; Goldenberg et al., 
2009; Kapoor & Lee, 
2013; Nooteboom, 2000; 
Schiele, 2010; Zahra & 
Nambisan, 2012) 
Identifying 31 network-
based interactions—
background changes, 
times of interaction, 
innovation type, feedback 
network, outcomes 
dependability, process 
pathway, distressed 
relationships, network 
reference points, 
individual interactions, 
evolving relationships, 
relationship lifecycles, 
dyadic interactions, 
adaptations, cross-
functional integration, 
centralisation vs. 
decentralisation, large vs. 
small firms, actor 
selection process, 
resource development, 
network boundaries, 
capability combinations, 
value-based networks, 
clustering, domain 
interests, degree of 
influence, stability, 
environment, channels of 
communication, 
opportunity 
identification, innovation 
strategy and outcome 
expectation—that 
generate 12 different 
types of network 
influences around the 
BCP 
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This study allows researchers to understand the effects of collaborative relationships 
and the changes that occur in the process based on different types of collaborations. 
This also forms the basis of studies that can be used for understanding resources, 
capability and performance mapping concerning the process. This study mainly 
contributes to understanding network evolution and termination behaviour. It 
confirms the strong effects of network relations and changing network structures and 
the differences in network perception on the individual stages of the BCP. 
Overall, in keeping with the findings of Aarikka-Stenroos and Sandberg (2012, 2014), 
this research reveals a strong link between networks and the commercialisation 
process. It highlights that understanding networks from the ARA perspective 
(Hakansson & Johanson, 1992) or based on ARA theory (Latour, 2005) is a limited 
approach; it is important to study processes by understanding individual interactions 
at the individual and organisational levels, as there is limited knowledge from an 
Provides an integrated 
conceptual framework for 
understanding how 
network interactions 
positively and negatively 
affect the stages of the 
BCP in the form of 
network movements, 
structure, relationships 
and acuity 
Advances the 
understanding of network 
behaviours by providing 
a basis for studying 
network interaction 
patterns around process-
based models 
Improves the 
understanding of the 
relationship development 
process in a technology 
network by contributing 
new information about 
the effect of dissolution 
of relationships on the 
commercialisation 
process 
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interaction perspective. One of the key issues in successfully commercialising 
technology-based innovations that has been ignored by participating actors and that 
has not received sufficient attention relates to minor network-related issues, including 
the background of individual actors vs. organisational structures, the role of 
transactional interactions between individual network entities at inter- or intra-
organisational levels, limited understanding, and the application of socialisation 
platforms and opportunities. The study also emphasised that network effects are not 
limited to the physical attributes of the networks such as structure, relationships, 
resources accessibility and configuration; they also include psychosomatic factors 
such as perceptions, communication compatibility and cultural understanding. 
Individual actor expectations from the surrounding circumstances also play a vital role 
in driving potential biotechnology innovations through successful commercialisation 
pathways. From a researcher’s point of view, this opens new avenues of inquiry. It 
also provides insights specific to the Australian biotechnology industry where issues 
related to commercialisation have been previously identified but limited attention has 
been paid to understanding the problems from a network focus. 
5.3 Implications for Industry 
For more than a decade, the Australian biotechnology industry has been focused on 
the issue of poor biotechnology commercialisation caused by lack of funding, lack of 
commercial understanding, limited networking and lack of understanding of 
regulatory frameworks (AusBiotech Annual Industry Report, 2016; AusBiotech 
Snapshot, 2017; Australian Government, 2012; BioSavvy, 2016; OECD, 2012; Vitale, 
2004). Industry reports over the last 10 years have repeatedly highlighted the same 
issues relating to the BCP and have increasingly emphasised the importance of 
networks within the industry. However, the industry has failed to identify the source 
of these issues. 
The industry has identified the role of networks in innovation processes and has 
applied network knowledge to develop several innovative solutions to solve problems 
in different biotechnology domains. However, commercialisation of biotechnology 
innovations has been a consistent issue because the industry only possesses a limited 
understanding of the advantages of network involvement during the 
commercialisation process. This study contributes by providing a clear understanding 
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of networks and network-based issues and by identifying the underlying causes 
regarding the same. It is expected that the findings will assist in developing 
resourceful pathways for commercial success. Three key managerial implications can 
be drawn from this research that will assist the biotechnology industry in Australia to 
better manage the issues related to the BCP. 
5.3.1 Implication 1: a clear understanding of the role of networks will assist in 
mapping potential networks to develop improved commercialisation strategies 
This research identified the role of ARA components of the network by studying the 
effects of network influences that result from interactions between the ARA 
components. Building on the ARA theory, this research identified the roles of the key 
network players in the biotechnology industry in Australia, including universities, 
VCs, research institutes and network facilitators (AusBiotech Snapshot, 2017). The 
literature also highlights the contributions of these actors in the biotechnology 
innovation and commercialisation processes (Aarikka-Stenroos & Sandberg, 2014; 
Leppaaho et al., 2017; Rothaermal & Thursby, 2007). However, the data from this 
research showed that these actors possess a limited understanding of the implications 
of being involved in a network and this hampers the BCP. The findings from Studies 
1, 2 and 3 show how network actors can influence the different stages of the 
commercialisation process in the form of conflicts, resource provisions, 
communication, knowledge sharing, limited skills and collaborations. This 
information will help managers in designing proactive approaches to counter 
managerial issues related to network actor resource management. 
Studies 2 and 3 also identified network-based influences that can positively and/or 
negatively affect the process. Measuring the effects of such influences will help 
managers understand complex network behaviours. This research forms the basis to 
further develop tools to measure network effects during the BCP. The analysis of 
network behaviours and the extent of their influence will allow managers to design 
policies that enhance commercialisation outcomes. It will also help the 
commercialising and innovating organisation develop strategies for operating within 
clusters of networks. There is limited understanding of the process of knowledge 
transfer within a cluster and the interactions and skills essential for those transfers. 
This study forms the basis to identify and map the network interactions necessary for 
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designing knowledge transfer strategies. Network mapping would allow for the 
identification of valuable innovation partners who offer complete solutions for 
commercialisation. 
5.3.2 Implication 2: insights from within the industry to understand the causes 
of commercialisation failures 
This research used an in-depth qualitative approach for data collection and analysis 
that resulted in the participation of 30 biotechnology experts in Australia whose 
profiles consisted of years of multidisciplinary experience. Participants came from the 
entire spectrum of process experience, from pre-commercialisation to post-
commercialisation. The participant sample included opinions from biotechnology-
based organisations, research institutes, academic institutions and government bodies. 
The participants provided opinions based on personal experiences regarding their 
involvement in the commercialisation process. All participants were key actors in the 
biotechnology network (AusBiotech Snapshot, 2017); hence, their opinions are 
relevant for identifying the issues related to poor commercialisation of biotechnology 
innovations. The data also helped in identifying the role of actors and their 
contributions to the process, and their perceptions of network involvement. This 
understanding regarding the role of network involvement will assist in developing 
improved commercialisation management strategies and recommendations essential 
for the successful commercialisation of biotechnology innovations. The findings show 
that risk management, risk mitigation and de-risking are key activities during the BCP; 
managers can use the findings based on this data to improve their capabilities of 
perceiving and identifying risks, uncertainties and unpredictability, owing to the 
volatile nature of the BCP. 
Large organisations possess extensive data on network interactions in the form of 
business cases, case studies, project files and success reports. Such data provides 
evidence of network sequences, heuristics and accumulated knowledge. Learning 
from past failures by measuring actor performance, mapping patterns of interactions, 
re-structuring the network and developing strategies for improving and maintaining 
potential relationships can be turned into opportunities to develop better 
commercialisation pathways. Managers can use the findings from this study to 
develop models that examine the structure of an organisation, teams within the 
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network involved in product development and commercialisation, shifting patterns of 
teams and individuals during the process, the ability of teams to acclimatise to new 
situations and unforeseen circumstances and then develop new schemes. 
The opinions of the experts helped in identifying barriers that barricade the BCP at 
different stages. This research suggests that identification of potential partners, 
collaboration issues and judgement of skills are key issues related to the poor progress 
of the commercialisation process. Based on the knowledge of the identified barriers, 
this study allows managers to develop strict selection criteria and network skimming 
techniques to select partners for mergers and alliances. The application of such 
knowledge will also help eliminate disadvantageous collaborations, which will further 
accelerate the process. In other words, managers will be able to develop more 
predictable technology network roadmaps. These roadmaps have been known to serve 
as a model for the integration of required capabilities, resources and knowledge 
exchanges and allow strategies and policies related to technological processes to be 
developed (Gerdsri, Puengrusme, & Vatananan, 2018). 
5.3.3 Implication 3: a framework for studying network configurations around 
the commercialisation process 
The conceptual framework developed in this research is useful for studying the BCP 
and examining network contributions to the process. Managers can use the framework 
as the basis to conduct comparisons between large and small firms based on 
configurations of network operations. The configurations are based on the types of 
actors, resources and activities and the value generated from the interactions between 
actors to access resources during the process of commercialisation. In the 
biotechnology field, studies of merger activities have been dominant and in-demand. 
The model will allow industry analysts to compare the data and identify configurations 
that can assist in cross-collaboration and increase inter-firm exchanges. It will also 
help in identifying how the useful network interaction patterns can be generalised to 
an extent and adapted from one organisation to another within a given network setting. 
Managers possess exploitation capabilities that can be extended through this research 
by understanding the process of relationship development and will facilitate in the 
selection of specific network interactions that are supportive and advantageous for 
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maintaining the useful relationships during the process. This will help in designing 
useful relationship management strategies within both the industry and academia. 
Academics can also leverage the transformative industry networks to build a 
relationship, external exploration and exploitation knowledge and rich social ties for 
commercialising research. 
5.4 Research Limitations 
This research provides a conceptualisation of network-based interactions and their 
integration in the context of the BCP and, as such, contributes to the 
commercialisation management and network theory literature. By presenting a set of 
findings regarding the nature, causes and effects of network-based interactions on the 
BCP, it establishes a productive foundation for future research. However, this research 
has four main limitations. 
First, because of the exploratory nature of the research, it suffers from the issue of 
limited generalisability of the findings in two ways. The established literature 
highlights that several exploratory network-based studies concerning innovation and 
commercialisation processes have been conducted using a case-study method 
(Aarikka-Stenroos & Sandberg, 2014; Oskam, Bossink, & Man, 2007). This study, on 
the other hand, utilised a qualitative approach with in-depth interviews of 30 
biotechnology experts from different domains within the biotechnology ecosystem. 
While the interpretation of a case-study approach is confined to a single study or two 
comparative case studies, the empirical data from this research provides a more 
holistic and diverse view of the phenomena under observation. Future research in this 
area could test the propositions offered in this study using different methods. 
Further, the findings and analysis of this research are limited to a specific population 
(Leung, 2015; Yin, 2009). For example, the sample size—although sufficient for the 
aims of this study—was relatively small and thus larger samples from different 
domains may strengthen the results. Although this study includes insights from 
various types of network actors, the networks might vary based on different market 
characteristics. To be generalisable, the conclusions and contributions of this research 
need to be advanced with further research. Such research would involve identifying 
the networks around the biotechnology industry in other countries and regions, as 
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other countries are also concerned with the commercialisation of biotechnology 
innovations and experience similar issues related to the BCP. For example, a study 
conducted by Moustakabal and Niosi (2017) highlighted issues related to early-stage 
and advanced-stage biotechnology commercialisation in Canada. Another study 
regarding commercialisation of biotechnology innovations in North America 
identified issues related to the regulatory approvals process and how it causes delays 
in taking innovations to market (Smyth, Kerr, & Gray, 2017). Thus, the prominence 
of commercialisation networks and the need to improve the commercialisation process 
justify the need for research at an international scale. 
Second, unless refined through further research, the application of the findings is 
limited to the biotechnology industry and does not extend to other technology-based 
industries. The review of the network and commercialisation literature showed that 
lack of commercialisation is a prominent issue in other industry settings, such as 
pharmacology (Jain, 2017; Sheperd, 2017), nanotechnology (Kaur, Kakkar, & Yadav, 
2014; Palmberg, 2009; Tsuzuki, 2016) and biofuel technology (Bibi et al., 2017; Singh 
& Rathore, 2017). As commercialisation infrastructures, the level of growth and 
development, the regulatory frameworks vary across industries, regions and countries. 
The network related barriers, promoters and dynamics identified in this research might 
vary from barriers, promoters and interactions in other technology industries and 
geographical regions, which limits generalizability. However, this study can be used 
as a reference point to replicate a similar methodology in a similar type of industrial 
setting. 
Third, the emerging need for a lean commercialisation approach is evident from the 
growing body of industry and academic literature (AusBiotech Snapshot, 2017; Festel, 
2015; Moktar & Velu, 2018; Thakur et al., 2018) that emphasises the need for lean 
biotechnology commercialisation models. However, based on the analysis of the 
current literature, this research provides a comprehensive conceptualisation of a 
networked BCP adapted from the stage-gate approach (Alexandre, Furrer, & 
Sudharshan, 2003; Davison & Lievense, 2016; Jolly, 1997; Kirchberger & Pohl, 2016; 
Lim, Garsney, & Gregory, 2006; Tayaran, 2011; Tinoco & Ambrose, 2017). In 
addition, the current models in the industry are very stage-gate oriented. However, 
due to the increasing involvement of customers and other downstream stakeholders 
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during the early stages of the commercialisation process, more research may be 
needed to understand the BCP using a lean and agile commercialisation process 
approach.  
The fourth limitation of this study is the timeframe in which the research was 
conducted. The findings suggest that changing network dynamics during the BCP 
affect the speed of the commercialisation process at different stages. The findings 
relating to the network-based dynamics in this research are based on the opinions and 
individual views of the participants. Although the expertise and experience of the 
participants are sufficient to examine the applicability of the findings and to consider 
them trustworthy, more research is needed to measure the effectiveness and effects of 
the dynamic interactions in the process. In addition, while this study comprehensively 
examined a cross-sectional reflective view of the industry to understand the effects of 
networks on the BCP at a specific point and time, there is a need to consider a 
quantitative longitudinal approach to study a live innovation and commercialisation 
process, which usually takes 5–15 years to measure the effect. 
5.5 Future Research 
An important objective of this study was to develop a network-based BCP model that 
would assist biotechnology organisations to develop successful commercialisation 
pathways. Synthesising a networked BCP model through the analysis of established 
theory and industry knowledge attained this objective. However, a clear limitation is 
that a qualitative approach was used to develop the model, which limits the 
generalisability of the model. Findings from Studies 1, 2 and 3 could be further 
investigated through quantitative research. Future research could quantitatively 
measure the effects of network-related components at each stage of the process and 
test the robustness of the model in an industry setting. From a theoretical perspective, 
this would contribute by measuring the capacity and the performance of different 
types of network mechanisms and the commercialisation process and by linking those 
findings to measure the success of commercialisation outcomes, such as licensing, 
patenting, joint ventures, adoption and diffusion or failures, during the BCP. This 
information would yield insights of strategic importance for the involved network 
actors from an organisational perspective regarding the role of different network 
effects at specific stages of the commercialisation process. 
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The conceptual model showing the BCP and the network links provides the basis for 
conducting network-mapping studies based on the collected data. A cross-sectional 
approach combined with a sequential process was suitable, given the views regarding 
the network as interdependent and continuous and the commercialisation process 
being long and extensive; however, other researchers may hold a different perspective 
of networks and commercialisation. Thus, this study provides an avenue for future 
researchers to study the implications of this model by conducting longitudinal studies 
to further explore the biotechnology innovation and commercialisation process, which 
usually takes 5–15 years. It is acknowledged that conducting such research in an 
organisational setting, specifically in the biotechnology industry where confidentiality 
issues are prominent, would be a tedious task. 
One of the major advantages of network research is that it can incorporate network 
analysis from various levels: micro, macro, individual, organisational, relationship-
based and perception-based. The three studies in this thesis contribute to the 
underdeveloped body of literature focused on interaction-based network analysis 
around a specific process. Future research could combine the findings from this study 
and other levels of analysis to conduct multi-level studies that provide empirical 
evidence concerning the successful management of the commercialisation process. 
Such a study would require the involvement of network actors from every end of the 
commercialisation process. Ideally, the analysis of such a large body of data would 
require multiple rounds of examination, given the intricacies of the biotechnology 
network would have to be studied from multiple perspectives of the networks. 
An opportunity to further extend this research relates to understanding how the BCP 
can be improved with the application of social media channels and other forms of 
digital marketing. Research on the business-to-business marketing of technological 
innovations has highlighted the importance of the role of social communication 
ecosystems and platforms (Hanna, Rohm, & Crittenden, 2011; Simeon, Kalangot, 
Doriane, Jonelle, & Tom, 2011). In the business-to-business marketing literature, 
social communication ecosystems have been defined as a network of different social 
media-based communication tools connected thorough numerous linkages for sharing 
different forms of information (Hanna, Rohm, & Crittenden, 2011; Ihl, Vossen, & 
Piller, 2012). However, limited research has been conducted to improve our 
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understanding of the influence of social media-based ecosystems on technology 
commercialisation. The limited knowledge regarding the impact and involvement of 
social media networks during innovation and commercialisation processes is another 
key issue discussed by the Biotechnology industry. The literature on social media 
networks and their impact on B2B processes can be  extended by understanding the 
effects of social media-based networks around the BCP and proposing a parallel 
model to the network-based BCP model. Research with such a focus would be useful 
for both industry and academia. 
Another key finding from this research concerns the role of lean and agile approaches 
for commercialising biotechnology. Industry experts highlighted the importance of 
lean and agile approaches for innovation and commercialisation. However, the data 
revealed that few organisations apply these approaches to their business models 
despite being aware of the relevance of such formats. In terms of future research, it 
would be interesting to identify how network management would change during such 
processes and what network components would affect the lean and agile approaches 
in this context. It would also be important from a manager’s perspective, as it would 
result in the development of improved commercialisation strategies. 
5.6 Final Summary 
This research has attempted to unveil the network-related dynamics around 
commercialising biotechnology innovations. Biotechnology products commonly 
exploit biological systems and living organisms and the industry covers several 
disciplines (e.g., genetics, molecular biology, biochemistry and bioprocessing). This 
industry forms the foundation for medical technologies, pharmaceuticals and the 
healthcare system in Australian and worldwide contexts. Given the ever-changing 
markets and market needs, the evolution of new technologies and new systems of 
developing technologies is likely to continue. This will involve the development and 
dissolution of several network chains that constantly affect the process, further 
generating the need for the identification of convenient and profitable methods to 
innovate and commercialise products. This further generates the need for more lean 
and agile approaches of commercialising technologies that are flexible and adaptable 
to changing market and stakeholder requirements. 
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With the continuous enhancement of the BCP and network effects model, the 
framework should find its application in the Biotechnology sector for years to come.  
The philosophical explanation and core reasoning of the model indicates that there are 
several ways to develop solutions to solve the issues related to biotechnology 
commercialisation.  
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APPENDIX 1 
Interview Instrument for Biotechnology Industry Experts 
(A consent form containing all the details of this research was given to the respondents 
prior to the interview) 
Thank you for your time today.  This interview will take between 45 and 60 minutes. 
The purpose of this interview is to gain your insights and opinions on the process of 
taking a new innovative product through to commercial viability and launch. I would 
like to audio record this interview so that I have an accurate record but I will turn it 
off at any time you indicate.  
The questions are all open ended. If a question is not relevant to your business, please 
let me know and we will move to the next question. 
Let’s get started with the interview.   
1. So can you tell me some core activities of your organisation? 
2. Would you shed some light on the new product development process of your 
organisation?  
3. How do you commercialise these new products?  
4. What are the issues that your organisation deals with when taking these new 
products to market?  
5. What type of organisations do you mainly deal with?  
6. How do you collaborate to meet your requirements for the NDP?  
7. What are the issues that your organisation comes across when working with 
other organisations?  
8. What are your recommendations for improving the commercialisation 
process? 
Are there any comments that you would like to make or any other information that 
you think I should be aware of? 
Thank you for your time.  
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APPENDIX 2 
Interview Instrument for Venture Capitalists 
(A consent form containing all the details of this research was given to the respondents 
prior to the interview) 
Thank you for your time today.  This interview will take between 45 and 60 minutes. 
The purpose of this interview is to gain your insights and opinions on the process of 
taking a new innovative product through to commercial viability and launch. I would 
like to audio record this interview so that I have an accurate record but I will turn it 
off at any time you indicate.  
If a question is not relevant to your business, please let me know and we will move 
to the next question. 
1. So can you tell me some core activities of your organisation? 
2. What type of organisation captures your interest for investment? 
a. How do you find out about these companies and organisations? 
3. Why is biotechnology an area of interest for your organisation to invest in? 
4. On what basis do you decide to invest in start-up Biotechnology 
organisations? 
b. At what point in the innovation and commercialisation process do you invest? 
5. What are the risks and uncertainties that you face when investing in the new 
product development process? 
6. This research is based on organisational collaboration which are involved in 
taking new high technology products to market. So according to you what are the 
challenges that an organisation faces during this process?  
7. What is the role of your organisation during the commercialisation of new 
Biotechnology products?  
8. What do you think is role of overall business networks during the process of 
Biotechnology commercialisation? 
9. What type of collaborations does your organisation have with other 
organisations that are involved in commercialisation of new biotechnology 
products?  
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10. What are your recommendations for improving the commercialisation 
process? 
 
Are there any comments that you would like to make or any other information that 
you think I should be aware of? 
Thank you for your time.  
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